Electrical techniques for predictive methods of cochlea and related treatments
The four-point impedance measurement technology monitors the impedance changes in the cochlear and determines the treatment plan. The problem of difficult monitoring of impedance changes in the cochlear implant electrode array after implantation is solved, achieving safe and effective treatment in the cochlear.
Patent Information
- Application Number
- CN202380036277.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-03-29
- Filing Date
- 2023-04-25
- Publication Date
- 2024-12-06
AI Technical Summary
Existing cochlear implant electrode arrays are difficult to effectively monitor and predict impedance changes in the cochlear after implantation, resulting in poor treatment effects and difficulty in timely adjusting treatment strategies to cope with potentially harmful developments.
By obtaining impedance data within the cochlear, evaluating these data to determine the treatment regimen, monitoring impedance changes after electrode array insertion is used using four-point impedance measurement techniques, and only performing treatment or increasing the attack of treatment if the second impedance value is greater than the first impedance value or increasing the attack of treatment to ensure the safe and effective operation of cochlear implants.
Real-time monitoring and prediction of internal impedance changes in the cochlear are achieved, ensuring the safety and therapeutic effect of cochlear implants, and avoiding hearing loss and other potential problems caused by increased impedance.
Smart Images

Figure CN119095533A_ABST
Abstract
Description
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS
[0002] This application claims priority to U.S. Provisional Application No. 63 / 334,644, filed on April 25, 2022, and entitled “ELECTRICAL TECHNIQUES FOR PREDICTIVE METHODS AND RELATED TREATMENTS OF A COCHLEA”, with Stephen O'LEARY as the inventor. This application also claims priority to U.S. Provisional Application No. 63 / 337,924, filed on May 3, 2022, and entitled “ELECTRICAL TECHNIQUES FOR PREDICTIVE METHODS AND RELATED TREATMENTS OF A COCHLEA”, with Stephen O'LEARY as the inventor. This application also claims priority to U.S. Provisional Application No. 63 / 455,470, filed on March 29, 2023, entitled “ELECTRICAL TECHNIQUES FOR PREDICTIVE METHODS AND RELATED TREATMENTS OF A COCHLEA”, inventor Daniel SMYTH. The entire contents of each application are incorporated herein by reference in their entirety. Background Art
[0003] Medical devices have provided a wide range of therapeutic benefits to recipients over the last several decades. Medical devices may include internal or implantable components / devices, external or wearable components / devices, or combinations thereof (e.g., devices having external components that communicate with implantable components). Medical devices, such as traditional hearing aids, partially or fully implantable hearing prostheses (e.g., bone conduction devices, mechanical stimulators, cochlear implants, etc.), pacemakers, defibrillators, functional electrical stimulation devices, and other medical devices, have been successful over the years in performing life-saving and / or lifestyle-improving functions and / or recipient monitoring.
[0004] Over the years, the types of medical devices and the range of functions performed by them have increased. For example, many medical devices, sometimes referred to as "implantable medical devices," now typically include one or more instruments, devices, sensors, processors, controllers, or other functional mechanical or electrical components that are permanently or temporarily implanted in the body of a recipient. These functional devices are typically used to diagnose, prevent, monitor, treat, or manage disease / injury or its symptoms, or to study, replace, or modify anatomical structures or physiological processes. Many of these functional devices utilize power and / or data received from an external device that is part of or operates in conjunction with the implantable component. Summary of the invention
[0005] According to an exemplary embodiment, there is a method comprising: obtaining data based on impedance values within a person's cochlea at a first time location and at a second time location after the first time location; evaluating the obtained data; and performing a treatment based on the evaluation.
[0006] In an embodiment, there is a method comprising: obtaining first data based on a first impedance value obtained using a cochlear implant electrode array positioned in the cochlea of a person, wherein the impedance value is a value of the impedance present in the cochlea within 6 hours after the electrode array is first placed in the cochlea; obtaining second data based on a second impedance value obtained using the cochlear implant electrode array still positioned in the cochlea of the person, wherein the second impedance value is for the impedance present in the cochlea at least 12 hours after the electrode array is first placed in the cochlea; and implementing treatment and / or increasing the aggressiveness of treatment only when the second impedance value is greater than the first impedance value.
[0007] In an embodiment, there is a method comprising: using a cochlear implant electrode array to detect recent physiological changes caused by implantation of the cochlear implant electrode array in the cochlea and / or detecting recent changes in potential variables affected by physiological changes caused by implantation of the cochlear implant electrode array; evaluating a percentage change in the detected recent physiological changes and / or the detected recent changes in potential variables; and controlling a component of the cochlear implant and / or another implanted component implanted in a person based on the evaluation.
[0008] An embodiment includes a non-transitory computer-readable medium having recorded thereon a computer program for performing at least a portion of a method, the computer program including code for statistically analyzing first data based on four-point impedance data obtained during different time periods using an implanted cochlear implant electrode array in the cochlea, and code for outputting an indication and / or a warning.
[0009] In an embodiment, there is a method comprising: obtaining a first set of intra-cochlear measurements, wherein the first set of intra-cochlear measurements represents four-point impedance measurements obtained by a cochlear implant on the day of implantation; obtaining a second set of intra-cochlear measurements, wherein the second set of intra-cochlear measurements represents four-point impedance measurements obtained by the cochlear implant on the day after implantation; comparing data based on the first set with data based on the second set; and formulating a prognosis based on the comparison and / or formulating a performance assessment based on the comparison.
[0010] In an embodiment, there is a method comprising: obtaining a first set of intra-cochlear measurements, wherein the first set of intra-cochlear measurements represents four-point impedance measurements obtained by a cochlear implant on the day of implantation; obtaining a second set of intra-cochlear measurements, wherein the second set of intra-cochlear measurements represents four-point impedance measurements obtained by the cochlear implant on the day after implantation; and determining a fitting profile of the cochlear implant based on a comparison of the first set of intra-cochlear measurements with the second set of intra-cochlear measurements.
[0011] In an embodiment, there is a system comprising an implantable portion of a cochlear implant electrode array and an external device, the implantable portion of the cochlear implant electrode array comprising a posterior telemetry circuit and a plurality of electrodes in direct or indirect signal communication with the posterior telemetry circuit, the external device being configured to be in signal communication with the implantable portion and to receive data from the implantable portion via the posterior telemetry circuit, wherein the implantable portion is configured to perform a four-point impedance measurement and provide results of the measurement to the external device via the posterior telemetry circuit, and the system being configured to evaluate the results and provide an indication of an impedance increase relative to a previous measurement, the impedance increase predicting future adverse development within the cochlea in which the electrode array is implanted. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Various embodiments are described below with reference to the accompanying drawings, in which:
[0013] Figure 1A is a perspective view of an exemplary hearing prosthesis to which at least some of the teachings detailed herein may be applied;
[0014] Figure 1B depicts a side view of a cochlear implant 100 external to a recipient;
[0015] Figure 1C Vestibular implants are depicted;
[0016] Figure 2A and 2B is a side view of an embodiment of an insertion guide for implanting a cochlear implant electrode assembly, such as the electrode assembly shown in FIG. 1 ;
[0017] Figure 3A and 3B are side and perspective views of an electrode assembly of an embodiment of an insertion sheath extending out of the insertion guide shown in FIG. 2 ;
[0018] Figures 4A-4E is a simplified side view depicting the position and orientation of a cochlear implant electrode assembly insertion guide tube relative to the cochlea at each of a series of consecutive moments during an exemplary implantation of the electrode assembly in the cochlea;
[0019] Figure 5-9 are exemplary system components of exemplary embodiments;
[0020] Fig.10 An exemplary four-point impedance measurement is depicted;
[0021] Fig.11 presents exemplary data according to some embodiments;
[0022] Figure 12-14 and 20-25 present exemplary algorithms for exemplary methods; and
[0023] Figure 15-19 Exemplary data according to some embodiments is presented. DETAILED DESCRIPTION
[0024] For ease of description only, the techniques presented herein are described herein with reference to the context of an illustrative medical device, i.e., a cochlear implant. However, it should be understood that the techniques presented herein may also be used with a variety of other medical devices that may benefit from changes in settings based on the location of the medical device while providing a wide range of therapeutic benefits to the recipient, patient, or other user. For example, the techniques presented herein may be used to determine the feasibility of various types of prostheses, such as vestibular implants, with respect to a particular human being. Unless otherwise stated, any reference to one of the above-described sensory prostheses corresponds to an alternative disclosure using one of the other above-described sensory prostheses, as long as the art is capable of doing so.
[0025] Figure 1Ais a perspective view of a cochlear implant, referred to as cochlear implant 100, implanted in a recipient, to which some of the embodiments and / or variations thereof detailed herein are applicable. In some embodiments, cochlear implant 100 is part of a system 10, which may include external components, as described in detail below. It should be noted that the teachings detailed herein also apply to so-called multi-modal devices. In exemplary embodiments, these multi-modal devices apply both electrical and acoustic stimulation to a recipient. In exemplary embodiments, these multi-modal devices evoke hearing perception via electrical hearing and bone conduction hearing. Therefore, unless otherwise indicated, or unless its disclosure is incompatible with a given device based on the current state of the art, any disclosure herein regarding one of these types of hearing prostheses corresponds to the disclosure of another of these types of hearing prostheses or any medical device for the subject matter.
[0026] In view of the above, it should be understood that at least some of the embodiments and / or variations thereof described herein relate to body-worn sensory supplemental medical devices (e.g. Figure 1A A hearing prosthesis which supplements hearing even in the absence of natural hearing ability, for example due to a deterioration of a previous natural hearing ability or due to the lack of any natural hearing ability, for example from birth).
[0027] The recipient has an outer ear 101, a middle ear 105, and an inner ear 107. The components of the outer ear 101, the middle ear 105, and the inner ear 107 are described below, and then the cochlear implant 100 is described.
[0028] In a fully functional ear, the outer ear 101 includes the auricle 110 and the ear canal 102. Sound pressure or sound waves 103 are collected by the auricle 110, directed into and through the ear canal 102. The eardrum 104, which vibrates in response to the sound waves 103, is at the distal end of the ear canal 102. This vibration is coupled to the oval or elliptical window 112 through three bones of the middle ear 105, which are collectively referred to as the ossicles 106 and include the malleus 108, the incus 109, and the stapes 111. The bones 108, 109, and 111 of the middle ear 105 serve to filter and amplify the sound waves 103, causing the oval window 112 to pivot or vibrate in response to the vibration of the eardrum 104. This vibration causes the perilymph within the cochlea 140 to generate waves of fluid motion. This fluid motion, in turn, activates tiny hair cells (not shown) inside the cochlea 140. Activation of the hair cells causes appropriate nerve impulses to be generated and transmitted via spiral ganglion cells (not shown) and the auditory nerve 114 to the brain (also not shown) where they are perceived as sound.
[0029] As shown, cochlear implant 100 includes one or more components that are temporarily or permanently implanted in a recipient's body. FIG. 1 shows cochlear implant 100 with external device 142 that (together with cochlear implant 100) is part of system 10 and is configured as described below to provide power to the cochlear implant, wherein the implanted cochlear implant includes a battery that is rechargeable via a transdermal link.
[0030] exist Figure 1A In the illustrative arrangement of FIG. 1 , the external device 142 may include a power source (not shown) disposed in the behind-the-ear (BTE) unit 126. The external device 142 also includes components of a transcutaneous energy transfer link, referred to as an external energy transfer assembly. The transcutaneous energy transfer link is used to transfer power and / or data to the cochlear implant 100. Various types of energy transfer (e.g., infrared (IR), electromagnetic, capacitive, and inductive transfer) may be used to transfer power and / or data from the external device 142 to the cochlear implant 100. In the illustrative embodiment of FIG. 1 , the external energy transfer assembly includes an external coil 130 that forms part of an inductive radio frequency (RF) communication link. The external coil 130 is typically a wire antenna coil composed of multiple turns of electrically insulated single or multiple strands of platinum or gold wire. The external device 142 also includes a magnet (not shown) positioned within the turns of the external coil 130. It should be understood that the external device shown in FIG. 1 is merely illustrative and that other external devices may be used with embodiments of the present invention.
[0031] The cochlear implant 100 includes an internal energy transfer assembly 132 that can be positioned in a recess of the temporal bone adjacent to the recipient's auricle 110. As described in detail below, the internal energy transfer assembly 132 is a component of a transcutaneous energy transfer link and receives power and / or data from an external device 142. In the illustrative embodiment, the energy transfer link includes an inductive RF link, and the internal energy transfer assembly 132 includes a primary internal coil 136. The internal coil 136 is typically a wire antenna coil composed of multiple turns of electrically insulated single or multiple strands of platinum or gold wire.
[0032] The cochlear implant 100 also includes a main implantable component 120 and an elongated electrode assembly 118. In some embodiments, the internal energy transfer assembly 132 and the main implantable component 120 are hermetically sealed within a biocompatible housing. In some embodiments, the main implantable component 120 includes an implantable microphone assembly (not shown) and a sound processing unit (not shown) to convert sound signals received by the implantable microphone in the internal energy transfer assembly 132 into data signals. That is, in some alternative embodiments, the implantable microphone assembly may be located in a separate implantable component (e.g., having its own housing assembly, etc.), which is in signal communication with the main implantable component 120 (e.g., via leads between the separate implantable component and the main implantable component 120, etc.). In at least some embodiments, the teachings detailed herein and / or variations thereof may be used with any type of implantable microphone arrangement.
[0033] The main implantable component 120 also includes a stimulator unit (also not shown) that generates electrical stimulation signals based on the data signals. The electrical stimulation signals are delivered to the recipient via the elongated electrode assembly 118.
[0034] The elongated electrode assembly 118 has a proximal end connected to the main implantable member 120 and a distal end implanted in the cochlea 140. The electrode assembly 118 extends from the main implantable member 120 through the mastoid bone 119 to the cochlea 140. In some embodiments, the electrode assembly 118 can be implanted at least in the basal region 116, and sometimes more deeply. For example, the electrode assembly 118 can extend toward the top end of the cochlea 140, known as the cochlear apex 134. In some cases, the electrode assembly 118 can be inserted into the cochlea 140 via a cochleostomy 122. In other cases, the cochleostomy can be formed through the round window 121, the oval window 112, the promontory 123, or through the top turn 147 of the cochlea 140.
[0035] The electrode assembly 118 includes a longitudinally aligned and distally extending array 146 of electrodes 148 disposed along its length. As noted, the stimulator unit generates stimulation signals that are applied by the electrodes 148 to the cochlea 140, thereby stimulating the auditory nerve 114.
[0036] Figure 1B1 is a side view of the cochlear implant 100 without other components (e.g., external components) of the system 10. The cochlear implant 100 includes a receiver / stimulator 180 and an electrode assembly or lead 118. The electrode assembly 118 includes a helix region 182, a transition region 184, a proximal region 186, and an intracochlear region 188. The proximal region 186 and the intracochlear region 188 form an electrode array assembly 190. In an exemplary embodiment, after the intracochlear region 188 is implanted in the cochlea, the proximal region 186 is located in the middle ear cavity of the recipient. Therefore, the proximal region 186 corresponds to a middle ear cavity sub-segment of the electrode array assembly 190. The electrode array assembly 190, and in particular the intracochlear region 188 of the electrode array assembly 190, supports a plurality of electrode contacts 148. These electrode contacts 148 are each connected to a corresponding conductive path, such as a wire, PCB trace, etc. (not shown), which is connected to the receiver / stimulator 180 through the lead 118, and the corresponding stimulation electrical signal of each electrode contact 148 is transmitted through the conductive path.
[0037] The electrode array 146 can be inserted into the cochlea 140 using an insertion guide. It should be noted that although the embodiments detailed herein are described in terms of using an insertion guide or other type of tool to guide the array into the cochlea, in some alternative insertion embodiments, no tool is used. Instead, the surgeon uses his or her fingertips, etc. to insert the electrode array into the cochlea. That is, in some embodiments, instead of and / or in addition to the insertion guide, an alternative type of tool can be used. By way of example only and not limitation, surgical forceps, etc. can be used. According to at least some exemplary embodiments, any device, system, and / or method for inserting an electrode array into the cochlea can be used.
[0038] Figure 1C An exemplary vestibular implant 500 is depicted according to one example. Figure 1AThe above cochlear implant of describes some specific features. In this regard, some features of the cochlear implant are used with the vestibular implant. For economy of text and graphics, the same numbers are used to refer to various elements of the vestibular implant that generally correspond to the elements of the cochlear implant described above. Nevertheless, it should be noted that some features of the vestibular implant 500 will be different from the features of the cochlear implant above. By way of example only and not by way of limitation, there may be no microphone on the behind-the-ear device 126. Alternatively, a sensor that has practical value in a vestibular implant may be included in the BTE device 126. By way of example only and not by way of limitation, a motion sensor may be located in the BTE device 126. There may also be no sound processor in the BTE device. Instead, other types of processors, such as those that process data obtained from sensors, will be present in the BTE device 126. A power source such as a battery will also be included in the BTE device 126. Consistent with the BTE device of the cochlear implant of FIG. 1, the transmitter / transceiver will be located in the BTE device or otherwise communicate signals with it.
[0039] The implantable component includes a receiver stimulator in a manner associated with the cochlear implant described above. Here, the vestibular stimulator includes a main implantable component 120 and an elongated electrode assembly 1188 (where the elongated electrode assembly 1188 has some features that are different from the elongated electrode assembly 118 of the cochlear implant, some of which will be described later). In some embodiments, the internal energy delivery assembly 132 and the main implantable component 120 are hermetically sealed within a biocompatible housing. In some embodiments, the main implantable component 120 includes a processing unit (not shown) for converting data obtained by a sensor, which can be an onboard sensor implanted in a recipient, into a data signal.
[0040] The main implantable component 120 also includes a stimulator unit (also not shown) that generates electrical stimulation signals based on the data signals. The electrical stimulation signals are delivered to the recipient via the elongated electrode assembly 1188.
[0041] It should be briefly pointed out that although Figure 1C The embodiments shown in represent a partially implantable vestibular implant, but embodiments may include a fully implantable vestibular implant, for example where the motion sensor is located in the implantable portion in a manner similar to a cochlear implant.
[0042] The elongated electrode assembly 1188 has a proximal end connected to the main implantable component 120 and extends through a hole in the mastoid 119 in a manner similar to the elongated electrode assembly 118 of a cochlear implant and includes a distal end that extends into the inner ear. In some embodiments, the distal portion of the electrode assembly 1188 includes a plurality of leads 510 that branch from the body of the electrode assembly 118 to electrodes 520. The electrodes 520 can be placed at the base of the semicircular canals, such as Figure 5 In an exemplary embodiment, one or more of these electrodes are placed near the branches of the vestibular nerve that innervate the semicircular canals. In some embodiments, the electrodes are located outside the inner ear, while in other embodiments, the electrodes are inserted into the inner ear. Note that while this embodiment does not include an electrode array located in the cochlea, in other embodiments, one or more electrodes are located in the cochlea in a manner similar to a cochlear implant.
[0043] Embodiments may include sensory prostheses that use some form of beamforming in some cases to improve, for example, hearing performance. Some embodiments utilize adaptive beamforming. This can be used to enhance signals from a particular direction (e.g., speech from the front), and / or suppress sounds from other directions (e.g., noise from the back or sides), which are typically unwanted or may otherwise obscure desired sources / noise (e.g., from the front, which may be a person speaking to the recipient of the prosthesis). In some embodiments, for devices with multiple microphones, this is accomplished by analyzing the signals received from the microphones.
[0044] The teachings detailed herein relate to identifying phenomena within the cochlea (or within the semicircular canals / vestibule—the teachings herein may be applicable to electrode arrays or electrodes that have been implanted in the semicircular canals in some scenarios—any disclosure of the cochlea, cochlear implant, or cochlear implant electrode array corresponds to alternative disclosures of the semicircular canals / vestibule, vestibular implant, or vestibular implant electrodes / electrode arrays—these are not the same—for the sake of text economy, we simply use this approach to describe these features). Some embodiments may include utilizing imaging (e.g., CT scans, X-rays, etc.), which requires the patient to be exposed to radiation during the process of obtaining medical images, and requires medical equipment in the operating room to provide and otherwise obtain imaging, as well as subsequent analysis by an expert to assess the correct insertion of the electrode holder. Some embodiments of the teachings detailed herein utilize this approach, while other embodiments specifically do not utilize this approach, but rather utilize other methods to assess or otherwise obtain information indicative of a given electrode array insertion scenario. Some embodiments include the act of measuring neuronal activation after stimulation. This exemplary embodiment may require subjective expert analysis and / or may also depend on having a good / acceptable neural response. However, in some cases, this is not always available. Again, as with the imaging described above, some embodiments herein utilize this approach while other embodiments specifically do not utilize this approach. In at least some exemplary embodiments, methods of determining insertion scenarios may utilize voltage measurements in the cochlea. In exemplary embodiments of such embodiments, interpretation of the voltage measurements obtained still requires subjective analysis by an expert. Additionally, these measurements may be more difficult to interpret than in the presence of alleged bubbles, open electrodes, shorted electrodes, and / or electrode extrusion. Some embodiments of the teachings detailed herein utilize the above-described voltage measurements in conjunction with expert analysis, while in other embodiments, some of the teachings detailed herein specifically avoid utilizing expert analysis to obtain or otherwise analyze electrode array insertion scenarios.
[0045] Some embodiments include obtaining voltage measurements from inside and / or outside the cochlea and analyzing them in an automated manner (by way of example only and not limitation) by comparing the voltage measurements to statistical data.
[0046] Figure 2A A method for converting a substantially electrode assembly 145 (corresponding to Figure 1B190) is a side view of an embodiment of an insertion guide for implanting an elongated electrode assembly represented by an implantable electrode assembly 190) into a mammalian cochlea represented by a cochlea 140. The illustrative insertion guide, referred to herein as an insertion guide 200, includes an elongated insertion guide tube 210 configured to be inserted into the cochlea 140 and having a distal end 212 from which the electrode assembly is deployed. The insertion guide tube 210 has a radially extending stop 204 that can be used to determine or otherwise control the depth of insertion of the insertion guide tube 210 into the cochlea 140.
[0047] An insertion guide tube 210 is mounted on a distal region of the elongated staging section 208 where the electrode assembly is positioned prior to implantation. A robotic arm adapter 202 is mounted to the proximal end of the staging section 208 to facilitate attachment of the guide to the robot, the adapter including through holes 203 through which bolts may be passed to bolt the guide 200 to the robotic arm, as will be described in detail below. During use, the electrode assembly 145 is advanced from the staging section 208 to the insertion guide tube 210 via a ramp 206. After the insertion guide tube 210 is inserted to an appropriate depth in the cochlea 140, the electrode assembly 145 is advanced through the guide tube to exit the distal end 212, as will be described further below.
[0048] Figure 2B An alternative embodiment of an insertion guide 200 is depicted which includes a handle 202 that is ergonomically designed to be held by a surgeon. This replaces the robotic arm adapter 202.
[0049] Figure 3A and 3B 1 and 2 are side and perspective views of a representative electrode assembly 145, respectively. As described above, the electrode assembly 145 includes an electrode array 146 of electrode contacts 148. The electrode assembly 145 is configured to place the electrode contacts 148 in close proximity to the ganglion cells in the modiolus. Such an electrode assembly (often referred to as a peri-modiolar electrode assembly) is preferably configured as follows: Figure 3A and 3B When not constrained by a stylet or insertion guide tube, the electrode assembly 145 assumes a curved configuration because it is manufactured with a curved bias so that it can conform to the curved interior of the cochlea 140. Figure 3B As shown, when not in the cochlea 140, the electrode assembly 145 generally resides in the plane 350 when returning to its curved configuration. That is, it should be noted that the embodiments of the insertion guide and / or variations thereof detailed herein can be applied to so-called straight electrode arrays that do not curl after the absence of a stylet or insertion guide tube, etc., but remain straight.
[0050] Figures 4A-4E1 is a series of side views showing sequential exemplary events that occur during an exemplary implantation of the electrode assembly 145 into the cochlea 140. Initially, the electrode assembly 145 and the insertion guide tube 310 are assembled. For example, the electrode assembly 145 is inserted (slidingly or otherwise) into the lumen of the insertion guide tube 300. The combined device is then inserted into the cochlea 140 to a predetermined depth, such as Figure 4A Typically, this introduction into the cochlea 140 is accomplished via a cochleostomy 122 ( FIG. 1 ) or through the round window 121 or the oval window 112 . Figure 4A In the exemplary implant shown, the combination of the electrode assembly 145 and the insertion guide tube 300 is inserted into approximately the base of the cochlea 140 .
[0051] like Figure 4A , the combined arrangement of the insertion guide tube 300 and the electrode assembly 145 is substantially straight. This is due in part to the rigidity of the insertion guide tube 300 relative to the biasing force applied to the inner wall of the guide tube by the pre-bent electrode assembly 145. This prevents the insertion guide tube 300 from bending or flexing in response to the force applied by the electrode assembly 145, thus enabling the electrode assembly to remain straight, as will be described in detail below.
[0052] As described, the electrode assembly 145 is biased to curl, and will curl in the absence of a force applied thereto to maintain it straight. That is, the electrode assembly 145 has a memory that enables it to adopt a curved configuration in the absence of an external force. Therefore, when the electrode assembly 145 is maintained in a straight orientation in the guide tube 300, the guide tube prevents the electrode assembly from returning to its pre-bent configuration. This causes stress in the electrode assembly 145. The pre-bent electrode assembly 145 will tend to twist in the insertion guide tube 300 to reduce the stress caused. In an embodiment configured to be implanted in the scala tympani of the cochlea, the electrode assembly 145 is pre-bent to have a radius of curvature that approximates the curvature of the inner side of the scala tympani of the cochlea. Such embodiments of the electrode assembly are referred to as a peri-modiolar electrode assembly, and this position within the cochlea 140 is generally referred to as a peri-modiolar position. In some embodiments, placing the electrode contacts at the peri-modiolar position provides specific utility with respect to electrical stimulation, and can reduce the required current level, thereby reducing power consumption.
[0053] like Figures 4B-4D As shown in , the electrode assembly 145 can be continuously advanced through the insertion guide tube 300 while the insertion sheath remains in a substantially stationary position. This causes the distal end of the electrode assembly 145 to extend from the distal end of the insertion guide tube 300. When doing so, the illustrative embodiment of the electrode assembly 145 bends or flexes due to its bending bias (memory) to obtain a position around the modiolus, such as Figures 4B-4DOnce the electrode assembly 145 is located at the desired depth in the scala tympani, the insertion guide tube 300 is removed from the cochlea 140 while the electrode assembly 145 remains in a stationary position. Figure 4E Shown in.
[0054] Conventional insertion guide tubes typically have a lumen that is sized to allow the entire conical electrode assembly to pass through the guide tube. Since the guide tube is able to receive a relatively large proximal region of the electrode assembly, there will be a gap between the relatively small distal region of the electrode assembly and the guide tube lumen wall. Such a gap allows the distal region of the electrode assembly to bend slightly until the assembly is no longer bent by the lumen wall.
[0055] Back to Figure 3A-3B The electrode assembly 145 around the modiolus is pre-bent in a direction that causes the electrode contact 148 to be located inside the bent assembly because this allows the electrode contact to face the modiolus when the electrode assembly is implanted in or near the cochlea 140. The insertion guide tube 300 maintains the electrode assembly 145 in a substantially straight configuration, thereby preventing the assembly from presenting Figure 3B The configuration shown in .
[0056] It should be noted that although the above-described embodiments disclose the use of an insertion tool, in some other embodiments, the insertion of the electrode array is not performed using an insertion tool. In addition, in some embodiments, when an insertion tool is used, the insertion tool is not as invasive as described in detail in the figures. In an exemplary embodiment, there is no distal portion of the tool. That is, the insertion tool stops at the position where the distal portion begins. In an exemplary embodiment, the tool stops at the stop 204. In this regard, the tool is almost non-invasive in the cochlea. In at least some exemplary embodiments, any device, system and / or method that can achieve insertion of the electrode array can be used.
[0057] From the above it will be appreciated that electrode arrays can be used to obtain data utilised in the methods herein, such as, by way of example only and not limitation, reading voltages at electrodes, and can also be used to provide stimulation electrodes (only in cases where this is not clear). Figure 5 An exemplary system for obtaining such information with a cochlear implant is depicted. Presented in functional terms, there is a test unit 3960 in signal communication with unit 8310 (which is optionally in signal communication with unit 7720 and unit 8320), details of which will be described below.
[0058] Unit 3960 may correspond to an implantable component of an electrode array, as seen in FIG1 . More specifically, Figure 6An exemplary high-level diagram of a receiver / stimulator 8710 (implantable portion of 100) of a cochlear implant looking downward is depicted. As can be seen, the receiver / stimulator 8710 includes a magnet 160 surrounded by a coil 137, which is in bidirectional communication with a stimulator unit 122 (although in other embodiments, the communication is unidirectional), which in turn communicates with an electrode array 145. The receiver / stimulator 8710 also includes a cochlear stimulator unit 122 in signal communication with the coil 137. The coil 137 and the stimulator unit 122 are encapsulated in silicon represented by element 199. In an exemplary embodiment, the receiver / stimulator 8710 is used as a test unit 3960 and is used to collect information about the position of the electrode array.
[0059] Figure 8 An exemplary RS (receiver / stimulator) interface 7444 is depicted, presented in a conceptual manner. The inductive coil 7410 is configured to establish a magnetic inductive field to communicate with a corresponding coil of a receiver-stimulator of a cochlear implant. The interface 7444 includes a magnet 7474 to hold the inductive coil 7410 against the coil of the receiver / stimulator of the cochlear implant in a manner similar to how an external component of a cochlear implant is held against an implanted component and how the coils of these corresponding components are aligned with each other. As can be seen, electrical leads extend from the coil 7410 to the control unit 8310, indicating signal communication between the interface 7444 and the control unit 8310. It should be noted that in alternative embodiments, 7444 can be an external component of FIG. 1 and can have some and / or all of the functionality just described, so that data can be obtained from the implanted portion outside of a clinical environment (e.g., during the recipient's daily life).
[0060] Fig. 9 An exemplary embodiment of a receiver / stimulator 8710 is depicted in signal communication with a control unit 8310 via electrical leads extending from an interface device 7444 having a coil 7410 surrounding a magnet 7474, as can be seen. The interface device 7444 communicates with the inductive coil of the receiver / stimulator 8710 via an inductive field so that data acquired by the implantable component 8710 (receiver / stimulator) can be transmitted to the control unit 8310.
[0061] Note also that in at least some alternative exemplary embodiments, the control unit 8310 may communicate with a so-called "hard ball" reference electrode of an implantable component of the cochlear implant to enable data to be transmitted from the receiver / stimulator 8710 to the control unit 8310 and / or vice versa.
[0062] It should be noted that Fig. 9 In the embodiment of the present invention, the control unit 8310 is in signal communication with various other components as described in detail herein, for the sake of clarity, Fig. 9The other components are not shown.
[0063] exist Figure 5 7700 and an input device 8320 are included in the system. In an exemplary embodiment, the input device 8320 can be a trigger of a handheld device that controls the actuator system 7720 and can stop and / or start the actuator to insert the electrode array. In an exemplary embodiment, the input device 8320 can be a trigger on the tool 8200.
[0064] The control unit 8310 may be a signal processor, etc., or a personal computer, etc., or a mainframe computer, etc., configured to receive signals from the test unit 3960 and analyze these signals to evaluate the data obtained (which may also be used to control the implant / control the application of current). More specifically, the control unit 8310 may be configured with software, etc. to analyze the signals from the test unit 3960 in real time and / or near real time as the electrode array is advanced into the cochlea by the actuator assembly 7720 (if present, and if not present, when the array is manually inserted / advanced). The control unit 8310 analyzes the input from the test unit 3960 after partial and / or complete implantation and / or after the surgery is completed and / or when the electrode array is advanced by the actuator assembly 7720 and / or when the electrode array is manually advanced by the surgeon. The controller / control unit may be programmed to also control stimulation / control the provision of current to the electrodes during the above events / situations. The controller 8310 may evaluate the input to determine if there is a phenomenon according to the teachings detailed herein. The controller may evaluate telemetry data from the implant via a device communicating with the implant or otherwise receive telemetry data from the implant. Figure 7 As shown in, or in addition to, the controller 8310 can output signals indicating the data obtained and / or indicating the conclusions reached by the control unit 8310 to an optional monitor 9876 or other output device (e.g., a buzzer, a light, etc.), which can provide the surgeon or other healthcare professional with data on the performance of the surgery or postoperative evaluation, etc. It should also be noted that in exemplary embodiments, the control unit 8310 can be a dumb unit in the sense that it only transmits signals to the implant (e.g., the control unit can instead be a series of buttons, for example, where the surgeon presses one button to provide stimulation to a given electrode). The control unit 8310 can be an external component of the cochlear implant.
[0065] Still, in some embodiments, the control unit 8310 is configured or otherwise programmed to evaluate the input and determine whether the input indicates that the electrode array is positioned in a given manner, that the electrode array is positioned in a manner different from that desired, or otherwise determine any of the features detailed herein. In an exemplary embodiment, upon such determination, the control unit 8310 may stop the array from advancing into the cochlea by stopping the actuator(s) of the actuator assembly 7720, and / or may slow the actuator(s) so as to slow the rate at which the electrode array is advanced into the cochlea, and / or may reverse the actuator(s) so as to reverse or otherwise retract the electrode array (partially or completely) within the cochlea. Alternatively, in embodiments where the actuator assembly 7720 is not present, the control unit 8310 may provide an indication to a surgeon, etc. (via an integrated component, such as a buzzer or light on the control unit, or an LDC screen, or via device 9876) to stop and / or slow down insertion, etc. In at least some exemplary embodiments, the control unit 8310 can be configured to override input from the input unit 8320 input by a surgeon or user.
[0066] Some exemplary embodiments use the receiver / stimulator 8710 as a test unit 3910, which is capable of performing the actions of obtaining data and providing current to the electrodes, and / or any one or more of the method actions detailed herein. In exemplary embodiments, the receiver / stimulator 8710 and / or the control unit 3810 and / or the actuator assembly 7720 and / or the input device 8320 are variously used to perform one or more or all of the method actions detailed herein, either alone or in combination with external components of the cochlear implant and / or with an interface 7444, which can be used after the receiver / stimulator 8710 is fully implanted in the recipient and the incision in which it is implanted has been closed (e.g., days, weeks, months, or years after the initial implantation surgery). The interface 7444 can be used to control the receiver / stimulator to perform at least some of the method actions detailed herein (while in some other embodiments, the receiver / stimulator can perform such method actions in an autonomous or semi-autonomous manner without communicating with external components), and / or can be used to obtain data from the receiver / stimulator after performing such method actions.
[0067] We will now describe Figure 5-9 Some exemplary applications of embodiments and some modifications thereto.
[0068] In view of the above, some embodiments include obtaining electrode voltage measurements along an electrode array inserted into the cochlea using, for example, one or more of the systems described in detail above and / or below. Some embodiments also include analysis of the electrode voltages, for example, by the systems described in detail above, such as automatic analysis and / or semi-automatic analysis, to determine one or more features herein / practice one or more method actions herein. Embodiments disclosed herein as using four-point impedance measurements include using one or more of the above-described devices to perform such measurements and transmit the results to an external and / or clinician or other healthcare professional. Any disclosure herein of implementing impedance testing includes disclosure of any one or more of the above-described devices and functions of the above-described devices. And in some embodiments, the above-described devices are configured to perform one or more of the method actions herein.
[0069] Bipolar stimulation of a cochlear implant generates dipoles within the cochlea, for example where two electrodes of an electrode array implanted in the cochlea or otherwise in the cochlea act as a source and a sink, respectively, when performing bipolar stimulation. The amount of current flowing out of the current source is at least effectively equal to (including equal to) the current flowing back into the current source, in some embodiments where the source and sink are located in the cochlea, and the perilymph immerses both the source and the sink in a continuous manner. In at least some exemplary embodiments, the cochlear implant electrode array 146 provides stimulation to the tissue using the current source and sink established by the two electrodes of the electrode array. In exemplary embodiments, the current source provides sufficient current into the recipient's tissue to evoke hearing perception. In some embodiments according to the teachings detailed herein, regardless of whether hearing perception is performed, although some embodiments apply a current that produces a current flow within the cochlea, where hearing perception is not induced and / or the threshold level at a given frequency for the recipient is higher than the current utilized, while in other embodiments, hearing perception is induced, the current flow generated by the stimulation electrode will flow according to the impedance within the cochlea.
[0070] Fig.10 An exemplary conceptual diagram of current flow between sources and sinks of an intracochlear electrode array is shown. Thus, if the relative voltage is measured between ICE6 (ICE is an intracochlear electrode—as distinguished from electrodes that are not in the cochlea, at least not in the cochlea when the measurement is performed) and ICE7, where electrodes 5 and 8 (ICE electrodes 5 and 8) are stimulation electrodes (source and sink), then in some exemplary scenarios, the voltage difference will be a certain value relative to the cochlea where blood is not present and another value (in at least some cases, a higher value) where blood is present in the cochlea. Thus, Fig.10 A 4-point impedance measurement scheme is depicted. By using such a measurement scheme, the differences between the 4-point (volume) measurements due to different biological media can be detected and used for practical value.
[0071] Embodiments include multi-contact cochlear electrode arrays (such as those detailed above), implants with extra-cochlear electrodes (or another component, such as a component that works with the implanted portion of a cochlear implant), receiver stimulators (such as receiver stimulators of the implanted portion), which can be fully implanted or powered by an external behind-the-ear (BTE) processor or other external device. The implanted portion can include a built-in amplifier that is configured to measure electrode voltages while delivering current to the same or adjacent electrode contacts.
[0072] In some cases, a method is performed whereby an implanted portion of a cochlear implant (e.g., a receiver stimulator) or another device (e.g., the control unit described in detail above) coordinates measurement of electrode voltages in response to electrical stimulation of one or more contacts so that a measure of body impedance between two electrode contacts can be estimated. In some embodiments, the body impedance is calculated for multiple locations along the electrode array. These measurements can be repeated continuously over time during insertion of the electrode array or after insertion (either during or after surgery) when the electrode array is stationary in place.
[0073] The method also includes detection and analysis, wherein, in some embodiments, the system or external device (e.g., BTE or computer / control unit) analyzes the impedance / measured voltage along the array (at one or more or all possible locations) to determine one or more characteristics determined below.
[0074] Fig.11 An exemplary graph depicting the impedance between read electrodes is shown. The graph depicts the impedance between two electrodes, where the number represents the electrode with the lower number (i.e., 2 represents read electrode pair 2 and 3, 20 represents read electrode pair 20 and 21, etc.). This number is called the base electrode (for no reason other than to establish a standard - if the base electrode was the higher number, the graph would start with 3 and end with 21, but the data would be the same). This could be an example of an impedance measurement taken at implant. For example, Fig.11 Can represent measurements taken immediately after electrode insertion in the operating room and / or measurements taken over a period of time less than 10 minutes (e.g., less than 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 minutes) after initial insertion of the electrode array.
[0075] Embodiments include using one or more sets of impedance measurements taken at specific time locations and / or separate time intervals as potential variables to identify or at least determine the plausibility of one or more adverse scenarios that have occurred and / or will occur within the cochlea due to the insertion of a cochlear implant electrode array in the cochlea, and initiating treatment based on the impedance measurements. In some embodiments, the impedance increase is present over a 24-hour period, but the period may be different in other embodiments, as will be described in further detail below. Embodiments include utilizing impedance measurements to detect biomarkers (again, in some embodiments by way of potential variables) that indicate changes within the cochlea that will cause the impedance between the electrodes of the cochlear implant to increase downrange in time, the impedance increase (if allowed to occur) being high enough that the increase will have a detrimental effect on the operation of the cochlear implant (e.g., requiring an increase in the power of the implant to evoke the same hearing perception as would be the case without the increase - in embodiments, the impedance increase may cause the load on the cochlear implant to increase by at least 10, 15, 20, 25, or 30% above that of other conditions all other things being equal, or any value or range of values in 1% increments therebetween). Embodiments also include using impedance measurements to determine impedance between at least two electrodes (in some embodiments, electrodes that are in close proximity to each other) and predict potential vertigo caused by implantation of the electrode array. More on this below.
[0076] In some embodiments, the foreign body reaction after cochlear implantation depends on several factors, including but not limited to intracochlear damage and surgical approach during electrode array insertion. Electrode array insertion may be a source of physical trauma to the cochlea. Exemplary physical trauma may be fractures of the bony spiral plate and displacement of the basilar membrane for the electrode array around the modiolus. Some embodiments herein include experiencing this during implantation of the electrode array, wherein the experience causes or at least produces a cascade of reactions that ultimately lead to the detected impedance difference. These traumas can trigger cell death pathways (e.g., necrosis), which can lead to a range of increases in impedance, making the cochlear implant more difficult to operate. These traumas may occur in some embodiments, and treatments herein that eliminate impedance differences may limit the severity and / or prevent this. This may be a passive cell death mechanism triggered by substantial physical trauma to the cells. Necrotic cell death involves cell swelling that leads to cell lysis, in which the intracellular contents are released into the perilymphatic space and cause a widespread acute inflammatory response. (In some embodiments, this may occur, and the teachings herein may include limiting and / or preventing this.) This involves an influx of inflammatory cells and repair cells (e.g., macrophages, leukocytes, and neutrophils) into the cochlea. In some embodiments, this influx can cause an increase in impedance over a period of about a day, and thus the increase in impedance can be an indication that this has occurred, and thus the increase in impedance can be an indication that treatment should be initiated. Necrosis-induced sensory cell death can occur after cochlear implantation, leading to hearing loss. Embodiments are directed to reducing and / or limiting this from occurring.
[0077] Following this hearing loss, further hearing loss may occur after cochlear implantation, for example up to 7 days after implantation, and embodiments are directed to limiting and / or avoiding this scenario. This hearing loss may occur even in the absence of physical trauma to the macroscopic elements of the cochlea. Embodiments include implementing the teachings herein in a cochlea without physical trauma to the macroscopic elements.
[0078] In some scenarios, there may be oxidative stress in the cochlear cells after electrode insertion, which may cause apoptosis of damaged hair cells and trigger an acute inflammatory response. At 12, 24 and 36 hours after implantation, hair cell death via apoptosis may gradually increase. Therefore, molecular damage may be caused by electrode insertion rather than a direct result of physical trauma. Potential causes of this damage include hydraulic trauma during electrode insertion, whereby changes in periosteal volume are associated with the severity of hearing loss. In addition, peri-modiolar implants are sometimes used with an outer sheath (as described above) to help place the array in the cochlea. Insertion of the sheath may cause large intra-cochlear pressure changes, which may be traumatic. All of these scenarios may occur in some embodiments of implanting a cochlear implant. Embodiments include using impedance measurements as potential variables to identify one or more of the above events, or at least indicate that one or more of the above events may occur, and thus initiate treatment.
[0079] The method includes stimulating one or more electrodes of a cochlear electrode array to induce current in the cochlea at multiple time locations, thereby performing a four-point impedance measurement. By way of example only and not limitation, in an exemplary embodiment, this may include stimulating electrodes 9 and / or 12 (where 9 and 12 are alternately used as source and sink when both are stimulated). Other electrodes (one or more) may be stimulated. In some exemplary embodiments, the electrode that is stimulated is the electrode that is as far as practical before the bottom turn (remember that it may be practical to have a reading electrode before the bottom turn). Any stimulation scheme that can implement the teachings detailed herein may be utilized in at least some exemplary embodiments. Further note that the implementation of the four-point impedance may include stimulating different pairs of electrodes in a temporally spaced manner, but where in general, the stimulation corresponds to a single time location.
[0080] Four-point impedance may include measuring one or more electrical characteristics at one or more locations in the cochlea resulting from the induced current at a plurality of different temporal locations.
[0081] In an embodiment, the impedance measurement for the first time location is for a fully positioned electrode array / after the electrode is fully inserted into the cochlea.
[0082] In an exemplary embodiment, the measurement electrodes utilized are those located before and / or at and / or near the bottom loop, and the other electrodes are not utilized, at least not effectively utilized (perhaps in some cases, all electrodes are utilized, but most of the data collection is based only on those electrodes before that location). In an exemplary embodiment, more than 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% of the data collected and / or utilized to perform one or more of the method actions herein comes from electrodes at and / or before the bottom loop.
[0083] In an exemplary embodiment, electrodes used as reading electrodes and / or excitation electrodes and / or electrodes used as reading electrodes in the method actions herein regarding evaluating impedance detailed herein (e.g., values can be obtained for all of more than these electrodes, but analysis of the transimpedance data is limited to data from these electrodes) and / or electrodes used herein for performing comparison / evaluation fall within a distance of no less than 0.5, 0.75, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 millimeters from a line intercepted by a tangent perpendicular to the beginning of the first base turn at the lateral wall (and therefore between the most proximal portion of the cochlea and that line). In embodiments, the electrodes used for comparison / evaluation herein / the electrodes from which data is used for comparison / evaluation are located no more than 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17 mm (as measured along the length of the array) from the proximal portion of the cochlea where the electrode array enters the cochlea and / or no less than 2, 3, 4, 5, 6, 7, 8, 9 or 10 mm from that location.
[0084] Fig.12An exemplary flow chart of an exemplary method (method 1200) according to an exemplary embodiment is presented. Method 1200 includes method action 1210, which includes obtaining data based on impedance values in the cochlea of a person at a first time position and a second time position after the first time position. In an embodiment, the first time position and the second time position are separated by less than 30 hours and greater than 12 hours. In an embodiment, the first time position and the second time position are separated by at least (including) 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45 or 50 hours, or any value or range of values therebetween in increments of 0.1 hours (e.g., 20.3 hours, 33.1 hours, 22.3 to 25.4 hours, etc.). In an embodiment, the interval between the first time position and the second time position is no more than (inclusive of) 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45, 50, 55, 60, 65 or 70 hours, or any value or range of values therebetween in increments of 0.1 hour (e.g., 15.3 hours, 28.1 hours, 20.7 to 28.8 hours, etc.).
[0085] In an exemplary embodiment, the act of obtaining data based on impedance values within a person's cochlea may include actually operating a cochlear implant electrode array using four-point impedance measurements. In an exemplary embodiment, the act of obtaining data based on impedance values within a person's cochlea may include receiving values from a third party, such as from a hospital remote from a data center or remote from a clinician or inner ear specialist viewing the data (and thus performing the method). Thus, the data based on impedance values may be impedance values, or may be a data set compiled based on impedance values or data compiled based on data compiled based on impedance values.
[0086] In an exemplary embodiment, the data may include impedance values for all or some of the read electrodes at a first time position. The data may include impedance values for all or some of the read electrodes at a second time position. It should be noted that the impedance values for all read electrodes are not necessarily present in the data set. In fact, in an exemplary embodiment, the data set at the first time position may or may not have one or more impedance values for one or more read electrodes, while the data set at the second time position may have one or more of these impedance values for the read electrodes. That is, as long as the data obtained can implement the teachings detailed herein, the data sets are not necessarily exhaustive or otherwise identical.
[0087] In an exemplary embodiment, the data obtained may be an average of the impedance of all or some of the read electrodes (some embodiments focus only on the substrate electrode - more on this below). In an embodiment, the data obtained may be the raw impedance of each read electrode. The data obtained may be a combination of the two. The data obtained need not necessarily be obtained at the time the impedance value is measured. That is, method act 1210 may occur hours or even days after the first time location and the second time location.
[0088] Method 1200 includes method action 1220, which includes an action of evaluating the acquired data. And the acquired data may be more than the data used in the actions of comparing or evaluating, etc. This does not require evaluating all acquired data, but some embodiments will include evaluating all acquired data.
[0089] In an embodiment, this may entail comparing the average of the impedance of the impedance values within the cochlea of the person at the first time location with the average of the impedance obtained at the second time location. In an embodiment, instead of the average value, the median value may be utilized. Even more complex statistical analysis / comparison may be utilized in method action 1220 (or the data in method action 1210 may be the result of such an analysis of the values at the first time location and the second time location, provided that the data can be evaluated).
[0090] In an embodiment, the act of evaluating the obtained data in method act 1220 may include comparing the obtained data to determine whether the average of the impedance values at the first time location is greater than, less than, or statistically equal to the average of the impedance values at the second time location. As will be described in more detail below, as a result of the work of the inventors, it has been determined that a certain amount of impedance difference between two time locations (e.g., locations separated by the time period detailed above) can indicate future harmful effects within the cochlea. Additional features of this will be described in more detail below. Currently, it has been determined that an increase of 10% or more in the average impedance value indicates a high probability that future changes to the cochlea will occur, which will result in an increase in impedance within the cochlea (e.g., relative to the environment present when the electrode array is implanted), which will have a harmful effect on the operation of the cochlear implant and / or may result in a loss of some or all residual hearing of the recipient.
[0091] In an embodiment, in addition to data based on impedance values, the act of evaluating the obtained data can also be based on statistical data. By way of example only and not limitation, the act of evaluating the obtained data can take into account the age and / or gender of the recipient. By way of example only and not limitation, a 5% increase in the average impedance value may indicate a need for therapeutic intervention, or there may be practical value in implementing a therapeutic intervention for an age group under 50 years old, while such an increase may not indicate a need for therapeutic intervention, or there may be practical value in implementing a therapeutic intervention for an age group over 50 years old. Statistical data for such statistical groups can be compiled to further refine the act of evaluating the obtained data.
[0092] And this leads to method action 1230, which includes an action of implementing treatment based on the evaluation. Here, if the average impedance value increase determined in method action 1220 shows, for example, an increase of 12% over a 24-hour period, a treatment regimen based on applying, for example, steroids to the recipient can be implemented. In an exemplary embodiment, the treatment regimen is a treatment regimen that is statistically likely to produce harmful effects that may exceed the beneficial effects. For example, steroids and thrombolytics are not routinely prescribed after every cochlear implant surgery due to potential side effects. Here, based on the evaluation of the obtained data, it can be predicted that certain negative effects may occur in the absence of treatment, where the probability of such negative effects is high enough to exceed the negative effects of implementing the treatment. In other words, method actions 1210 and 1220 provide a method for systematically prescribing further treatment at a reasonable risk. These method actions also provide a method for locally prescribing further treatment, such as some controlled release systems in the implant, or middle ear interventions as examples and not limitations. And note that these are just a few examples of the types of prescription interventions that can be used. Additional prescription interventions will be described in more detail below in a non-exhaustive manner. The point here is that by obtaining impedance values within / over a specific period of time and applying statistical analysis to them, a risk balance assessment can be performed that will allow therapies to be applied ethically (ranging from the casual prescribing of drugs / implementation of therapies to the concept of defensive medicine) and / or otherwise less blindly than otherwise.
[0093] It should be briefly noted that while many of the methods herein propose implementing treatments based on evaluation / comparison of data from four-point impedance, in addition or as an alternative thereto, embodiments may also include recommending treatment / prescribing treatments based on comparison / evaluation and / or controlling a medical device (e.g., an implantable medical device) and / or formulating and / or providing a prognosis / performing a prognostic action. For the purpose of text economy, unless otherwise stated, any disclosure of one item herein corresponds to an alternative disclosure of any one or more items of the other items, as long as the art is capable of doing so.
[0094] Thus, it can be seen that in embodiments of method 1200, the evaluation of the acquired data indicates an increase in impedance value from a first time location to a second time location, and the action of administering treatment is an action that would not be performed if the evaluation did not indicate an increase. And in some embodiments, the increase must be above / at a certain level, which level may vary depending on the statistical classification into which the person / recipient falls.
[0095] In an embodiment, the data obtained indicates that the impedance value (e.g., the average impedance value), at least some impedance values of interest (e.g., the value of the reading electrode before the bottom gyrus or the reading electrode detailed herein, etc.) increased by at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15% or more, or any value or range of values in 0.1% increments therebetween, and the value may vary depending on the recipient's statistical background (age, race, gender, degree of hearing loss, by way of example only and not limitation). For example, a recipient with total hearing loss may be set to a level of 7.5% increase, while a recipient with residual hearing may be set to 5%. The idea here is that the recipient may have all of the hair cells in his or her cochlea in a dead state, so the introduction of the cochlear implant electrode array is unlikely to cause a response that will cause the impedance to increase within the above time period, so any such increase should be evaluated more cautiously than in the case of a person with residual hearing, where a higher level of increase in impedance values can be expected (all without the deleterious effects of the downward arrangement on the ultimate increase in impedance within the cochlea). For clarity, in an exemplary embodiment, if the data obtained indicates that the impedance value increases by any of the above values (which are selected according to the embodiment), then the treatment will be implemented, and if the data obtained indicates that the impedance increase is less than any of the above values, then the treatment will not be implemented. Alternatively, in an embodiment, the magnitude of the treatment can vary according to a percentage change, as will be described in detail below.
[0096] Still, as will be described in detail below, studies have shown that an increase of at least 10% in the average impedance value from a first time position to a second time position is responsible for achieving one or more of the therapeutic treatments detailed herein or other therapeutic treatments when considering at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 or 80% of the reading electrodes (values from these reading electrodes, again, some reading electrodes will not be used for various reasons) or any value or range of values in 1% increments therebetween.
[0097] As described above, in some embodiments, the first time position and the second time position are spaced no more than 36 hours.For convenience, at least the first time period and the second time period should be spaced for example 24 hours (for example, plus or minus 1 or 2 or 3 or 4 hours), or the second position should occur before the end of the standard business hours of a day after the first time position.Therefore, in theory, if the first time position is present at, for example, 9 am on Monday, and the second position is present at 5 pm on the following Tuesday, then the time difference will be 32 hours.In an embodiment, the time interval can be later (for example, 10:00 pm on the following Tuesday, after the hospital changes to the evening shift).Embodiment can include such scene, wherein if the first time position is present at, for example, 7 pm on Monday, the second time position can be present at, for example, 7 am on the following Wednesday, so the two time positions will be spaced for a whole day.
[0098] In an embodiment, the first time location and the second time location are separated by no more than 36 hours, 48 hours, 60 hours, and in some embodiments, no more than 72 hours.
[0099] In the embodiments, Fig.10 and 11In accordance with the discussion of the invention, impedance values within the cochlea at a first time location and a second time location are obtained using a cochlear implant electrode array implanted in a person (or in the process of being implanted in a person). In an embodiment, the first time location occurs during or shortly after the completion of the surgery to implant the electrode array into the cochlea, and occurs on the same day of the surgery. In this regard, some embodiments include performing a four-point impedance measurement before "closing" the incision in the skin to enter the implant site. In some embodiments, the four-point impedance measurement is performed shortly after the incision in the skin is closed, for example within 20 or 15 or 10 or 5 minutes thereafter. In fact, in an exemplary embodiment, the four-point impedance measurement is performed within 120, 90, 60 or 50 or 40 or 30 or 20 or 10 or 5 minutes of the electrode array first entering the cochlea, or any value or range of values in 1 minute increments therebetween and / or starting from the completion of a "packing" exercise (where tissue or another substance is packed around the cochlear implant electrode array at the opening into the cochlea to establish a barrier). In an embodiment, the measurement is performed while the recipient is in the recovery room on the day of surgery. In some embodiments, the measurements are taken while the recipient is anesthetized, because the skin over the implant site may be "painful" (embodiments may use external components of the cochlear implant, or external components that interface with the implant as detailed above, which will involve skin contact over the implant and may not be as pleasant, as well as some of the time ranges mentioned above). In fact, the recipient may only feel irritated after being weaned from anesthesia, and may not want anything (or anyone) to touch his or her head for psychological reasons. A corollary to this is that in some embodiments, the first time position may exist when the recipient first goes to sleep after he or she is weaned from anesthesia (and note that all of the above time ranges are relative to the first time position). The first time position may be just the position where the recipient allows someone to place the external component on his or her head, at least without pain or with acceptable sensitivity. Therefore, in some embodiments, the first time position may exist within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 hours of the electrode array first entering the cochlea, but embodiments should be practiced with the first time period as close to the first entry time as reasonably possible.
[0100] However, as seen above, there is a time correlation between the first time position and implanting the array into the cochlea. In at least some exemplary embodiments, the first time position is the "same day" as implanting the electrode array into the cochlea. In at least some exemplary embodiments, the first time position should not extend to the next day (calendar day) after implantation, but of course this can vary depending on the time of surgery, where for example a surgery at 9pm may well ensure that the first time position is on the next day / day, so the above time period is measured from the first time the array enters the cochlea.
[0101] Thus, in some embodiments, the first time position may exist within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 hours of the electrode array first entering the cochlea, but embodiments should be practiced with the first time period as close to the first entry time as reasonably possible.
[0102] Still, embodiments may include scenarios in which the first time period is before the surgery is completed or just after the surgery is completed, or at least before the patient is removed from the operating room and / or before the patient is moved to a more permanent recovery room (as opposed to an intermediate room where additional postoperative actions can be taken without occupying the operating room).
[0103] In an embodiment, the first temporal location may be between final electrode array placement in the cochlea and leaving the operating room.
[0104] In an exemplary embodiment, impedance values within the cochlea are obtained using a cochlear implant electrode array at a first time location and a second time location, the first time location being an intraoperative time location relative to implantation of the cochlear implant electrode array, and the second time location being the intraoperative time location plus one day.
[0105] Also note that there may be a time difference between the act of obtaining data based on the impedance value and the act of acquiring the impedance value. This is because method act 1210 may be performed by a different person, or may occur after the act of actually performing the four-point impedance to obtain the actual impedance value on which the data obtained in method act 1210 is based.
[0106] In embodiments, the treatment performed by method act 1230 is to perform an optional cleavage of a prodrug previously provided to the cochlea. In embodiments, the prodrug may have already been placed in the cochlea (e.g., co-located with the electrode array, and thus implanted in the cochlea during insertion of the array), and then activated when method act 1230 is performed. Alternatively, there is a substance that has already been cleaved in the cochlea (again, e.g., co-located with the electrode array), and then the act of method act 1230 is to provide the prodrug systemically.
[0107] In embodiments, method 1200 further comprises the following method actions: obtaining additional data based on impedance values within the cochlea at a third time location at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16 weeks or more after the second time location (e.g., by performing four-point impedance using an electrode array in the implanted cochlea) and evaluating the obtained additional data, and continuing, suspending, and / or adjusting implant therapy based on the evaluation of the additional data. In embodiments, the average impedance value decreases, for example, by 3, 4, 5, 6, 7, 7, 8, 10, 11, 12, 13, 14, or 15%, or any value or range of values therebetween in increments of 0.1%. In embodiments, the method comprises continuing and / or increasing the level of therapeutic treatment even if there is a decrease.
[0108] In an embodiment, the treatment performed includes prescribing one or more of a systemic steroid, an anticoagulant, a thrombolytic, an antifibrotic, an antiproliferative, or an NSAID. As will be described in more detail below, in at least some embodiments, the implant is configured to deliver a therapeutic substance to the inner ear of the recipient, and the treatment performed by method action 1230 can change the amount of therapeutic substance delivered and / or the rate at which the therapeutic substance is delivered. For example, the volume or concentration of the liquid therapeutic substance in the implant can be adjusted to control its release rate by osmosis or diffusion.
[0109] Fig.13 Another exemplary algorithm for the exemplary method (method 1300 ) is shown. Method 1300 includes method act 1310, which includes an act of obtaining first data based on a first impedance value obtained using a cochlear implant electrode array positioned in the cochlea of a person, wherein the impedance value is a value of impedance present in the cochlea within X hours of the electrode array first being placed in the cochlea (or within X hours from final placement of the cochlea or within X hours from the end of a closure procedure, or within X hours from the time the recipient leaves a surgical room), where X can be 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.25, 1.5, 1.75, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, or 18 or more, or any value or range of values therebetween in increments of 0.1.
[0110] Method 1300 includes method action 1320, which includes obtaining second data based on a second impedance value obtained with the cochlear implant electrode array still located in the cochlea of the person, wherein the second impedance value is for the impedance present within the cochlea at least Y hours (or any other time mark described above) after the electrode array is first placed into the cochlea, wherein Y can be 4, 4.5, 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39 or 40 or more, or any value or range of values therebetween in increments of 0.1. In an embodiment, Y does not exceed 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 41, 42, 43, 44 or 45 or more, or any value or range of values therebetween in increments of 0.1.
[0111] Method 1300 also includes method act 1330, which includes an act of administering the treatment and / or increasing the aggressiveness of the treatment only when the second impedance value is greater than the first impedance value.
[0112] In an embodiment, the treatment administered is a treatment that may have a deleterious effect on a human being, and an increase in the aggressiveness of the treatment may have a deleterious effect on a human being. In an embodiment, the first impedance value and the second impedance value obtained using a cochlear implant electrode array are obtained using a four-point impedance technique. In an embodiment, the first impedance value is an impedance value that exists within 6, 5, 4, 3, 2, or 1 hour of the electrode array first entering the cochlea, consistent with the above teachings, and the second impedance value is an impedance value that exists more than 18 hours and less than 30 hours since the electrode array first entered the cochlea, again consistent with the above teachings.
[0113] In an embodiment, the first impedance value and the second impedance value obtained using the cochlear implant electrode array are mainly affected by the environment around and / or near the electrodes used to measure the first impedance value and the second impedance value or otherwise within the cochlea.
[0114] In embodiments, the treatment that is administered is a treatment for a disease that is symptom-free when administered, and the treatment whose aggressiveness is increased is a treatment for a disease that is symptom-free when increased. In some embodiments, method 1300 further includes an act of normalizing the first data to account for changes in the impedance measurements that may statistically dissipate over time.
[0115] As described above, it is not necessary to use all impedance values, or more accurately, it is not necessary to use all reading electrodes or data therefrom. In an embodiment, the first impedance value is the impedance value of Z of the first 3, 4, 5, 6, 7, 8, 9 or 10 reading electrodes of the electrode array or any value or range of values therebetween in increments of 1, the first of the number of electrodes being the most basal electrode, where Z can be 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 or any value or range of values therebetween, and 1, 2, 3, 4 or 5 reading electrodes can be read starting from the first one. In addition, the second impedance value is the impedance value of any one or more or all of these electrodes (they do not need to be the same and can have the same constraints just detailed). In some embodiments, the first impedance value is the impedance value of Z of the first number of reading electrodes of the electrode array, the first of the first number of electrodes being the most basal electrode, and the first number of reading electrodes being located in the basal portion of the cochlea, and the second impedance value is the impedance value of the first number of reading electrodes or any one or more or all of the Z of the first number. Also note that the second impedance value may include other read electrodes not used for the first impedance value (eg, to compensate for extraneous data points or faulty electrodes).
[0116] In some embodiments, values from one or more read electrodes may be disregarded or otherwise ignored, for example when the values appear to be irrelevant or otherwise anomalous. In fact, as described above, embodiments include normalizing or otherwise statistically adjusting the first data. The second data may also be normalized or otherwise statistically adjusted.
[0117] In some embodiments, the first impedance and / or the second impedance may be obtained using any one or more of the following reading electrodes, starting with the most basal reading electrode (as distinct from the most basal electrode which may not be a reading electrode) (and they need not be the same but may be): reading electrodes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 and / or 30 (currently, the industry uses a total of up to 22 intracochlear electrodes on most cochlear implant electrode arrays, but embodiments may use a wider number of electrodes on the array).
[0118] In an embodiment, the first impedance value is the impedance value of all or a subset of a first number of reading electrodes of the electrode array, a first of the first number of electrodes being the most basal electrode, and the first number of reading electrodes subtending at least 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 3 In some embodiments, the second impedance value is an angle of no more than 100, 310, 320, or 330 degrees, or any value or range of values in 1 degree increments therebetween, and in some embodiments, no more than 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, or 360 degrees, or any value or range of values in 1 degree increments therebetween, within the cochlea. In embodiments, the second impedance value is the impedance value of all or a subset or another subset of the first number of read electrodes.
[0119] In an embodiment, the bottom-most first, second, third, fourth, fifth, sixth and / or seventh reading electrodes (eg, reading electrodes 1, 2, 3; 1, 2 and 5; or 1 and 6) are excluded from the electrodes for the first value and / or the second value.
[0120] There may be scenarios where impedance rise occurs that are different from impedance rise caused by physiological changes that cause impedance increase 2, 3 or 4 months later (which may be the result of an immune response), and may be the result of a broad response or otherwise caused by factors different from those factors that the teachings herein rely on in some embodiments. For example, significant trauma that causes blood to enter the cochlea and may cause impedance rise (local or global). In addition, impedance rise in the cochlea may be the result of an overall body reaction, such as an allergic reaction in the inner ear before and after implant surgery. And the rise may be broad-based, affecting the entire cochlea, or at least a large part of the cochlea, or at least a large part of the cochlea relative to the electrode.
[0121] In view of this, embodiments include distinguishing between impedance values (including impedance increases) resulting from these other scenarios (or at least scenarios that are not the result of the physiological changes in the cochlea described in detail herein) and impedance values (including increases) of potential variables that represent physiological changes that lead to the impedance increase 2, 3, or 4 months thereafter.
[0122] In this regard, analysis of the shape of an impedance curve and / or curve representing an impedance increase that can be developed according to the teachings herein can include distinguishing impedance increases that predict an impedance increase within 2, 3, 4 or more months from impedance increases that do not predict an impedance increase within 2, 3, 4 or more months. As an example, statistical analysis techniques can be performed on data obtained during / proximal to surgery and / or data obtained the next day after surgery (or whenever it occurs according to the teachings herein) to distinguish between various scenarios that cause impedance increases / changes, or at least identify impedance increases that are used to predict subsequent impedance increases.
[0123] A corollary to the above is that while many embodiments have focused on impedance changes, embodiments may include focusing on a characteristic shape of the impedance increase curve that is indicative / predictive of impedance 2, 3, or 4 months thereafter. By focusing on the shape of the curve (exclusively or non-exclusively) or otherwise focusing on the distribution of the data, predictions may be made even if the increase is "diluted" or has components of impedance increase that correspond to physiological changes that are unrelated to the impedance increase in range.
[0124] Furthermore, in some scenarios, trauma will be more likely to occur outside the substrate region relative to locations in the substrate region. Therefore, there may be local blood release that will increase the impedance at, for example, the reading electrode outside the substrate region. This may skew the data.
[0125] Thus, in view of the above, embodiments may include focusing on the basal electrode relative to other electrodes. In addition, there may be localized impedance increases due to factors other than those corresponding to physiological changes in the cochlea (e.g., localized bleeding near the electrode). These values may skew the average impedance increase, potentially causing the percentage increase to be above the treatment threshold when treatment is not needed or another treatment may be more appropriate. Therefore, embodiments focusing on the basal electrode or otherwise comparing basal readings to non-basal readings may be used to avoid "false positives." Conversely, in embodiments, the lack of a characteristic increase in impedance at a basal location (relative to other locations) may indicate that other factors have caused the impedance increase. This may also be a catalyst for implementing one or more therapies because the inability to assess whether the impedance increase may be sufficient to implement therapy / increase a therapy that would not otherwise be implemented. In some embodiments, the entire increase curve will shift upward by a certain amount (possibly linearly).
[0126] In an embodiment, method 1300 further includes obtaining third data based on a third impedance value obtained using a cochlear implant electrode array still located in the cochlea of a person, wherein the third impedance value is for impedance present in the cochlea at least 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 days after the second impedance value is present, or any value or range of values in increments of 1 day therebetween, wherein the third impedance value is less than the second impedance value (e.g., less than any of the above values). The method further includes continuing to implement the treatment and / or increasing the aggressiveness of the treatment for at least 30 days after obtaining the third data.
[0127] And again, it should be noted that in some embodiments, data collection can be performed from more than all electrodes used for analysis. That is, analysis can be limited to data from less than all electrodes from which impedance values are obtained. Any disclosure herein of limitations on the utilization of read electrodes for collecting data also corresponds to an alternative disclosure of limitations on data used to perform the comparisons and / or analyses detailed herein, where more data than the data used for analysis / comparison can be obtained.
[0128] Fig.14 An exemplary flow chart of an exemplary method (method 1400) including method act 1410 is shown, the method act including implanting a cochlear implant including a cochlear implant electrode array in a person, wherein the act of implanting the cochlear implant in the person causes recent physiological changes within the cochlea of the person. Some of these changes are described below. Method 1400 includes method act 1420, which includes detecting recent physiological changes and / or detecting recent changes in potential variables affected by physiological changes using the cochlear implant electrode array.
[0129] Method 1400 includes a method act 1430 , which includes evaluating a percent change in a detected recent physiological change or a detected recent latent variable change, and a method act 1440 , which includes implementing a therapeutic substance delivery regimen based on the evaluation.
[0130] In an embodiment, one of the changes detected is an increase in impedance within the duct of the cochlea where the electrode array is located. This may be the impedance increase detailed above.
[0131] In embodiments, the near-term physiological changes occur within 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 hours of implantation of the cochlear implant, or any value or range of values in 0.1 hour increments therebetween, or at least within the first entry of the array and / or a component for accessing the cochlea (e.g., a drill) into the cochlea and / or final placement of the array in the cochlea.
[0132] In an embodiment, the act of evaluating the percent change includes comparing first data effectively obtained during or immediately after the procedure with second data obtained 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, or 40 hours after the first data was obtained, or any value or range of values therebetween in increments of 0.1 hours. Some embodiments have first data corresponding to the first time position mentioned above, and second data corresponding to the second time position mentioned above.
[0133] In an embodiment, method 1400 further includes: implanting a second cochlear implant comprising a second cochlear implant electrode array in a second person, wherein the act of implanting the second cochlear implant in the person causes a second recent physiological change in a second cochlea of the second person; detecting the second recent physiological change and / or a second recent latent variable change using the second cochlear implant electrode array; evaluating a percentage change in the detected second recent physiological change and / or the detected second recent latent variable change; and not implementing a therapeutic substance delivery regimen based on the evaluation of the percentage change in at least one of the second changes, wherein the percentage change in at least one of the second changes is less than A%, and the percentage change in the recent first change exceeds A%, wherein A can be 5, 5.5, 6, 6.5, 7, 7.5, 8, 8.5, 9, 9.5, 10, 10.5, 11, 11.5, 12, 12.5, or 13, or any value or range of values therebetween in increments of 0.1. And note that method actions 1410, 1420, and 1430 may be repeated 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, or 25 days or weeks or months. , 21, 22, 23, 24 or 25 times or more, or any value or range of values in increments of 1 therebetween, wherein method act 1440 will be performed at least and / or no more than 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 or 80%, or any value or range of values in increments of 1% therebetween (e.g., between 33.5% and 47%) times, with any of the above values of A%. The idea here is that for some people, the treatment will be performed, and for others it will not, depending on the A% value.
[0134] In an embodiment, the percent change in the detected recent change is at least a % increase in the average of four-point impedance values at at least 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14 or 15 measurement locations along the electrode array or any value or range of values in increments of 1 therebetween.
[0135] In embodiments, the therapeutic substance delivery regimen is in addition to the dexamethasone treatment. In this regard, in at least some exemplary embodiments, the treatment may be a treatment that is already incorporated into the cochlear implant electrode array (embodiments include incorporating dexamethasone into the electrode array). For example, the therapeutic substance delivery regimen may include increasing the rate at which dexamethasone is released into the cochlea.
[0136] An embodiment includes a non-transitory computer readable medium having recorded thereon a computer program for performing at least a portion of a method, the computer program including code for statistically analyzing first data based on four-point impedance data obtained using an implanted cochlear implant electrode array in the cochlea during different time periods, and code for outputting an indication of a state of the cochlea. By way of example only and not limitation, the output may be a measure of trauma and / or damage that may be used as a guide by a clinician. As an example, the output may be a green or safe indicator for low contact, an orange or moderate indicator indicating that the patient should be monitored, and / or a red or severe indicator indicating that intervention should be implemented. The code may alternatively or additionally be used to output a warning.
[0137] It should be noted that any disclosure of any method action herein corresponds to disclosure of a computer-readable medium having code for performing the function, as long as the function is capable of being performed in the art, and vice versa. In an embodiment, the medium also includes code for automatically controlling an implantable component of a cochlear implant of which the electrode array is a part to perform a four-point impedance test to obtain four-point impedance data. In an embodiment, the medium includes code for automatically implementing a therapeutic action based on a statistical analysis. The code may be in an implant, such as a fully implantable cochlear implant (and may therefore perform one or more or all of the method actions herein that can be automatically implemented by the implant). In an embodiment, the warning or indication is an increased likelihood of harmful fibrosis in the cochlea. In an embodiment, the medium includes code for controlling an implantable component of a cochlear implant of which the electrode array is a part to release a therapeutic substance based on a statistical analysis.
[0138] Fig. 20An exemplary flow chart of an exemplary method (method 2000) including method action 2010 is presented, wherein the method action includes an action of obtaining a first set of intra-cochlear measurements, wherein the first set of intra-cochlear measurements represents four-point impedance measurements taken by the cochlear implant on the day of implantation. In embodiments, this may include performing the four-point measurements detailed above, or obtaining measurements from a third party. The first set of measurements may be a collection of all measurements available from the electrode array, which may be 19 measurement locations in an embodiment of a 22-electrode cochlear implant electrode array. However, in exemplary embodiments, this may be less, for example, only readings before and / or up to the basal gyrus. Thus, the first and / or second set of intra-cochlear measurements include average impedances obtained from a corresponding subset of intra-cochlear electrodes of the cochlear implant, wherein the corresponding subset of electrodes includes electrodes up to (and in some embodiments including) the basal gyrus in the basal region of the cochlea of the implant recipient. That is, the first and / or second set may include all measurements, and as will be described in detail below, only some measurements are utilized in the comparison. And in some embodiments, the first and / or second sets of intra-cochlear measurements include average impedance measurements obtained from all electrodes implanted within the cochlea of the recipient.
[0139] Consistent with the above teachings, method 2000 also includes method action 2020, which includes an action of obtaining a second set of intra-cochlear measurements, wherein the second set of intra-cochlear measurements represents four-point impedance measurements obtained by the cochlear implant on the second day after implantation. The group can have the same number of values as the first group, or can have a different number of values. Regarding the more general scenario where the values will be different, in some cases, one or more of the electrodes may fail after implantation. Or, more accurately, one or more leads of such an electrode may fail. In any case, it may be that there are fewer values in the second set of measurements. Alternatively, obtaining fewer values may only be practical. In addition, in some embodiments, the second set of measurements will be a complete set as in the case of the first set of measurements. Any set of values that can implement the teachings detailed herein can be utilized in at least some exemplary embodiments. And although the teachings involve obtaining multiple sets of measurements, other embodiments may include multiple sets of values based on the measurements. For example, the values can be normalized.
[0140] Method 2000 also includes method action 2030, which includes the action of comparing the data based on the first group with the data based on the second group. In an exemplary embodiment, method action 2030 can be a statistical comparison. As an example only and not a limitation, all or some values of the first group of measured values (for example, the measured values associated with the position before the first bottom loop) can be averaged to obtain its mean value and / or median or mode, and the mode is within the statistical range. And this can be completed for the value (all or some of them) of the second group of measured values. And the number of values from the utilization of the second group does not need to be the same as the number of values utilized by the first group. Again, in some embodiments, normalization and / or data review can be implemented. Irrelevant data can be ignored or removed or otherwise at least smoothed.
[0141] As seen, method 200 also includes method action 2040, which includes an action of formulating a prognosis based on the comparison. In an exemplary embodiment, this may include predicting whether there will be a meaningful and / or problematic and / or harmful impedance in the cochlea one, two, three, four, five, six or more months after obtaining the second set of measurements, or any value or range of values in 1 week increments (unlike obtaining these measurements, again, the action of obtaining the measurements may occur after the action of actually obtaining the measurements). In an embodiment, the prognosis includes predicting whether the output current of the cochlear implant may need to be adjusted in a significant manner (to account for the impedance increase). In an exemplary embodiment, this may include predicting whether there will be fibrous tissue growth in the cochlea, or whether there is a statistical probability that there will be meaningful fibrous tissue growth. The fibrous tissue growth may be significant fibrous tissue growth. In an embodiment, the fibrous tissue growth may be tissue growth that produces impedance in the cochlea, which may have a harmful effect relative to other situations. In some embodiments, the fibrous tissue may impinge on structures within the cochlea and adversely affect residual hearing. For example, the fibrous tissue may impinge on the basilar membrane and interfere with the natural perception of low-frequency sounds. Treatment herein may reduce and / or eliminate this fibrous tissue growth.
[0142] In embodiments, the prognosis is that there will be a statistically significant chance that at one or more future locations detailed herein (e.g., two months or three months or four months thereafter), there will be a physical phenomenon within the cochlea that generates impedance within the cochlea with respect to utilization of electrodes that, on average, at least in certain portions of the cochlea, such as locations anterior to the basal gyrus or in at least some locations anterior to the basal gyrus, necessitates that the electrode array output current at a higher current level (including a significantly higher current level) relative to other situations without the physical phenomenon in order to meet the threshold level and / or comfort level. In exemplary embodiments, the impedance is predicted to increase by at least 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 125, 150, 175, or 200% or more, or any value or range of values therebetween in 1% increments, within 2, 3, 4, or 5 months on average (mean, median, and / or mode).
[0143] Thus, in embodiments, the prognosis is a prognosis of future efficacy of a cochlear implant for accurately reproducing sound at a time after and / or before the first set is obtained and / or at 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 weeks or more after the first set is obtained or any value or range of values in 1 day increments therebetween, where the accuracy is at least partially affected by an increase in impedance in the cochlea relative to, for example, a situation where there is no increase in fibrous tissue growth in the cochlea. Embodiments include scenarios where the prognosis is a prognosis of electrical impedance and / or fibrous tissue growth within the cochlea at a time after and / or before any one or more of the above values and / or at any one or more of the above values. And it should be noted that in at least some scenarios, there is always some form of fibrous tissue growth within the cochlea. And this can affect impedance. However, the teachings detailed herein detect or otherwise protect against scenarios where there will be significant fibrous tissue growth that will affect the performance of the cochlear implant, such as, for example, requiring the cochlear implant to have a higher output current than would otherwise be the case to induce the same level of volume relative to the induced hearing perception. All other things being equal, the greater the impedance, the more current that needs to be output by the electrode to achieve the same volume.
[0144] In an embodiment, the method 2000 further includes an act of recommending an intervention based on the comparison. In an exemplary embodiment, the method 2000 further includes an act of recommending an intervention when the comparison indicates an increase in impedance of A% or more compared to the first set of intra-cochlear measurements. In an embodiment, the second set of intra-cochlear measurements includes an average impedance obtained from a subset of intra-cochlear electrodes of the cochlear implant, wherein the subset of electrodes includes electrodes in the basal region of the cochlea implanted in the recipient up to the basal gyrus. In some embodiments, the method 2000 includes recommending an intervention when the comparison shows that the second set of intra-cochlear measurements indicates an increase in impedance of 5, 6, or 7% or more compared to the first set of intra-cochlear measurements (again, based on an average of the impedance measurements of all or some of the electrodes).
[0145] Embodiments include controlling a cochlear implant based on a prognosis. Embodiments include adjusting settings that will be used to control a cochlear implant based on a prognosis. For example, the compliance voltage of one or more stimulation current sources / channels within the cochlear implant may be adjusted based on the comparison performed in method act 2040 to ensure or otherwise provide or increase the chance that sufficient electrical stimulation will be delivered to the recipient. Typically, this will be an increase in output current relative to what would otherwise be the case. By way of example only and not limitation, a cochlear implant includes mapping data stored in the cochlear implant that is used to control the output of the electrodes based on received inputs that are based on ambient sounds captured by a microphone or other sound capture device of the cochlear implant. A given mapping will cause the output perceived by the recipient to be different from another mapping, and sometimes significantly different from another mapping, all for the same input. Thus, embodiments include utilizing the comparison performed in method act 2030 and / or the prognosis performed in method act 2040 to adjust control of the cochlear implant, or otherwise select a mapping to be used for the cochlear implant relative to other mappings, or otherwise create a mapping that is different relative to other mappings that would be used without the prognosis and / or comparison. In some embodiments, these mappings may be significantly different, and in some embodiments, a given mapping selected or otherwise recommended may be a mapping that is highly unpleasant or otherwise undesirable in a cochlea that is not experiencing the predicted impedance rise or various physiological changes detailed herein.
[0146] In some embodiments, the mappings formulated or otherwise selected above may be mappings implemented in a time period after the first and / or second measurements are made. For example, in an embodiment, during a time period when, for example, the impedance value is lower than the impedance value predicted in a later time period (e.g., three months after implantation), the first mapping may be utilized within the first month or at least the first month of utilizing the cochlear implant. The first mapping may be operated at a lower current level relative to the second mapping. These lower current levels may be significantly lower. Then, after a certain time period of utilizing the first mapping, a second mapping may be implemented that will replace some or all of the settings of the first mapping. At least for some channels, such as, for example, channels associated with electrodes located before the first basal gyrus, for a given input, the second mapping may have a higher current level output relative to the first mapping. In an embodiment, the second mapping may be automatically implemented after a set time period or when it is determined that the impedance in the cochlea begins to rise and / or has risen. And in this regard, it should be noted that impedance measurement is not limited to a time range within one or two or three days of implantation. Embodiments may include periodically and / or continuously testing the impedance in the cochlea. A useful feature here is that an expected impedance rise or otherwise an impedance rise that eventually occurs can be predicted so that planning for this can be implemented. One exemplary plan is that there is a pre-positioned or pre-created map that can be used when and / or after the impedance rise occurs, which is the second map described above. Another exemplary plan involves automatic adjustment of the compliance voltage of the implant to accommodate expected physiological changes within the cochlea.
[0147] In some embodiments, implementation of the mapping may occur automatically when an impedance rise is indicated by a certain amount, wherein, for example, the cochlear implant may measure impedance within the cochlea autonomously and / or under the control of a remote clinician. In embodiments, impedance measurements are recorded (or obtained) daily or every 12 hours or some practical period, and these impedance measurements may be evaluated (automatically) by a cochlear implant with an external component or a remote component, or may be sent to a remote location for evaluation daily or weekly or some other practical period. When the impedance begins to rise to at least a certain level or a sufficiently high gradient is seen, a remote clinician or the like may implement a second mapping, or, for example, mapping may be automatically implemented in embodiments where the impedance rise is evaluated in the cochlear implant or a component possessed by the recipient. Thus, embodiments include combining predictions of alternating increases in impedance with continuous monitoring or otherwise sufficiently effective monitoring of impedance within the cochlea, and associating impedance rise measurements with a map stored in the cochlear implant or otherwise uploadable to the cochlear implant, or otherwise adjusting the settings of the cochlear implant to accommodate the impedance rise, and these actions may be performed automatically due to initial generation. This is in contrast to situations where these impedance increases are seen, but they occur unexpectedly or in an unpredicted manner. That is, the predictive quality of the teachings detailed herein allows for the proactive development of mappings and the implementation of such proactive development more quickly relative to other situations. By way of example only and not limitation, in an exemplary embodiment, a setup or other new mapping may be implemented within 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12 hours of the predicted subsequent impedance increase (as opposed to the impedance difference between day one and day two), or any value or range of values in one minute increments therebetween. Thus, this may provide a practical reaction time such that the recipient will have a more satisfying experience, or at least a practical experience, with his or her cochlear implant, even though the impedance is increasing relative to other situations where the protection provided by the teachings detailed herein is not present.
[0148] Embodiments include transition maps. The impedance will not rise from a level to a predicted level, for example overnight or within hours or minutes or even days. The impedance rise will occur more gradually, and therefore there may be a map that transitions from a first map to a second map, thereby moving, for example, the increase in output current for a given stimulation. In some embodiments, the transition map is not necessarily a map at all, but rather an algorithm that, for example, alone, increases or otherwise makes adjustments to the first map to gradually increase values on a time basis and / or based on a correlation with impedance values read within the cochlea, or alternatively reduces the current level of the second map, the reduction being steadily or periodically or in a practical manner reduced over time to accommodate the increase in impedance within the cochlea.
[0149] Embodiments may include developing more than two mappings, such as three or four or five or six or more mappings, wherein respective mappings are implemented over time and / or based upon impedance increase to adapt to impedance increases, and ultimately conditioning the recipient to use a higher, more aggressive output mapping when the predicted impedance increases to a predicted impedance level or a relatively high impedance level.
[0150] Embodiments also include delaying the so-called "turning on" of a cochlear implant relative to other circumstances of standard practice or statistically based practice. By way of example only and not limitation, if the comparison indicates an elevated impedance as described above, where the prognosis indicates that there will ultimately be a significant amount of fibrous tissue growth within the cochlea, the turn-on date of the cochlear implant may be delayed by at least, for example, 10, 15, 20, 25, 30, 35, 40, 45, or 50 days or more, or any value or range of values in one-day increments therebetween. In an exemplary embodiment, this may have practical value with respect to preventing additional tissue growth that may occur due to activation of the cochlear implant electrode array, where it is conceivable that the electrical current may induce fibrous tissue growth that may increase impedance in the cochlea over a two-month or three-month or four-month period. Conversely, in an exemplary embodiment, there may be an action of applying a relatively high current to the tissue using at least some of the electrodes such that the current will potentially prevent fibrous tissue growth at these locations relative to other circumstances.
[0151] Thus embodiments may include ramping up use of electrodes based on impedance increase as part of therapy. For example, a soft start may be implemented on electrodes that see impedance increase. This may allow more time for the healing process to occur, at least in areas of high four-point impedance.
[0152] In some cases, the trickle current and / or turn-on may be later for those with the higher impedance increase described above. And in some embodiments, the application of white noise, for example, may be used as part of some therapies.
[0153] Fig.21An exemplary method (method 2100) according to an exemplary embodiment is presented. Method 2100 includes methods 2010, 2020, and 2030 described in detail above. Method 2100 also includes method action 2040, which includes formulating a setting for a cochlear implant based on the comparison. Consistent with the teachings detailed above about formulating a mapping for a cochlear implant, the setting can be an output level for a given channel of the cochlear implant. The output level can be a threshold level and / or a comfort level. And consistent with any adaptation and / or mapping formulation detailed herein, at least in some exemplary embodiments, the adaptation and / or mapping formulation or additional setting is customized for a specific recipient. By way of example only and not limitation, the setting can be a threshold and / or comfort level setting for any one or more channels of the cochlear implant. Consistent with the teachings detailed herein, in at least some exemplary embodiments, the setting can be a setting for a channel associated with an electrode located before the first basal gyrus. The setting can be for a subset of these electrodes, or can be for all or nearly all electrodes or additional channels of the cochlear implant. The key here is that in at least some exemplary embodiments, cochlear implant settings are tailored based on the comparison, or in other embodiments based on a prognosis of what will occur within the cochlea several months after the second set of data has been acquired using four-point impedance.
[0154] A corollary to this is that in at least some exemplary embodiments, method 2100 includes an act of determining a fitting profile for a cochlear implant based on a comparison of a first set of intra-cochlear measurements with a second set of intra-cochlear measurements, wherein in at least some embodiments, the settings are settings utilized in the formulated fitting profile. In embodiments, the fitting profile may be, for example, a mapping or some other data set that may be utilized by the cochlear implant. This does not mean that the act of fitting occurs, although it may occur. It simply means that a fitting profile is formulated that may be used to actually fit the cochlear implant. But of course, in some embodiments, an act of fitting the cochlear implant utilizing the determined fitting profile is included. And, in some embodiments, there is an act of fitting the cochlear implant based on the comparison, wherein the determined fitting profile is not done by the same person who actually fits the cochlear implant.
[0155] In some embodiments, the adaptation profile formulated is an adaptation profile for a statistically high impedance profile within the cochlea, while in other embodiments, or more accurately, in other scenarios, the adaptation profile is an adaptation profile for a statistically normal impedance profile within the cochlea. By way of example only and not limitation, relative to the former, if the comparison indicates or predicts that there will be a significant increase in any impedance according to the teachings described above or otherwise in detail herein, the impedance increase is considered to be a statistically high increase or otherwise corresponds to a statistically high impedance value for a population similarly positioned based on demographics. By way of example only and not limitation, the person in question may be 10% to 90% male and / or female of human factors engineering or any value or range of values in 1% increments therebetween, who were born in the United States, the European Union, the United Kingdom, France, the Federal Republic of Germany, Japan, Australia, New Zealand or the People's Republic of China and are citizens thereof, have lived in these jurisdictions for most of their lives, were born on any date or range of dates between January 16, 1930 and May 1, 2022, or are otherwise aged between 1 and 100 years old, and any increment in 1 year increments therein. Thus, the statistical significance values of any one or more of these human factors engineering groups can be compared.
[0156] In an exemplary embodiment, for a given human factors engineering cohort, the statistical difference may be a standard deviation from the mean of 0.25, 0.5, 0.75, 1, 1.25, 1.5, 1.75, or 2 or more, or any value or range of values in increments of 0.05 therebetween.
[0157] Embodiments include determining a first mapping for a cochlear implant based on a comparison of a first set of intra-cochlear measurements with a second set of intra-cochlear measurements, wherein the first mapping is a default mapping for turning on a cochlear implant. This is described in detail above. Embodiments may include determining a second mapping for a cochlear implant based on a comparison of the first set of intra-cochlear measurements with the second set of intra-cochlear measurements, wherein the second mapping is a default mapping for a cochlear implant at a time period of about 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15 weeks from implantation, or any value or range of values in 1 week increments therebetween.
[0158] Embodiments include determining a transition profile from a first mapping to a second mapping. This may be based on a comparison and / or formulation of the first mapping and the second mapping.
[0159] As described above, embodiments include comparative monitoring of four-point impedance changes following cochlear implantation. In some embodiments, four-point impedance monitoring provides information about the overall biological environment surrounding the electrode array that is not discernible with conventional impedance. In fact, testing in adult cochlear implant recipients who had no measurable hearing prior to implantation and were implanted with a peri-modiolar cochlear implant showed that such monitoring can have practical value as described above. In this regard, a test was implemented to verify some of the concepts detailed above, and the test will now be briefly described. It should be noted that any disclosure herein of test actions and / or features and / or events associated with the following details of the test corresponds to disclosure of method actions and / or method actions or parameters associated with method actions herein. Any device and / or system for implementing the test detailed below corresponds to disclosure thereof.
[0160] In this test, the mean values of the four-point and common ground impedances of all electrode contacts were calculated intraoperatively, 1 day, 1 week, 4 / 6 weeks, and 3 months after implantation. Linear mixed models were applied to the impedance data to compare between impedance and time points. In addition, patients were divided into groups according to the normalized change of the four-point impedance from intraoperatively to 1 day after surgery. Then, the normalized changes of all other time points were calculated and compared between the two groups. In this test, a significant increase in four-point impedance occurred 1 day and 3 months after surgery, especially in the basal half of the array. The four-point impedance at 1 day highly predicted the four-point impedance at 3 months. The four-point impedance at other time points showed a slight increase or no increase compared to intraoperatively. Patients with an average increase of more than 10% in the four-point impedance from intraoperatively to 1 day had significantly higher values at 3 months (p=0.012). These patterns were not observed in the common ground impedance. It has been found that the increase in four-point impedance within 24 hours of cochlear implantation has predictive value for the increase in impedance in the next 3 months.
[0161] It should be briefly noted that although the following focuses primarily on method acts, devices and / or systems that can implement these methods, at least some of the method acts of the methods are included in some embodiments. In an exemplary embodiment, there is a computing device programmed or configured to perform one or more of the method acts detailed herein, such as a laptop computer and / or desktop computer, or (one or more) devices detailed above. In addition, remote processing can be used to perform the teachings detailed herein. By way of example only and not limitation, for example, a remote server remote from the surgical site or otherwise remote from the cochlear implant electrode array (which is used to implement at least some of the method acts detailed herein or is otherwise used to obtain the impedance values detailed herein) can be used to perform any one or more of the method acts herein, as long as the art is capable of doing so. In an embodiment, there is a chip and / or processor configured to implement at least some of the method acts herein. There is also a computer system including, for example, a computer system such as a computer system. Figure 1AThe device 10 and / or Figure 7 Embodiments of a system of one or more of the components of a cochlear implant, the system comprising, for example, an implantable portion of a cochlear implant electrode array and an external device, the implantable portion of the cochlear implant electrode array comprising a rear telemetry circuit and a plurality of electrodes in direct or indirect signal communication with the rear telemetry circuit, the external device configured to be in signal communication with the implantable portion and configured to receive data from the implantable portion via the rear telemetry circuit (the external device may be any of the behind-the-ear device and / or the external component and / or the control component or control unit or the external device detailed herein). And it should be noted that in some embodiments, the system need not include an implantable component, but instead, the system may be configured to receive data based on four-point impedance measurements from any source, whether from an implantable component or from a data distribution device that provides information to the system. Indeed, in an exemplary embodiment, the data based on the four-point impedance measurements may be input to the system by a person. In any case, in an exemplary embodiment, the implantable component is configured to achieve four-point impedance measurement and provide the results of the measurement to an external device via a post-telemetry circuit, and the system includes circuitry and / or software configured to evaluate the results and provide an indication of the presence of an impedance increase relative to a previous measurement, the impedance increase predicting future adverse development within the cochlea in which the electrode array is implanted. In an exemplary embodiment, the system is configured to perform one or more of the method actions detailed herein, provided that the art is capable of doing so. Indeed, in an exemplary embodiment, the system includes artificial intelligence capabilities and / or is a trained neural network system and / or is an expert system configured to analyze data and perform one or more of the method actions detailed herein.
[0162] Embodiments include methods and systems that prescribe further treatment locally (e.g., some controlled release systems in the implant, or middle ear interventions as examples only) due to impedance rises identified within a full day interval from implantation to a second set of measurements, or any other time period detailed herein, potentially having practical value in predicting the final rise in impedance in the coming months. Embodiments include methods and systems that prescribe further treatment systematically (e.g., systemic steroids, anticoagulants, thrombolytics, antifibrotics, antiproliferative agents (e.g., anti-NBF), NSAIDs, etc.) at reasonable risk, which may not be the treatment that will be implemented without additional assessment (the assessment may correspond to those detailed herein). Embodiments can provide objective measurements of the effectiveness of medical interventions. Embodiments can provide biomarkers that are non-invasive for insertion. Embodiments can include automated measurements performed on day 2 with BTE or implants or devices detailed above. Subsequent measurements can be completed remotely. In addition, embodiments can include the application of prodrugs provided to the ear, wherein in some embodiments, the method includes only cleaving the prodrug if a four-point impedance increase is seen. Thus, in at least some exemplary embodiments, methods include providing one or more therapeutic substances in the cochlea at the time of implantation, such as in a manner co-located with a cochlear implant electrode array, such as in a hole of the electrode array and / or as part of a substance entrained with a carrier member of the electrode array. In some embodiments, the lytic agent can be administered systemically, or in any manner that can have practical value, etc.
[0163] In some embodiments, the therapeutic substance may be provided as part of a local reservoir that may be controllably open to the cochlea but otherwise remain sealed from the perilymph or otherwise prevented from interacting with the perilymph, at least in the short term. In some embodiments, the material may diffuse over time, but the diffusion may be sufficiently low that the effect of the substance is minimal - this is in contrast to releasing the therapeutic substance in a manner that will have efficacy / releasing the therapeutic substance over a sufficiently short period of time that the therapeutic substance will have an effect on the recipient, which in at least some exemplary scenarios may be problematic even if there are other practical aspects of release, which problematic scenario is one of the reasons why therapeutic substances are not implemented or otherwise utilized as a matter of course. For example, if the therapeutic substance can be released from the reservoir in a manner that will have efficacy. Otherwise, the therapeutic substance will remain in the reservoir and not otherwise be released, or will be released in sufficiently minimal increments over a period of time so that the deleterious effects associated with the therapeutic substance are minimized and / or will not otherwise occur. This is a way to eliminate the therapeutic substance in a way that avoids accidental release at some point in the next 10 or 20 years. Alternatively and / or in addition, a negating substance may be applied which will negate the effect of the therapeutic substance or otherwise inactivate or otherwise neutralize the therapeutic substance, which may be done upon completion of a comparison between the first set of data and the second set of data where any impedance increase is shown to be below any threshold value detailed herein.
[0164] In at least some exemplary embodiments, the action of deactivating or otherwise negating the therapeutic substance initially located in the cochlea may be performed within a comparative one or two or three or four or five days and / or weeks and / or months. In exemplary embodiments, the action may be performed after the third or fourth month after implantation, after which a sufficient period of time has passed to ensure that the impedance value has indeed not increased, or more specifically, that the impedance value has not increased significantly within the time frame of interest.
[0165] Thus, embodiments may include an implant utilizing a reservoir that includes a therapeutic substance. The therapeutic substance may be activated or otherwise applied when it is predicted that fibrous tissue growth will be present or otherwise when there is an increase in impedance as detailed herein. Otherwise, the therapeutic substance will not be utilized. In exemplary embodiments, the therapeutic substance may diffuse over a very long period of time and thus have virtually no negative impact on the recipient relative to a situation where the therapeutic substance is used as part of a treatment regimen. In at least some embodiments, the rate at which the therapeutic substance is released into the cochlea and / or the amount of the therapeutic substance released into the cochlea may be increased from a baseline release rate or amount in response to an increase in impedance as detailed herein.
[0166] Therefore, reference Fig. 22In an embodiment, there is a method, method 2200, which includes various method actions, wherein in this exemplary embodiment, the method includes method action 2210, which includes using a cochlear implant electrode array to detect recent physiological changes caused by implanting the cochlear implant electrode array in the cochlea and / or detecting recent changes in potential variables affected by physiological changes caused by implanting the cochlear implant electrode array. This can be performed using four-point impedance or any other detection device that can be of practical value. Method 2200 also includes method action 1430, which is described in detail above and will not be repeated here for the purpose of text economy. (The method may also include method action 1410.) But as seen, method 2200 also includes method action 2240, which includes actions to control a component of the cochlear implant and / or another implant component implanted in a person based on the evaluation.
[0167] In an exemplary embodiment, with respect to the action of controlling the cochlear implant, this may include outputting a current at a level higher than would be the case for a given input in the absence of control based on the assessment. Referring to the above examples of utilizing different mappings and / or utilizing different current levels for thresholds and / or comfort levels, if the assessment indicates an impedance increase in the cochlea that is predicted or otherwise produced after two months or three months or four months, a different mapping may be utilized, or the current level of the output current may be increased relative to other situations. There may be a delayed activation time or start of use time for the cochlear implant described above. And, in some embodiments, a therapeutic substance may be released from the cochlear implant based on the assessment. With respect to this latter aspect, in embodiments where, for example, there is a reservoir, the therapeutic substance is in the cochlear implant or is otherwise part of the cochlear implant attached to the cochlear implant, which is implanted together with the cochlear implant, the cochlear implant may be controlled to release the therapeutic substance.
[0168] Thus, in an exemplary embodiment, the action of controlling the cochlear implant performs the implementation of a therapeutic substance delivery regimen. In an exemplary embodiment, the action of controlling the cochlear implant releases the therapeutic substance from the cochlea implanted in the person when the cochlear implant is implanted. This can be consistent with the concept of providing a therapeutic substance with the cochlear implant as a preventive measure or otherwise pre-positioning the therapeutic substance so that re-entry into the cochlea is not required after the implantation procedure. Thus, embodiments include controlling the cochlear implant to deliver the therapeutic substance without having to perform additional surgical procedures after the day of implantation or after the implantation process is over or otherwise after the patient leaves the operating room. And, consistent with at least some exemplary embodiments, the action of controlling the cochlear implant provides a person with treatment to limit future impedance increases within the cochlea, which also covers elimination or complete prevention. In an exemplary embodiment, the future impedance increase can be any of the impedance increases detailed herein that are predicted to occur within one month or two months or three months or four months or more months after the day of implantation of the cochlear implant.
[0169] Embodiments include scenarios where an action to control a cochlear implant controls a mechanical component of the cochlear implant to release a chemical from the cochlear implant that will not be released in the short term without an assessed percentage change above or at a certain level. In an exemplary embodiment, this may entail an action to open a valve to release a therapeutic substance in the form of a fluid located in a reservoir into the cochlea, where, for example, the reservoir may be located in the cochlea or may be located in the middle ear, and there may be a conduit from the reservoir into the cochlea, the conduit being part of an electrode array, where an outlet of the conduit is located in the cochlea. The valve may be located in the cochlea or upstream of the outlet. In some embodiments, these actions to control the cochlear implant are performed automatically, and in other embodiments are performed under the control of a clinician or the like. In an exemplary embodiment, the cochlear implant may be any one or more of the devices disclosed in U.S. Patent Application Publication No. 2021-0308371 to Daniel Smyth, published on October 7, 2021, and / or U.S. Patent Application Publication No. 2022 / 0032020 to Daniel Smyth, published on February 3, 2022, or may have any one or more of the features disclosed in the above patent application publications, all of which are exemplary and non-limiting. Still referring to Fig. 22 , method action 2240 includes, as an alternative action, controlling another implant component implanted in a person based on the evaluation. In an exemplary embodiment, during the process of implanting a cochlear implant, or more accurately, during a time period when there is a passage into the middle ear or otherwise into the outer wall of the cochlea that enables the cochlear implant electrode array to be inserted into the cochlea, a port prosthesis or the like is implanted. In at least some exemplary embodiments, a possible second cochleostomy is obtained (assuming a first cochleostomy for the electrode array exists) or a second access location is otherwise obtained to access the interior of the cochlea. A device that can be dedicated to the action of providing a therapeutic substance to the cochlea can be implanted or otherwise attached to the cochlea so that the therapeutic substance can be provided to the cochlea at a later point in time. Thus, an embodiment includes an action of implanting a second implant that can perform one or more of the functions detailed herein, the second implant being separate from the cochlear implant.
[0170] In some embodiments, there may be a polymer on the surface of the electrode array (e.g., carrier element) that is triggered in action by some form of stimulation, such as by light or by certain RF or sound frequencies, etc. In addition, in some embodiments, a substance may be injected into the cochlea, or may be ingested by a person, such that a substance otherwise carried as part of the cochlear implant is activated or triggered to effectuate therapy.
[0171] In some exemplary embodiments, the time frame for initiating treatment occurs within one, two, three, four, five, six, seven, or eight days after the second time location, or any value or range of values in one-day increments therebetween, and as described above and herein, the therapy can be initiated prior to any noticeable growth of fibrous tissue within the cochlea.
[0172] In an exemplary embodiment, the second implant is a dedicated therapeutic substance delivery device or a delivery device that supports a dedicated therapeutic substance. The second implant may include a reservoir and / or a valve that may be controlled, for example, by the cochlear implant or by another component or by an external signal. By controlling the implant, the therapeutic substance may be metered into the cochlea if an analysis or other action evaluating the percentage change indicates that there is a practical value in doing so, at least where the practical value overcomes one or more or all of the deleterious effects associated with providing the therapeutic substance. (And in an exemplary embodiment, the second implant may include a pressure relief valve that may, for example, release the therapeutic substance into the middle ear all at once or over time, rather than releasing the therapeutic substance into the cochlea, as a way to "dispose of" the therapeutic substance when it is determined that the therapeutic substance is not needed or should not otherwise be provided.)
[0173] Any disclosure herein of actions associated with a cochlear implant electrode array with respect to performing therapy, etc. corresponds to an alternative disclosure of doing so with that alternative or another implant, for purposes of text economy, to the extent the art permits to do so, unless otherwise indicated. In an exemplary embodiment, the other implant is an implant without electrical cochlear stimulation capability (but again, may be controlled by or otherwise coupled to or in signal communication with the cochlear implant).
[0174] In an exemplary embodiment, the implant can be any one or more of the devices disclosed in U.S. Patent Application Publication No. 2020 / 0297924 of Daniel Smyth, published on September 24, 2020, and U.S. Patent Application Publication No. 2020 / 0238062 of Kenneth Oplinger, published on July 30, 2020, or have any one or more of the features disclosed in the above patent application publications.
[0175] And note that embodiments include utilizing any one or more of the devices and / or teachings of the following patent applications and / or any of the patent applications detailed above with respect to implementing the therapeutic actions detailed herein (whether this is controlled in accordance with method action 2240 or otherwise used solely for implementing therapy): U.S. Patent Application No. 63 / 212,582 to Wolfram Dueck, filed June 18, 2021; U.S. Patent Application No. 63 / 152,777 to Wolfram Dueck, filed February 23, 2021; U.S. Patent Application No. 63 / 152,777 to Wolfram Dueck, filed February 23, 2021; and U.S. Patent Application No. 63 / 152,777 to Daniel Smyth, filed August 20, 2021, all of which are provided by way of example only and not limitation. And to be clear, other techniques and devices may be used.
[0176] Unless otherwise indicated herein, any device, system, and / or method capable of achieving the therapeutic treatments detailed herein may be utilized in at least some exemplary embodiments, provided that it is within the skill of the art to do so.
[0177] Moreover, it should be understood that while method 2200 is presented in the context of controlling an implant (whether it is a cochlear implant or another type of implant separate from a cochlear implant) individually and / or together, embodiments may include utilizing any of the exemplary therapeutic substance delivery devices detailed by reference above, in combination with any one or more of the method actions herein, or otherwise implementing the therapeutic method actions detailed herein, as is possible in the art, unless otherwise indicated.
[0178] By implementing early postoperative assessments to identify early postoperative changes in intra-cochlear physiology, early interventions can be implemented that might not have otherwise been implemented without the teachings detailed herein. As seen above, early changes in impedance within the cochlea (e.g., an increase of at least a certain amount as detailed above) within the limited time period detailed herein can indicate higher impedance later (e.g., two months or three months or four months later), as described above. This later impedance increase can be the result of fibrous tissue growth or cell damage, etc. Therefore, an embodiment includes implementing treatment based on determining that an impedance increase of one or more of the amounts detailed above has occurred within one or more of the above-mentioned time periods detailed above. As described above, comparisons can be made across two or three days, which can be used to predict future impedance scenarios within the cochlea (at least generally, such as statistically higher impedance levels).
[0179] The above-described impedance increase within the above-described time period can be considered a practical predictor of more significant fibrosis that is about to occur. In this regard, some fibrosis will occur in nearly all cochlear implant scenarios. The embodiments herein predict significant fibrosis, which is different from normal fibrosis / expected and / or fibrosis that otherwise does not result in a significant amount of impedance increase, compared to fibrosis, which may later cause deleterious effects, such as increased impedance within the cochlea two months or three months or four months after implantation. Based on this generation, a decision can be made as to whether to intervene, where the act of intervention itself may have deleterious consequences. That is, based on this prediction, more intense medical therapy can be implemented relative to other situations, again where more intense medical therapy may have deleterious effects.
[0180] Thus, consistent with the teachings detailed above, in embodiments, therapies or other actions taken after determining that impedance is elevated, or actions that would not be taken in the absence of a need for such some indicator or the presence of an indicator indicating a statistical likelihood that a negative effect will occur at some point in the future. The idea is that in some cases, the therapy implemented may have a statistically significant or at least some increased non-trivial chance of producing (one or more) powerful side effects, which would otherwise be undesirable except for the practical value of utilizing these substances or otherwise these chemical compositions with respect to the problems determined to provide these. By utilizing the predictive teachings detailed herein, a cost-benefit analysis can be better performed (or indeed, a cost-benefit analysis can be performed in the first case, while in some scenarios, the therapist goes by the seat of his pants as to whether to implement such a therapy, at least before there is fibrous tissue growth). Thus, embodiments include implementing one or more of the therapies detailed herein to reduce or otherwise prevent the growth of fibrous tissue in the absence of any or at least significant fibrous tissue growth or otherwise the initiation thereof.
[0181] Embodiments include using predictive biomarkers to predict the potential for future fibrous tissue growth, and then using these predictive biomarkers to provide preventive treatments that would not have been implemented or would have been unlikely to be implemented under all other circumstances being equal. As detailed above, embodiments utilize impedance increases at levels detailed herein within time periods detailed herein as predictive biomarkers. It should be noted that in some embodiments, anti-fibrotic agents can be used for treatment, while in other embodiments, electrodes can be used to trigger treatment. In this regard, electrodes can be used at certain frequencies and / or certain currents in a manner that can reduce or otherwise prevent fibrous tissue growth.
[0182] In at least some exemplary scenarios, the impedance increase can be the result of an acute inflammatory response, which can be the result of a large number of macrophages continuously sending signals that more fibrosis is entering the cochlea. Therefore, embodiments can use the impedance increase to detect this situation or otherwise determine that this is the case, and predict the increase in fibrosis so that treatment can be implemented. Therefore, in an embodiment, within 12, 24 or 36 hours of the cochlear implant electrode array first entering the cochlea, there is an increase in the amount of substances (such as macrophages) in the cochlea that cause subsequent fibrous tissue growth, and the second set of intra-cochlear measurements captures the potential variables associated with the increase. In an embodiment, the impedance increases by various amounts detailed herein over the times detailed herein corresponding to the potential variables.
[0183] Embodiments include the use of systemic anti-fibrotic drugs (or any other treatment detailed herein), such as those that would not be used as a matter of course without a valid reason (as described above), but the impedance increase combined with its predictive value can prove this. In this regard, in some embodiments, the risk of giving these drugs to everyone as a matter of course without any reason is great (and too great in some embodiments). Therefore, the methods herein provide a reasonable basis for giving systemic therapy. In addition, embodiments may include enhancing baseline treatment based on impedance increase. Due to the predictive nature of impedance increase, if after 2 or 3 or 4 or 5 months, there is no impedance increase or the impedance increase is otherwise statistically significantly lower than the impedance increase expected based on the empirical observations detailed above, the teachings detailed herein can provide an indication that the drug or therapy is effective.
[0184] therefore, Fig.23An exemplary flow chart of an exemplary method (method 2300) is presented. Method 2300 includes method actions 2010, 2020, and 2030, which are described above and will not be repeated for the purpose of text economy. Method 2300 also includes method action 2340, which includes an action of formulating a performance assessment based on the comparison. In an embodiment, the performance assessment is used to evaluate the efficacy of the treatment regimen implemented based on the comparison. Here, the application of the treatment substance has an open scenario because it is actually impossible to know whether the treatment itself works to date. Of course, it can be seen that there is no fibrous tissue growth in the absence of a subsequent impedance increase, or any other scenario detailed herein, and the treatment is declared effective. However, it is usually unclear whether the treatment works or it is just a coincidence that fibrous tissue growth, etc. is not produced. In other words, it is usually uncertain whether fibrous tissue growth actually occurs, and therefore it is uncertain whether the application of the treatment prevents fibrous tissue growth. But now, using the prediction technology disclosed herein, there is a higher level of confidence (if not certainty, then close) that fibrous tissue growth, or otherwise higher impedance within a time frame of 2 or 3 or 4 or more months will occur. Thus, if growth does not occur after therapy, or high impedance does not otherwise occur, there may be a statistically significant confidence correlation between the application of therapy and the prevention of tissue growth or high impedance. Thus, the teachings detailed herein can provide a performance assessment that would not otherwise exist, or at least a level of performance assessment that did not exist prior to the teachings detailed herein.
[0185] And note that while method 2300 is presented as its own method, as with any one or more or all of the teachings detailed herein, any one or more of the method actions herein may be combined with any one or more of the other method actions detailed herein, unless otherwise noted. Thus, for example, method action 2340 may be combined with method action 2040 detailed above, as an example, and in an exemplary embodiment there is any method of performing method action 2040 and / or method action 2340.
[0186] A corollary to the above is that in some embodiments, therapy may be discontinued after a given period of time, e.g., after two or three or more months of providing therapy. Repeated impedance measurements may be made during and / or after therapy is discontinued. Indeed, data collection of impedance values at the first and second time locations detailed above may be repeated frequently or otherwise as long as the recipient is alive (e.g., daily, or hourly, or at least every 2 or 3 or 4 or 5 hours or 6 hours, or any value or range of values in one minute increments therebetween), and any increase that may be found within the above time periods may indicate that future impedance increases may occur, or that some trauma has occurred, or that the physiological state of the cochlea has otherwise changed in a way that may have harmful consequences in the future, thereby providing a prediction that some harmful scenario will occur in the future, and treatment or new treatment may be implemented accordingly.
[0187] The predictive value of continuing the teachings detailed herein can later provide an idea of the indicators that a given therapy is effective, which can provide a basis for stopping or otherwise adjusting the therapy. This can also provide a basis for transitioning from one therapy to another. Based on an evaluation of the performance of the therapy, there can then be a basis for changing from an anti-proliferative fibrotic therapy to a bone preventive therapy. For example, a nonsteroidal anti-inflammatory agent may be tried first, then a thrombolytic agent may be tried, then treatment may switch to an anti-proliferative agent, and then to a drug to prevent bone formation.
[0188] Embodiments include using the teachings herein as a means of early evaluation of improvements to new devices. For example, the teachings above may be a biomarker of atraumatic insertion. That is, a given electrode array of a given model / design has superior insertion characteristics relative to other electrode arrays in terms of reducing / eliminating damage to the cochlea or otherwise causing some form of deleterious event.
[0189] Thus, again referring to method action 2340, the performance assessment can be used to assess the reproducibility level of trauma associated with the type of electrode array inserted into the cochlea. By way of example only and not limitation, in an exemplary embodiment, if any particular level of impedance rise is seen in a statistically significant manner over the time periods detailed herein for, for example, one type of electrode array produced by a manufacturer or with respect to a given type relative to another type of electrode array produced by the same manufacturer or that is an industry standard (e.g., pre-curved, straight, disabled electrodes, but electrodes, semi-circular electrodes, 12 vs. 16 vs. 22 electrodes on the array, etc.), all other things being equal, it can be assessed whether the given electrode array causes more trauma during insertion relative to other electrode arrays. This can provide a basis for changing the use of such an array and / or provide a basis for developing alternative technologies, or otherwise serve as a basis for developing alternative technologies for implanting the array, etc., at least in some cases.
[0190] Furthermore, the techniques herein can be used to monitor repeated bad insertion techniques. Good insertion techniques will have less impedance increase.
[0191] Thus, embodiments include scenarios where a performance assessment is used to assess the level of reproducibility of trauma associated with the type of surgical technique used to insert an electrode array into the cochlea. By way of example only and not limitation, this can be used to identify surgeons who implement less invasive approaches relative to other surgeons, which can be used to identify less invasive implant techniques relative to other implant techniques (e.g., lateral wall hugging versus circummodiolar hugging or central location, etc.).
[0192] Embodiments include automated measurements. In addition, subsequent measurements may be performed remotely and / or using automated algorithms. However, in some embodiments, the test may be performed under human control / command, and may be a combined automated and "manual" test.
[0193] Examples of treatments detailed herein may include anti-NBF drugs that prevent new bone formation. Examples include using the teachings herein to inform modifications in surgical techniques, such as using healon irrigation or monitoring for surgical improvements.
[0194] It should also be noted that in some embodiments, a precursor prodrug can be applied in the middle ear and based on the impedance increase, a trigger can be implemented to activate the base drug. Prodrug drugs based on stimulation and / or light and / or radiation in the inner ear and / or middle ear can be used as part of the therapy. Drug release coatings can be used and the prodrug can change its composition to make it active and / or inactive, depending on the impedance increase.
[0195] In an exemplary embodiment, the therapeutic substance delivered to the recipient as a result of the evaluation of the impedance measurement can be a so-called "thrombolytic" drug. In an embodiment, the delivered substance can be one or more of the following: Eminase (anistreplase), Retavase (reteplase), Streptase (streptokinase, kibikinase), t-PA, drugs including Activase, TNKase (tenecteplase), urokinase and / or Kinlytic (rokinase). In an embodiment, the therapeutic substance is a substance that treats thrombolysis.
[0196] It should be noted that while in many cases the therapies detailed herein have focused on the application of therapeutic substances, the therapies are not limited thereto. By way of example only and not limitation, therapies implemented based on the impedance increase present during the time periods detailed herein may include electrotherapy and / or activation therapy as detailed herein. In at least some exemplary embodiments, any therapy that can have practical value in preventing an alternative impedance increase predicted based on an impedance increase within one or two days after implantation may be utilized. In addition, other actions, such as preventive actions or caregiver actions, may be taken based on impedance measurements. Some examples associated with electrotherapy and caregiver actions will now be described in detail.
[0197] Fig.24 An exemplary flow chart of an exemplary method (method 2400) is presented. The method is intended to address vertigo issues associated with implantation of a cochlear implant electrode array. In short, method 2400 includes method action 2410, which includes an action of obtaining data based on one or more intra-cochlear measurements, wherein the one or more intra-cochlear measurements are acquired by a cochlear implant. Consistent with the above teachings, method action 2410 can be performed by actually utilizing the cochlear implant or otherwise obtaining data directly therefrom in real time. By way of example only and not limitation, method action 2400 can be further performed by obtaining measurements from a third party. In an exemplary embodiment, data is obtained from a remote location, such as a hospital or even the recipient's home (in an exemplary embodiment, one or more intra-cochlear measurements of method act 2410 may be obtained in an automated manner by an implanted cochlear implant, and the measurements may be provided to an external component via telemetry, and the external component may provide it to the remote location via a wired or wireless link (e.g., the external component may be Bluetooth compatible, and the external component may communicate with a smart phone, etc., which may transmit the measurements to the remote location—note that some embodiments may have Bluetooth compatible implants)—this embodiment is applicable to the vertigo embodiment or other embodiments detailed herein, as far as is possible in the art). The point is that, in order to perform method act 2410, the actor does not necessarily need to operate the cochlear implant or otherwise obtain data directly from it.
[0198] In an exemplary embodiment, the one or more intra-cochlear measurements of method act 2410 are measurements taken according to any one or more time periods detailed herein. In an exemplary embodiment, the measurements are taken 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, or 48 hours or more after implantation of the cochlear implant is completed and / or after any time triggering action detailed herein (e.g., the cochlear implant electrode array first enters the cochlea), or any value or range of values therebetween in increments of 0.1 hours and / or at and / or after. As will be described below, embodiments include taking measurements 72 and / or 96 and / or 120 hours and / or more after completion of implementation and / or after any time-triggering actions detailed herein.
[0199] And it should be briefly noted that, consistent with the teachings detailed herein, the act of obtaining data can occur after the measurement is made, and need not be obtained in real time, although embodiments may include such circumstances. In exemplary embodiments, the data is obtained one day or two days or three days or four days or more days after the measurement is made, or any value or range of values in one-hour increments therebetween.
[0200] As can be seen from method 2400, method 2400 does not require a second set of measurements at a different time location, although it can include such a situation. In this regard, at least some embodiments of method 2400 involve evaluating their impedance values at the time of acquisition (relative to how these impedance values may change or change at a later time) and predicting future events based on this. Therefore, method 2400 also includes method action 2420, which includes an action of formulating a prediction of the occurrence of vertigo in a recipient of a cochlear implant caused by the implantation of a cochlear implant in the future based on the data. Therefore, one or more intra-cochlear measurements obtained at, for example, 24 hours after the implantation is completed can be evaluated, and based on the evaluation, it can be determined that the recipient will experience the possibility of vertigo caused by the implantation of a cochlear implant. This is different from, for example, a pre-existing vertigo condition. In this regard, in at least some exemplary scenarios, the recipient will experience vertigo due to the fact that the electrode array has been placed in his or her inner ear. In other exemplary scenarios, the recipient will not experience vertigo. By evaluating one or more intra-cochlear measurements, an estimate can be made as to whether the recipient will experience vertigo / the likelihood of such an experience and / or the severity of the vertigo (which can be quantified by a risk of falling scale, a vertigo severity scale, etc., and / or a subjective measure of vertigo can be used, and there may be objective concepts such as SCC and otolith function, as well as any other future ways of measuring or assessing the severity of vertigo), on which the above prediction is based. In short, an embodiment includes a method that includes performing method 2400 and also obtaining data indicating whether the recipient experienced vertigo before the implantation of a cochlear implant. Pre-existing vertigo may be due to many problems / pre-existing conditions, and the vertigo may persist after the implantation of the cochlear implant. This is discussed in more detail below. The pre-existing vertigo may be vertigo that the recipient has learned to cope with or otherwise developed a coping mechanism. In addition, the recipient may be receiving treatment / previously received treatment for an underlying disease / disorder and / or symptom. In contrast, vertigo associated with the implantation of a cochlear implant may be vertigo of a severity and / or type that the recipient is not accustomed to. Thus, there may be utility value in predicting vertigo associated with method 2400 regardless of whether the recipient suffers from vertigo associated with other conditions. Thus, in an exemplary embodiment, the predictions made are in addition to any other predictions for vertigo, which are in addition to vertigo caused by implantation of a cochlear implant. That is, this is distinguished from predictions that are not related to the implant.
[0201] In embodiments, the teachings herein may have practical value in identifying individuals before they leave a hospital / implantation center who may be at "risk" of future vertigo, for example, after surgery. For example, if an elderly person becomes vertigo, it may be unsafe for the person to go home (a fall may result in a hip fracture, and a hip fracture may often result in an acceleration of an end-of-life situation), and therefore, it may be recommended (and may be recommended) that the person remain in the hospital (or be forced, or at least "refuse" to "allow" discharge—the hospital may not be able to "hold" the person in the hospital, but may refuse to grant discharge), or at least in some assisted care center, rather than going home or otherwise not being in some form of care center. A corollary to this is that there may be some force, or at least suggestion to increase support, such as increasing social support, to be placed in place. In embodiments, a visiting nurse or home aide may be assigned or at least recommended. Alternatively, discharge may be conditional on approximately 24 hours of personal assistance / other presence at the person's residence or some more limited assistance / other presence. This may be expensive, or otherwise incur additional costs over and above what would otherwise be the case (additional "housing provision" (e.g., "use" of a hospital bed / room costs a certain amount per day, including care by hospital staff, food, tests, etc.) and / or additional care at home, as well as the increased likelihood of income loss for loved ones who are with the person, etc.). Therefore, some way of forecasting / predicting the likely presence of vertigo due to operation / implantation of the implant may be practical, and a corollary to this is that some form of prediction that there will be no (or will be unlikely to be present in a significant / clinically significant) form of vertigo due to the implant / surgery may be practical, as this will impact discharge timing / procedure / conditions. To be clear, embodiments include determining a low likelihood of vertigo due to surgery / implant, and therefore discharging the person under "normal" / non-enhanced care / requirements (beyond the normal care / requirements for a cochlear implant recipient of that person's demographic / human factors engineering type, all other things being equal).
[0202] And note that in some embodiments, given this, the severity of vertigo (e.g., how "vertigo" a person is likely to get) is itself uncertain or otherwise a secondary issue. Instead, the outcome of vertigo, in the context of the individual's health, age, and / or living independence, is the goal of method action 2420 in at least some embodiments. It should be noted, however, that the goal here may be to determine that the predicted vertigo will be of a different kind or of a different severity than the vertigo that the recipient is accustomed to experiencing. In other words, if the person has experienced vertigo in the past, future vertigo may be associated with past vertigo, and thus the recipient may be accustomed to / understand / know / have experienced how to protect or otherwise defend him or her from such vertigo in a limited way or even at least treat the vertigo to which he / she is accustomed in a limited way. In contrast, vertigo caused by cochlear implants / surgery may be of a different kind and / or degree, requiring some additional warning / protection / intervention or other different course of action.
[0203] Thus, embodiments may include prescribing and / or mandating alternative nursing support for a person based on the prediction, relative to otherwise without the prediction. Embodiments may include prescribing and / or mandating an extended stay in a healthcare facility after a surgical procedure based on the prediction, relative to otherwise without the prediction. Embodiments may include prescribing and / or mandating an extended stay in a healthcare facility after a surgical procedure based on the prediction, relative to otherwise without the prediction. Embodiments may include prescribing and / or mandating a person to stay in a healthcare facility for at least 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192, or more hours, or any value or range of values in 1 hour increments therebetween (where a prescription for two days corresponds to, for example, "at least 48 hours") after a surgical procedure, relative to otherwise without the prediction.
[0204] Embodiments include providing / prescribing / mandating, etc. enhanced / alternative / extended care / stay during a time period when a person is more vulnerable to injury due to vertigo relative to other times. It should be noted that in embodiments, it may be that a person may leave the healthcare facility where the surgery was performed after surgery (e.g., within 12, 24, 36, or 48 hours of surgery) and then return or travel to another center at least 24, 36, 48, 60, 72, 84, 96, 120, 144, 168, 192 or more hours after discharge / leaving the facility, or any value or range of values in 1 hour increments therebetween, wherein during the return period of enhanced vulnerability, but upon returning to the facility or traveling to another center, the person does not experience vertigo, at least not related to the implant / surgery at the time. In embodiments, the person does experience vertigo after returning / traveling to the center.
[0205] In embodiments, elevated basal impedance relative to vertex impedance (in postoperative measurements) may also be used as a predictor. Thus, embodiments include comparing one or more impedance values between electrodes or any other impedance value associated with multiple basal electrodes detailed herein with one or more impedance values between electrodes or any other impedance value associated with one or more vertex electrodes detailed herein. And, consistent with the teachings detailed herein, the average median and / or mode value of the basal values may be used relative to the data to be compared with the vertex values or any other statistical data point detailed herein, as long as doing so provides practical value. And it should also be noted that in some embodiments, intermediate electrodes may be used in place of and / or in addition to vertex electrodes.
[0206] Thus, in an exemplary embodiment, method action 2420 generates a prediction that vertigo will occur in the future, and in another exemplary embodiment, method action 2420 generates a prediction that vertigo will not occur in the future. It should be noted that in some embodiments, the prediction may be unclear whether vertigo will occur in the future. In embodiments, the methods herein may indicate when the reliability of the prediction is low or otherwise subject to some further evaluation or questioning. When vertigo is predicted not to occur, it may occur, and vice versa. In an exemplary embodiment, method 2400 is performed 10, 15, 20, 25, 30, 35, 40, 45 or 50 times for as many different recipients and / or for as many different ears, or any value or range of values spaced in increments of one, over a period of 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29 or 30 weeks or months, or any value or range of values in increments of one therebetween (a recipient may receive two cochlear implants, so method act 2400 would be performed for each ear), with an accuracy of at least 65, 70, 75, 80, 85, 90, 91, 92, 93, 94 or 95%, or any value or range of values in increments of 1% therebetween.
[0207] In an exemplary embodiment, there is a method action that requires evaluating one or more corresponding levels of one or more measured values obtained in method action 2410. In an exemplary embodiment, the act of formulating a prediction is based on the evaluation of the one or more corresponding levels. In an exemplary embodiment, the measured value is an impedance value, such as any impedance value detailed herein. In an exemplary embodiment, the act of evaluating the level includes determining whether the impedance value is at and / or above and / or below a predetermined value. Thus, in an embodiment, the one or more intra-cochlear measurements are one or more impedance measurements, and method 2400 may further include evaluating one or more relative levels of the one or more impedance measurements (e.g., whether the level is relatively high or relatively low) and formulating a prediction based on the relative levels. More on this later.
[0208] With respect to impedance values, a full set of impedance values may be obtained for each possible electrode pair (in the case of four (4) point impedance - note that in some embodiments, standard impedance measurements / monopolar impedances (MP1, MP2, or MP1+2) may be used, or alternatively measurements from each electrode to a common return, which may be an extracochlear electrode, which may be an electrode contact or ball, or may be an electrode pad on a receiver-stimulator, or a combination of these)). In embodiments, point-to-point or two-point impedances may be used for impedance measurements, such as an intracochlear electrode and an extracochlear electrode, or an intracochlear electrode and another intracochlear electrode. That is, in embodiments, the data obtained in method action 2410 includes only a subset of the full set of impedance values that were actually obtained. Furthermore, the data obtained in method action 2410 may include only a subset of a subset of the impedance values that were actually obtained relative to the total number of values that could be obtained. It should be noted that this is the case for any of the embodiments detailed herein. In this regard, in an exemplary embodiment, impedance values may be measured or otherwise obtained for each electrode pair, but only impedance values for the base electrode and / or vertex electrode and / or intermediate electrode are obtained in method action 2410. Of course, a complete set of impedance values may be obtained, and only a subset may be utilized to evaluate one or more corresponding levels of one or more measured values. As an example, in an exemplary embodiment, the act of evaluating requires evaluating only the level of the base electrode. In at least some exemplary embodiments, any evaluation of one or more corresponding levels of one or more measured values that can implement the teachings detailed herein may be utilized.
[0209] It should also be noted that embodiments of evaluating one or more corresponding levels of one or more measured values may include statistical analysis. By way of example only and not limitation, the action of evaluating one or more corresponding levels may be performed by, for example, obtaining the mean, median, and / or mode (whether the entire set or a subset) of the impedance values of each electrode pair and evaluating the level of the mean. More on this later. Therefore, the data obtained may be statistical analysis data of one or more impedance measurements from the cavity and / or one or more impedance measurements from the cavity.
[0210] Fig.25 Another exemplary flow chart of an exemplary method (method 2500) is presented. Method 2500 includes method action 2510, which includes the action of obtaining data indicating the presence and / or absence of inflammation and / or blood and / or cell structure (number of cells) in a cavity of a person after a surgical procedure. In an exemplary embodiment, consistent with the teachings herein, the surgical procedure can be implanting a cochlear implant electrode array into the cochlea. Still, in other embodiments, this can be implanting an electrode or electrode array into a vestibular canal or some other part of the labyrinth of a person. Further, consistent with the teachings herein, impedance values can be used to assess or otherwise determine whether there is and / or no inflammation or blood or cell structure in a cavity (e.g., cochlea). Therefore, in an embodiment, the data obtained can be an impedance value. That is, in an embodiment, the data can be data based on impedance values. For example, a statistical value or a coordinated data set can be the data obtained. It should be further noted that in an exemplary embodiment, the data obtained can be imaging data or some other information set indicating the presence and / or absence of inflammation and / or blood and / or cell structure in the cavity. Any device, system and / or method capable of determining or otherwise indicating the presence and / or absence of inflammation and / or blood and / or cellular structures within a cavity of a person that can implement the teachings detailed herein may be utilized in at least some exemplary embodiments.
[0211] As seen, method 2500 also includes method action 2520. Method action 2520 entails formulating a prediction of the likelihood of a future occurrence of vertigo in a recipient of a cochlear implant caused by implantation of a cochlear implant based on the data. In an embodiment, this may be performed by evaluating one or more impedance measurements. For example, if the impedance level is at and / or above a particular value, it may be determined that there is a likelihood that a future occurrence of vertigo caused by implantation of the cochlear implant exists. If the impedance level is at and / or below a particular value, it may be determined that a future occurrence of vertigo caused by implantation of the cochlear implant is low.
[0212] In an exemplary embodiment, the prediction may be a percentage-based prediction. In an exemplary embodiment, the prediction may be based on the obtained data obtained in method act 2510 that the likelihood that the recipient will experience vertigo associated with or otherwise caused by the implantation of a cochlear implant is at least 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, or 100%, or any value or range of values therebetween in 1% increments. In an exemplary embodiment, the prediction may be based on the obtained data obtained in method act 2510 that the likelihood that the recipient will experience vertigo associated with or otherwise caused by the implantation of a cochlear implant is no more than 35, 30, 25, 20, 15, 10, or 5%.
[0213] The likelihood level may have practical value in prescribing treatment or otherwise recommending a future course of action. By way of example only and not limitation, if the percentage likelihood of vertigo occurring in the future is higher than a given percentage, at least with respect to a given person, a recommendation may be made to take care of the person. By way of example only and not limitation, if the person is, for example, 70 years old, and is therefore relatively susceptible to greater harm to the person due to a fall, the person may be advised to use a wheelchair for a given period of time during a specified period of time after implantation. In an exemplary embodiment, the suggestion may be that the person should not be alone or otherwise spend as much time with able-bodied persons as possible, or that otherwise able-bodied persons spend more time with the recipient within a given period of time. That is, in an embodiment, the person may not necessarily need to be able-bodied. Instead, the person may simply be someone who can observe or otherwise keep an eye on the recipient and obtain medical attention in the event that vertigo causes physical problems or otherwise causes harm to the recipient. Still, in an embodiment, there is practical value in making the recipient behave more cautiously in terms of physical activity or otherwise moving. In an exemplary embodiment, the recipient may be advised to use one or more canes and / or crutches or other walking aids during a given period of time, or otherwise at least have one or more items readily available. For example, the recipient may carry a cane with them, but may not necessarily use the cane, but if the recipient experiences vertigo, the cane is available and may be used.
[0214] In an exemplary embodiment, the recipient may be warned not to drive a vehicle during a certain time period and / or warned not to perform certain sports during a certain time period, or otherwise advised to always hold onto some kind of handrail when going up stairs or moving around hard surface objects.
[0215] Embodiments include prescribing a medicament or other therapeutic substance to treat vertigo or at least reduce the likelihood of vertigo, as an alternative and / or in addition to the above actions (e.g., extended hospital stay). By way of example only and not limitation, any one or more of the therapeutic substances described in detail herein may be prescribed. In embodiments, an antiemetic is prescribed. In embodiments, an antihistamine is prescribed. In embodiments, prochlorperazine is prescribed. In embodiments, an anti-inflammatory substance is provided or at least prescribed. In embodiments, a higher salt diet or a specific diet is recommended. Antibiotics may be prescribed and / or used. A therapeutic substance to avoid vomiting and / or nausea may be prescribed. In embodiments, a steroid medication may be prescribed. A diuretic may be prescribed. A substance having a combination of glucocorticoid and mineralocorticoid activity may be prescribed.
[0216] In an embodiment, electrical therapy may be used to treat vertigo (which includes avoiding vertigo). By way of example only and not limitation, a cochlear implant may be used to provide an electrical current that may affect the vestibule, or more precisely, affect the signals provided to the brain from the vestibule, or otherwise affect the signals provided to the brain, to counteract or otherwise minimize the effects of vertigo. In an exemplary embodiment, a vestibular stimulator or anti-vertigo stimulation device may be applied to the recipient. In practice, depending on the likelihood of vertigo severity, a second surgery may be performed to implant one of these vertigo compensation devices into the recipient. In an embodiment, balance disturbances may be addressed by using electrical stimulation to mask "noise" in the vestibular system. In an embodiment, one or more of the teachings of U.S. Pat. No. 11,351,372 and variations thereof are used in the method. For example, while in the teachings of the '372 patent stimulation is delivered to the otolith organ, in other embodiments stimulation is applied to the cochlea using a cochlear implant, which stimulation may be specifically controlled by an external component, including the use of subthreshold electrical stimulation (or suprathreshold electrical stimulation, if it is desired to "reach" its vestibular system / nerve).
[0217] Thus, embodiments include using electrical stimulation to improve balance dysfunction expected after cochlear implantation. In one embodiment, there is a method, wherein, based on a prediction of vertigo, there is an action of generating an electrical stimulation signal, the electrical stimulation signal configured to improve a recipient's sense of gravity balance by masking vestibular noise generated by the peripheral vestibular system, and delivering the electrical stimulation signal to the cochlea via one or more of a plurality of electrodes of the cochlear implant, and in some embodiments, also to at least the lower branch of the vestibular nerve. In an embodiment, the cochlear implant includes a stimulator unit configured to generate and deliver one or more continuous electrical pulse sequences to the inner ear, and in some embodiments, the one or more continuous electrical pulse sequences may reach the lower branch of the vestibular nerve of the recipient via one or more of a plurality of electrodes, wherein the one or more continuous electrical pulse sequences are configured to suppress, in some embodiments, primarily in the lower branch of the vestibular nerve and / or in some embodiments partially in the upper branch, erroneous balance information generated by the peripheral vestibular system of the inner ear, which would otherwise be sent to the recipient's brain via the vestibular nerve. Embodiments include methods of doing so / controlling a cochlear implant to do so.
[0218] Embodiments include applying / delivering one or more continuous pulse sequences to the inner ear such that the recipient experiences a sense of balance continuously over time periods (e.g., throughout the day, or at least during episodes of vertigo) when the recipient is in an upright position, performing certain activities, etc. (and so in embodiments the recipient can control the cochlear implant to implement anti-vertigo actions). In embodiments, in order to provide the recipient with an experience of a sense of balance, the electrical stimulation signals are typically delivered over an extended period of time so as to account for the recipient's imbalance in some way, taking into account the recipient's specific characteristics and the residual effects of the stimulation. In some examples, the electrical stimulation signals are delivered to the recipient continuously throughout the day (e.g., the stimulation signals are delivered continuously for 8 hours, 12 hours, 14 hours, etc.), and this can begin at a predicted / predicted start time, or start slightly earlier as a precautionary measure. In other embodiments, the cochlear implant can be controlled to deliver the stimulation signals to the inner ear, and in some embodiments ultimately reach the vestibular nerve at a specific duty cycle that ensures that the recipient experiences a sense of balance continuously, or at least counteracts vertigo.
[0219] In an embodiment, a cochlear implant is used as a "balance prosthesis" or "balance implant". The implant can be controlled to help the recipient cope with vertigo. In an embodiment, the implant is an implant according to the implant described in U.S. Patent No. 9,339,649 or a variation thereof. In an embodiment, the implant is a combination of a cochlear implant and the implant of the '649 patent. Thus, an embodiment may include treating balance disorders in an active rather than reactive manner. In some specific embodiments, this can be accomplished by using a vestibular nerve stimulator, or at least using a cochlear implant to at least subtly stimulate the vestibular nerve by generating an electrical stimulation signal that is specifically configured to induce a response in one or more segments of the vestibular nerve (e.g., the vestibular ganglion, the lower branch of the vestibular nerve, and / or the upper branch of the vestibular nerve). That is, in some embodiments, there is stimulation applied to one or more portions of the peripheral vestibular system (e.g., the ampulla associated with the semicircular canals).
[0220] Thus, embodiments include treating a person with a therapeutic substance and / or an electrical stimulation device to reduce the likelihood and / or magnitude of future vertigo caused by a surgical procedure relative to what would otherwise occur without treatment. In embodiments, an existing implant (e.g., the implant that caused the vertigo in the first place) is used to treat the person, either through electrical stimulation and / or utilizing a therapeutic substance, which, for example, may be delivered from the implant. In embodiments, a cochlear implant may include one or more vestibular electrodes, or may otherwise be configured to provide stimulation to the vestibule, etc., in a manner that may be of practical value with respect to treating vertigo. Embodiments may include utilizing a standard cochlear implant, wherein one or more basilar electrodes are utilized to provide stimulation pulses that will affect the vestibular nerve.
[0221] Still, embodiments may focus on treatment and / or other protective measures and preventive measures. There is practical value in predicting the likelihood that more serious attempts can be made to mitigate or otherwise prevent the harmful effects of vertigo from occurring. In this regard, if there is no underlying data to support the conclusion that vertigo may occur, a broad, comprehensive statement of the likelihood that vertigo may occur without underlying support may be ignored by the recipient, or may not be effectively explained to the recipient or another recipient's family. By rough analogy, airline passengers will typically sit at route cruising altitude without wearing seat belts. But if turbulence is predicted, people are likely to use their seat belts. This analogy can be further extended because it is generally a good idea to always wear seat belts in an airplane regardless of whether there is turbulence. However, people are people, and people do not always participate in best practices or otherwise most cautious practices. Therefore, the prediction can be similar to the prediction of turbulence in the air at a future time location, and therefore actions that do not necessarily avoid turbulence but mitigate the effects of turbulence can be taken. So likewise, the effects of vertigo can be mitigated by, for example, refraining from performing certain activities or certain positioning of the body, and otherwise having a caregiver watch more closely so that if a vertigo attack occurs (because it is more likely to occur), that person can more easily help the recipient in the moment of need. An embodiment may include "warning" a close relative / loved one / caregiver that the recipient may be experiencing vertigo. This is as opposed to the recipient having to wait potentially minutes and / or hours for a caregiver to arrive. In fact, it may be as simple as offering assistance to the recipient to travel from the bathroom to the bedroom, or vice versa. Or helping to move from a kitchen, which may have sharp countertops or other hard surfaces, to an area with carpet and / or sofas.
[0222] Embodiments include predicting the time position of the onset of vertigo and / or the length of time that vertigo occurs. By way of example only and not limitation, embodiments may include making or otherwise formulating a prediction of the likelihood of vertigo occurring 12, 18, 24, 30, 36, 42, 48, 60, 72, 84, 96, 108, 120, 132, or 144 hours after the implantation of the cochlear implant is completed or otherwise any action starting at the trigger time period detailed herein (e.g., inserting an electrode array in the cochlea for the first time), or any value or range of values in increments of one hour therebetween, and such onset may occur 96, 120, 144, 168, 192, 220, 250, or 300 hours after any action starting at the trigger time detailed herein, or any value or range of values in increments of one hour therebetween. In exemplary embodiments, any of the above percentages of the likelihood of vertigo occurring may be the case for any one or more of these time positions. In an exemplary embodiment, the prediction may be that the time period of increased likelihood of vertigo may exist within 5, 6, 7, 8, 9, 10, 15, 20, 25 or 30 days or more from the onset of vertigo or any value or range of values in increments of one day therebetween. Thus, embodiments may include providing the above-mentioned recommendations for enhanced care for these time periods, and otherwise associating the recommended actions with these time periods and / or time locations. Buffers may also be applied at the beginning and / or end. After the time period has passed, implementation of the recommended action plan will cease in at least some exemplary embodiments.
[0223] It should also be noted that embodiments may include utilizing actual empirical results. By way of example only and not limitation, if after a certain time period from the estimated time location of the onset of the possibility of vertigo, the recipient has not experienced vertigo or at least severe vertigo within a certain time period, then therapy or another recommended action may be stopped. By way of example only and not limitation, if the recipient has not experienced vertigo 48, 60, 72, 96, 120, 144, 168, 192, 220, or 250 hours after the time during which the period during which the possibility of vertigo is thought to have begun to begin, or any value or range of values in one-hour increments therebetween, then treatment may be stopped. Thus, in an exemplary scenario, a prediction may occur that the recipient may experience vertigo caused by the implantation of a cochlear implant beginning at least 168 hours from the completion of the cochlear implant surgery (which in this scenario may be before, hence "at least"). If, after, for example, 96 hours or a week from the 168 hour mark, the recipient has not experienced vertigo, or has otherwise not experienced dangerous vertigo or otherwise severe vertigo, then the treatment regimen or recommended course of action can be discontinued (e.g., the caregiver can return to his or her home or stop living with the recipient, the recipient can begin driving a car again, etc.). This may also be the case if, for example, the recipient experiences vertigo during a certain time period, and then the recipient has not experienced vertigo or otherwise experienced severe vertigo for, for example, 60 hours (or any time period described herein) since he or she last experienced severe vertigo.
[0224] It should be noted that these exemplary scenarios should not be confused with the recipient's own report that he or she is experiencing vertigo and the health care provider recommending or otherwise indicating a course of action to resolve the vertigo. This is not a forecast or prediction. This is a response to an event that has already occurred. In other words, the forecasts and predictions detailed herein are for events that have not yet occurred and would otherwise be completely speculative, but are used for the innovative teachings detailed herein. In fact, by analogy, this can be similar to whether an insurance company will sell an insurance policy for vertigo to a recipient of a cochlear implant. If the recipient is experiencing vertigo, the insurer will not sell an insurance policy (at least not at a reasonable rate) to ensure protection against vertigo because the recipient has experienced vertigo. Instead, the insurer can conceivably use the teachings detailed herein to evaluate whether an insurance policy should be sold to cover vertigo or what premium should be charged otherwise. But it should be clear that this example is provided to give a qualitative example of the practical value of predictions and to distinguish predictions from the more common case of guesswork or other post-analysis.
[0225] And note that, in embodiments, the methods detailed herein are performed without regard to demographic and / or historical characteristics of the recipient. In this regard, in exemplary embodiments, the controlling factors for method actions 2420 and 2520 and / or continued treatment or otherwise recommended action plans are the data obtained in method actions 2410 and 2510, respectively. In other words, by way of example only and not limitation, demographic data and / or historical data may or may not be used to evaluate or otherwise as part of a determination process to formulate a prediction or otherwise determine that a recommended action plan or additional treatment plan is appropriate. However, in some embodiments, the controlling factor will be the data obtained in the just-mentioned method actions. In at least some exemplary embodiments, even if historical data and / or demographic data, etc. indicate that the recipient may be prone to vertigo after implantation, if the data obtained in the just-mentioned method actions indicate a low likelihood of vertigo, this will dominate, and vice versa.
[0226] In an embodiment, the method further comprises an action of comparing the obtained data with predetermined data. By way of example only and not limitation, the impedance value obtained between a given electrode (intracochlear electrode) and / or electrode pair (intracochlear electrode pair or at least one intracochlear electrode) may be compared with a predetermined value, wherein in at least some embodiments, (one or more) electrodes are all intracochlear electrodes, and in other embodiments, at least one electrode is an intracochlear electrode. Further, by way of example only and not limitation, two or more impedance values may be compared with a predetermined value and / or multiple predetermined values. In an exemplary embodiment, the action of formulating a prediction is based on whether the comparison indicates that the obtained data is above and / or below and / or at the predetermined data. In an exemplary embodiment, by way of example only and not limitation, there may be a predefined data set for each electrode pair (e.g., by way of example only and not limitation, pairs 2-3, 3-4, 4-5, 5-6). In an exemplary embodiment, the predefined data set may be the W, X, Y, and Z impedance values of the corresponding pairs. For example, if the impedance values of each pair are respectively lower than W, X, and Z, but the value of pair 4-5 is higher than or at, for example, Y, then it may be predicted that vertigo will occur. That is, in an exemplary embodiment, it can be determined that vertigo will not occur because only one of the four pairs shows an increased value. In an exemplary embodiment, there must be one or two or three or four or five or six or seven or eight or nine or ten or any value or range of values in increments of one therebetween that is at and / or above a particular set of values to determine that there will be an increased likelihood of vertigo. In fact, there can be practical value in "ignoring" or otherwise ignoring a limited amount of data as irrelevant. Further, there can be practical value in performing statistical analysis on the data, such as obtaining the mean and / or median and / or mode value of one or more impedance values.
[0227] In an exemplary embodiment, the impedance values of any one or more or all of electrodes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 or 22 (where 1 is the most basal electrode,), and / or the impedance values of adjacent electrode pairs relative to the four-point impedance can be utilized or otherwise obtained and evaluated to make a determination about whether there is an increased possibility of vertigo. For example, the impedance values of four or five or six most basal electrodes (or electrode pairs) can be utilized, and if other impedance values are obtained first, other impedance values can be ignored or disregarded. That is, the impedance values of some electrodes can be weighted more heavily than the impedance values of other electrodes. Therefore, in an exemplary embodiment, the impedance values of four or five or six most vertex electrodes (or electrode pairs) can be more or less weighted than the impedance values of other electrodes (such as the aforementioned basal electrodes). And for each pair or group of pairs (e.g., linear or geometric), the weighting can be different. The weighting may have utility value with respect to, for example, obtaining a mean and / or median and / or mode or otherwise performing statistical analysis on the data.
[0228] By way of example only and not limitation, in at least some embodiments, all electrode pairs, the most basal electrode pairs, the most vertex electrode pairs, the intermediate pairs, the most basal pairs and the intermediate pairs, the intermediate pairs and the most vertex pairs, the pairs consisting of electrodes 2-3, 3-4, 4-5, 5-6, 6-7, 7-8, 8-9, 9-10, 10-11, 11-12, 12-13, 13-14, 14-15, 15-16, 16-17, 17-18, 18-19, 19-20, and 20-21 or any combination thereof (including pairs (starting from 2-3) 1 and / or 2 and / or 3 and / or 4 and / or 5 and / or 6 and / or 7 and / or 8 and / or 9 and / or 10 and / or 11 and / or 12 and / or 13 and / or 1 4 and / or 15 and / or 16 and / or 17 and / or 18 and / or 19) having an average body impedance greater than and / or equal to 130, 135, 140, 145, 150, 155, 160, 165, 170, 175, 180, 185, 190, 195, 200, 205, 210, 215, 220, 225, 230, 235, 240, 245, 250, 260, 270, 280, 290, 300, 310, 320 or 330Ω or any value or range of values therebetween in increments of 0.1Ω (e.g., 163.5, 172.4, 166.6 to 186.6, etc.) can be used as a basis for declaring an increased likelihood of vertigo, and therefore predicting it.
[0229] In an embodiment, the data obtained in the method actions detailed above is one or more of the following: (i) an average four-point impedance across at least 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, or 21 electrodes of a cochlear implant, or any value or range of values in increments of 1 therebetween (where, as an example, the impedance across at least four electrodes can be electrode pairs 2-3 and 3-4 and 4-5, or 2-3 and 5-6, etc.); (ii) a maximum four-point impedance within the cochlea (e.g., identifying the maximum impedance between two electrodes); (iii) an average impedance within the cochlea (the average of all impedance readings); or (iv) a maximum impedance within the cochlea at locations corresponding to the basal, middle, and / or apical thirds of the cochlea. In an embodiment, the impedance data is normalized data, such as data normalized relative to intraoperative impedance. In an exemplary embodiment, the normalization techniques detailed herein may be utilized. In an embodiment, an impedance value that is elevated by a certain amount relative to the intraoperative impedance may indicate future vertigo. Any one or more of these data may be compared to a baseline / threshold and evaluated for prediction.
[0230] In an embodiment, one or more of the data of the method includes an average basal four-point impedance value, or the method includes generating an average basal four-point impedance value (for example, if the data provided is raw impedance values). And the method can further make the prediction of the occurrence of vertigo based on the average basal four-point impedance value.
[0231] Thus, in some embodiments, the data obtained in the method actions are data indicating impedance between electrodes in at least the basal portion of the cochlea, in at least the middle portion of the cochlea, and / or in at least the apex portion of the cochlea. The impedance between may be a four-point impedance, or may be a body impedance between the electrodes.
[0232] It should be noted that embodiments may include performing one or more of the actions herein while ignoring surface effects from electrodes, so long as the given technology involved is capable of achieving such actions, or variations or similar actions thereof.
[0233] Embodiments include periodically testing / measuring / obtaining impedance values. In embodiments, the data of the method detailed above is data acquired (different from acquisition—data can be acquired and obtained by the same entity, and acquired and obtained by different entities, acquisition is, for example, actual acquisition using a cochlear implant) at at least a first time position. The first time position can be any of the above positions. In embodiments, the method also includes obtaining second data acquired at a second time position at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140 or 150 hours after the first time position or any value or range of values in increments of 1 hour therebetween. It should be noted that additional data can be acquired in between. In fact, in embodiments, data can be acquired at a rate of less than one hour, every two hours, every three hours, etc. If subthreshold currents are utilized, in some cases data may be acquired continuously, but in embodiments there is practical value in limiting the use of the cochlear implant until after the healing period is complete. In this exemplary embodiment, the data acquired at the first time location is consistent with the data acquired at the second time location. By way of example only and not limitation, the impedance value is above the threshold value described above. This may be an average median and / or mode variation of the evaluation data, or may be a single datum. In embodiments, the impedance value or statistical analysis value is within 5, 10, 15, 20, 25, 30, 35, or 40% of the data acquired at the first time location (where the datum is used as the denominator). In an exemplary embodiment, the method further comprises obtaining third data and / or fourth data and / or fifth data and / or sixth data and / or seventh data and / or eighth data, wherein the data are continuously acquired in a manner of at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 95, 100, 110, 120, 130, 140 or 150 hours or any value or range of values in increments of 1 hour therebetween. In an embodiment, for at least some and / or all of these data, the above-mentioned phenomenon associated with the value is seen.
[0234] Thus, for embodiments in which the method includes identifying a therapy and / or a recommended course of action based on the data, the method may further include continuing the therapy and / or the recommended course of action based on the consistency.
[0235] In an embodiment, when data acquired after a first time position is inconsistent with the data acquired at the first time position, this may be an indication in some embodiments that vertigo is no longer likely to occur. In an exemplary embodiment, if the data at the subsequent time position meets any of the criteria detailed above regarding indications that vertigo is likely not to occur, the embodiment may include stopping treatment or otherwise stopping the recommended course of action. Therefore, for embodiments in which the method includes identifying a therapy and / or a recommended course of action based on the data, the method may also include interrupting the therapy and / or the recommended course of action based on the inconsistency.
[0236] Thus, an embodiment may include a method wherein a prediction is formulated that there is a likelihood that the recipient will experience vertigo (including any percentage likelihood as detailed above). The method may include recommending a course of action based on any one or other actions described herein. The method also includes obtaining second data based on one or more second intra-cochlear measurements, wherein the one or more second intra-cochlear measurements are obtained by a cochlear implant at least 72, 96, 120, 144, 168, 192, 220, 250, 270, 300, 325, or 350 hours after the one or more intra-cochlear measurements are obtained and / or after the implant is completed or any time trigger described herein is triggered, or any value or range of values in increments of 1 hour therebetween. The method may include the action of formulating a second prediction that the recipient is unlikely to experience vertigo after the time location of obtaining the second data. And note that data collection may be performed prior to the time period for obtaining the second data. In fact, in an exemplary embodiment, data is collected two or three or four or five or six or seven or eight or more times between the data collection on which the prediction is based and the second data collection. In an embodiment, data may be acquired hundreds or even thousands of times or possibly even tens of thousands of times, as long as this does not adversely affect the implantee. In an embodiment, the various method actions detailed herein may be automated. By way of example only and not limitation, the cochlear implant may be programmed to automatically perform impedance measurements, or may be controlled to perform impedance measurements. In fact, in an embodiment, the analysis of the measured values may also be automated. An algorithm may be present or otherwise prepared to determine whether there is a possibility of vertigo. By way of example only and not limitation, if the average, median and / or mode of any electrode group is to be relied upon, or if the raw number meets or exceeds a threshold, the prediction may be automatically determined, and / or vice versa (including meeting or being below a threshold). However, in common practice, the initial assessment will be performed by a person, and then potential automatic data collection may be performed. And therefore, in an embodiment, by way of example only and not limitation, additional data collection may be evaluated or otherwise analyzed, and it may be determined that the elevated impedance level still exists or that inflammation still exists in addition, and therefore the prediction of continued vertigo still exists. On the contrary, an evaluation may be automatically performed to determine that the impedance value is now below or at a threshold indicating that vertigo is not possible in the future. Still, in embodiments, an assessment that the value is low or at a threshold may be made automatically, and then a human may make another assessment to determine (endorse) a prediction that vertigo is unlikely to occur. Thus, the above method may include formulating a second prediction that the recipient is unlikely to experience vertigo after the time location at which the second data was obtained. In embodiments, the outlook without vertigo may be at least 1, 2, 3, 4, 5, 6, 7, or 8 weeks, and the vertigo is associated with the cochlear implant.
[0237] In addition, in embodiments where remedial action is taken based on determining the likelihood of dizziness (e.g., recommending that the recipient take medication, or that the recipient avoid using ladders, etc.), there is a method where, based on a second prediction, the remedial action is aborted (e.g., recommending that the recipient do something that was previously recommended not to do, etc.).
[0238] In an embodiment, the predicted dizziness is a dizziness that prevents the recipient from standing upright for 5, 10, 15, 20, 25, 30, 35, 40, 45, 50, 55 or 60 seconds without adjusting the position of his or her feet. In an embodiment, the predicted dizziness can be a prediction of the time spent by a person leaving a chair and / or walking a certain distance and returning to a chair. The length of time can be a measure of dizziness. And the test herein can be used to estimate the time or otherwise estimate the qualification associated with the time. In an embodiment, the predicted dizziness is a dizziness that prevents the recipient from meeting the baseline just mentioned immediately after getting up from a seated position. In an embodiment, the predicted dizziness is a dizziness that prevents the recipient from touching his or her nose three times with eyes closed within 30, 45 or 50 seconds. In an embodiment, the predicted dizziness is a dizziness that prevents the recipient from passing a manual / body sobriety test implemented by the laws of the Commonwealth of Virginia, the Commonwealth of Pennsylvania, the United Kingdom or New South Wales as of December 21, 2022. In an embodiment, the predicted dizziness is dizziness that prevents the recipient from walking in a straight line with his or her arms out to the side for three (3) meters. Note that in all of these examples, the recipient can do this before the dizziness begins.
[0239] In an embodiment, the predicted dizziness is not debilitating dizziness, but rather is dizziness that merely makes the recipient uncomfortable, irritable, or nauseous. In an embodiment, the predicted dizziness makes the recipient want to lie down.
[0240] In embodiments, the recipient experiences vertigo at the above rates in the absence of therapeutic substance treatment and / or electrical stimulation.
[0241] In an embodiment, vertigo (nystagmus) is measured using a rotating chair test, a video nystagmus map (VNG), a computerized dynamic posturography (CDP), and / or an evoked potential test. That is, the predicted / predicted vertigo is the vertigo that will be indicated as vertigo by one or more of these tests. And in some embodiments, in the absence of treatment, the predicted vertigo occurs in a manner that will be detected by one or more of these tests. In an embodiment, the vertigo recorded by one or more of these tests may or will require some form of intervention by an ordinary, reasonable health care professional / ordinary person skilled in the art, or will otherwise prompt a health care professional in the art of at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, or 90% or more, or any value or range of values in increments of 1% therebetween to recommend intervention.
[0242] In an embodiment, the data obtained in method actions 2410 and 2510 are used to assess the severity of vertigo / predict / predict the severity of vertigo. In an embodiment, the higher the impedance value (raw or statistical or other), the more severe the vertigo. Therefore, an embodiment includes changing the recommended action / treatment plan based on the predicted severity. By way of example only and not limitation, if the data obtained in method actions 2410 and / or 2510 indicate that the vertigo will be mild and otherwise not severe, the recommendation may be to take only some slight precautions or otherwise pay attention to the onset of the vertigo sensation and be prepared to take action accordingly. If, for example, the prediction is for moderate vertigo, the recommendation may be to avoid driving or otherwise operating heavy machinery or riding a bicycle, etc. If the prediction is for severe vertigo, the recommendation may be to stay in bed as much as possible during the predicted time period and / or stay in a comfortable recliner or otherwise sofa, or otherwise always have another person present or otherwise next to you, or otherwise avoid hard objects or sharp objects, such as avoiding the kitchen or bathroom, and also having someone present when in such an area. Indeed, in an exemplary scenario, the recommendation may be to wear a bicycle helmet, etc., when not in bed or sitting, as a beneficial precaution.
[0243] It should be noted that in an embodiment, there is a correlation between the impedance value or impedance data and the severity of the results of the vertigo test. By way of example only and not limitation, an impedance value greater than 25, 30, 35, 40, 45, or 50% or more of the above impedance values or other thresholds for predicting the possibility of vertigo may indicate a moderate vertigo situation, and by way of example only and not limitation, an impedance value greater than 35, 40, 45, 50, 55, 60, 65, 70, 80, 90, or 100% or more of the above impedance values or other thresholds for predicting the possibility of vertigo may indicate a severe vertigo situation.
[0244] In an embodiment, the recommended action plan for predicting vertigo can be to install handles near the bathroom and / or shower and / or toilet, always use handrails when going up and down stairs, use canes and / or walkers, and practice exercises that can improve balance, such as vestibular rehabilitation therapy, yoga, Tai Chi, gymnastics, or Taekwondo (post-implantation procedures). The recommended action plan can also be to remove debris on the floor or objects on the floor that people may trip over, or otherwise move objects with a high center of gravity, or otherwise surround small pets and / or children. In some embodiments, there is no fire during a given time period, and / or the recipient is away from the stove, etc. In fact, in an embodiment, hard surfaces such as fireplace hearths can be covered with protective pads. A corollary to this is that, in an embodiment, objects that move randomly or even move in a pattern can be removed or eliminated or otherwise reduced (in terms of quantity or appearance). As an example only and not a limitation, an automatic vacuum cleaning robot may be disabled for a period of time. For example, strobe lights will be disabled, and televisions may be disabled, or at least watching programs on television will be limited to programs without a lot of movement or chaotic movements. In an exemplary embodiment, the recommendation may be that the recipient sit on the side of the bed for a period of time, such as one minute or two minutes or three minutes or more, before leaving the bed. In an embodiment, the recommendation may be that the recipient stand up from a sitting position, and then remain standing for 30 seconds or one minute or two minutes or more before continuing to walk. In an embodiment, the recipient may be advised to avoid [poorly lit and / or] dark places, or otherwise the recipient keeps the lights on or otherwise at a higher level than would otherwise be the case. In an exemplary embodiment, the recipient is advised to avoid heights, or to avoid using stairs or ladders or otherwise wearing, for example, high heels, etc. In an exemplary embodiment, the recipient is advised not to run or swim or ski or engage in certain exercises that involve running or otherwise walking along busy streets or walking on concrete or asphalt surfaces, etc.
[0245] In an exemplary embodiment, the method includes reacquiring impedance values or otherwise obtaining data indicating impedance values or information and / or blood in the cochlea. These actions can be performed 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80 or 90 days or more after completing the implant surgery and / or any trigger detailed herein. In an exemplary embodiment, the data can be re-evaluated, and if the data indicates that the likelihood of future vertigo caused by implantation of the cochlear implant is low, the recommendation can be avoided or otherwise changed. On the contrary, if the data indicates that the likelihood of vertigo persists, the recommendation can be maintained or otherwise modified. In fact, if the data indicates an increase in severity, more severe measures or suggestions can be taken or otherwise at least recommended. Therefore, an embodiment can include performing any one or more of the methods detailed above, and making a recommendation that the recipient take any one or more of the actions detailed herein due to determining that the recipient has a high likelihood of experiencing vertigo in the future due to the cochlear implant. Then, after, for example, five days or 10 days or 15 days or any of the time periods detailed above, the data can be reacquired, the data can then be obtained and analyzed, and based on the results of the data, further recommendations can be made and / or previous recommendations can be revoked.
[0246] It should be briefly noted that embodiments include ignoring vertigo that occurs within the first, second, third, and / or fourth day after implantation. In an exemplary embodiment, as an example, the recommendation is primarily based on or at least based on control information regarding whether the recommended action to take preventive measures due to prediction of future vertigo is based on data obtained from inside the cochlea or other cavity and / or data related to inflammation and / or blood in the cochlea or other cavity. In fact, in an exemplary embodiment, there is a method of warning the recipient or otherwise providing the recipient with recommendations to take within the first week after implantation, and then indicating to the recipient that the recipient does not need to worry about vertigo caused by the cochlear implant after five or six or seven or eight or nine or 10 or 11 or 12 days from implantation or any time trigger applicable.
[0247] Thus, embodiments include predicting / predicting vertigo following cochlear implantation. Vertigo may include unsteadiness, dizziness, new onset vertigo, and / or non-specific vertigo. In embodiments, vertigo is independent of age, cause of hearing loss, and preoperative vestibular function. In embodiments, the recipient does not have pre-existing vertigo / does not suffer from a condition that causes pre-existing vertigo and does not have pre-existing vertigo associated with the original cause of their hearing loss (e.g., Meniere's disease, delayed endolymphatic hydrops, autoimmune inner ear disease).
[0248] Embodiments include using to measure or otherwise confirm inflammation, such as the extent of inflammation, the level of inflammation, as quantified by impedance, such as four-point impedance (4PI). Embodiments include using 4PI to measure the body impedance between electrodes, and in embodiments, an increase in cell density (e.g., from blood, inflammatory cells, or fibrosis) between the measuring electrodes will result in a higher impedance. In embodiments, there is a positive correlation between 4PI and the percentage of fibrosis in the cochlea after cochlear implantation and the presence of blood.
[0249] In embodiments, the prediction is not related to prediction of vertigo within one day or two days or three days of completing the implantation of the cochlear implant. In this regard, in some embodiments, it may be more common to experience vertigo at the one day or two day mark, so predicting this situation may be similar to predicting that there will be precipitation in the next month.
[0250] In an embodiment, the information used to determine whether there is an increased likelihood of vertigo is the average basal 4PI (calculated from the average of the 6 most basal measurements). In an embodiment, the average 4PI is used and / or the maximum basal 4PI is used, and its value is compared with a predetermined value to determine whether there is an increased likelihood of vertigo. Therefore, in an embodiment, if the value is lower than a predetermined value and / or equal to a predetermined value, it is determined that there is no increased likelihood of vertigo, and vice versa.
[0251] Embodiments may include, but are not limited to, utilizing the most basal 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 measurements and not using the other measurements to determine if there will be an increased likelihood of vertigo.
[0252] In embodiments, CI-related vertigo at 1 week post-surgery is predicted in recipients with a statistically higher 1-day mean basal 4PI, and in some embodiments, this significant difference in mean basal 4PI continues at 1 week. In embodiments, the value of impedance (e.g., mean median and / or mode and / or (one or more) individual impedance values) can be at least 50, 75, 100, 125, 150, 175, 200, 225, 250, 275, 300, 350 or 400%, or any value or range of values therebetween in 1% increments, for those recipients predicted to have an increased likelihood of vertigo compared to those predicted not to have an increased likelihood of vertigo. In an exemplary embodiment, patients predicted to have an increased likelihood of vertigo have these impedance values relative to recipients who do not display or otherwise ultimately do not display symptoms of vertigo within the time frame detailed herein. In an exemplary embodiment, patients predicted to have an increased likelihood of vertigo have these impedance values relative to at least 50, 55, 60, 65, 70, 75, 80, 85, 90, 95 or 100% or any value or range of values in 1% increments therebetween of recipients who did not experience vertigo during the aforementioned time period within at least 10, 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 or 80 consecutive predictions.
[0253] In embodiments, the predicted vertigo and / or the actually induced vertigo is post-operative cochlear implant-related vertigo, characterized by the onset of new instability (not present prior to implantation) and / or the absence of rotational vertigo one week after completion of surgery.
[0254] In the example, there was no correlation between the mean basal 4PI and the SVV angle 1 week after surgery.
[0255] In embodiments, the identified inflammation is utricle inflammation. In other embodiments, the inflammation is other than utricle inflammation. In embodiments, recipients who ultimately do experience vertigo do not experience acute labyrinthine dysfunction.
[0256] The techniques herein are intended to preserve the patient's preoperative natural hearing in order to enable electroacoustic stimulation, thereby allowing for an improved hearing experience relative to other situations. Although "soft" surgical techniques have been widely developed, in more than half of cases, patients still lose residual hearing after cochlear implantation. There are two types of hearing loss that are commonly reported: immediate or delayed hearing loss. Immediate hearing loss may be the result of damage within the cochlea during implantation, in which the overall structure within the cochlea is damaged, resulting in cochlear cell death or structural destruction involved in the natural hearing pathway. Delayed hearing loss may occur several months after cochlear implantation, where the determining factors are largely unknown. Foreign body reactions and fibrosis formation may often cause delayed hearing loss. At least some embodiments include using readings from within the cochlea to avoid or otherwise reduce the likelihood of these situations occurring relative to other situations without the teachings herein.
[0257] Electrical impedance is a measure of the electrical opposition presented by a circuit when an electric current is applied, and can be used to obtain data about the environment within a person's cochlea. These data can be used to assess the integrity of the implant and compliance with stimulation. Impedance can be measured in (at least) two ways. The first is to use a monopolar or common ground configuration, where the common ground impedance (CGI) stimulates one intracochlear electrode while the remaining electrode serves as a ground and is largely affected by changes occurring at the electrode-tissue interface.
[0258] A second impedance measurement, four-point impedance (4PI), can be used. As detailed above, 4PI involves four adjacent intracochlear electrodes, where current is applied to the two outer electrodes while the voltage difference is measured between the two inner electrodes. This configuration minimizes the effects of the electrode-tissue interface because different electrodes are used for stimulation and voltage recording, which allows for a more direct measurement of the environment surrounding the electrode array. Four-point impedance was an outcome measure in a clinical trial testing a steroid-eluting electrode array, which was thought to reduce inflammation within the cochlea, with the results showing reduced values in the steroid-eluting group compared to controls. Studies on the use of 4PI are conflicting. A clinical report involving 2 participants reported no significant differences in 4PI from 1 day to 1 year after cochlear implantation.
[0259] There are currently no measures that can be used as early detection of inflammation and fibrosis as it relates to hearing outcomes. Instead, the above test identifies fluctuations in impedance measurements after cochlear implantation and identifies relationships to cochlear pathology that could potentially impact hearing. Specifically, changes in four-point impedance measurements are tracked over time and this provides insight into changes in the intra-cochlear environment after implantation. The above test investigates the effects of cochlear implantation with a 532 / 632 perimodiolar array that can be used in patients with minimal residual hearing. TM cochlear implant recipients.
[0260] In the above tests, electrical impedance was measured in adult cochlear implant candidates. All candidates were implanted with either a cochlear CI532 or CI632 core implant. TM =The 10-year-old patient received a 30-day follow-up hearing test (6-month follow-up) using a 30-day follow-up hearing aid (Cochlear, Sydney, Australia) with 22 half-band electrodes and a pre-curved modiolar array. The implants were inserted into the scala tympani via an enlarged round window approach or a cochleostomy anterior to the round window. Implant opening occurred 2 weeks after implantation. Based on pre-implantation audiometry, the candidates had no measurable hearing (or >80 dB HL), so hearing results were not collected. The surgical approach (cochleostomy or round window insertion) was recorded.
[0261] Impedance measurements were performed immediately after the implant was placed in its final position during surgery; 1 day, 1 week, 4 / 6 weeks, and 3 months after implantation. Stimulation was a charge-balanced biphasic pulse of 25 μs duration, 7.5 μs interphase gap, and a current level of 120 (approximately 0.11 mA). A single voltage measurement was made at the end of the first phase of the biphasic pulse using the implant's built-in voltage measurement capability. The measurements were transmitted to an external sound processor connected to a Freedom Sound Processor connected via USB to a PC laptop (Dell, TX, USA). TM Programming Device (POD). Two types of impedance were measured in the tests: CGI and 4PI. Common ground yields one measurement per intracochlear electrode, and therefore 22 per stimulation. However, with 4PI, since the implant contains 22 intracochlear electrodes, it provides 19 groups of 4 consecutive electrodes along the array, and therefore 19 impedance measurements.
[0262] High-resolution temporal bone CT scans were obtained after cochlear implantation to assess the angular depth of insertion and other events that affect impedance, such as tip folding. For this purpose, the original DICOM files were analyzed by multiplanar reconstruction (MPR) using the HOROS medical image viewer (The Horos Project, Geneva, Switzerland). The analysis was performed using a single-slice image with a thickness of 150 μm, which shows the best view of the cochlea (including all intracochlear electrodes, the round window, and the modiolus of the cochlea). According to the technique previously described by Miguel et al. (Miguel A'R, Arugo AA, Barreiro SAB, González JCF, Macías AR, "Imaging evaluation of electrode placement and effect on electrode discrimination on different cochlear implant electrode arrays", European Archives of Oto-Rhino-Laryngology, 2018; 275(6): 1385-1394), the coordinates of all intracochlear electrodes, the round window, and the modiolus of the cochlea were collected and then analyzed in a custom script in MATLAB (Mathworks) to obtain the angular insertion depth.
[0263] Data were analyzed using R statistical software (version 4.04 (R Core Team, R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria 2021), package: emmeans (Lenth RV, emmeans: Estimated Marginal Means, aka Least-Squares Means 2021, R package version 1.6.1.), lme4 (Bates D, M. Bolker B, Walker S., Fitting Linear Mixed-Effects Models Using lme4, Journal of Statistical Software, 2015; 67(1): 1-48)) All statistical analyses were performed. Linear mixed effects models were fitted to the impedance data. In all models, the impedance data were transformed on a logarithmic scale to ensure that the model assumptions were met, however the results are reported after inverse transformation of the data. The first linear mixed effects model was fitted to the impedance of each electrode to compare the impedance along the electrode array across time and between impedance types. The number of electrodes and time and all interaction terms were included as fixed effects. The number of electrodes was treated as a categorical variable. The random effects were patient, time within the patient, and number of electrodes within the patient. This was applied to the CGI and 4PI data. A second model was fitted to determine the different patterns of 4PI in patients after cochlear implantation. The change in the mean 4PI measurements over time was normalized to the mean impedance measured intraoperatively. This model was similar to the previous model; however, the patients were grouped according to the changes seen 1 day after surgery. This model was fitted to the CGI and 4PI. No adjustments were made for multiple comparisons.
[0264] From 21 cochlear implant recipients, 88 4PI measurements were collected, including 21 measurements intraoperatively, 19 at 1 day, 16 at 1 week, 17 at 4 / 6 weeks, and 15 at 3 months. For the CG, 84 measurements were obtained, 18 from surgery, 19 at 1 day, 15 at 1 week, 17 at 4 / 6 weeks, and 15 at 3 months.
[0265] For CGI and 4PI, estimated marginal means across time were calculated for each electrode along the array.Overall tests from the first linear mixed model indicated time, number of electrodes, and the interaction between number of electrodes and time effects 4PI (all p<0.002). Fig.17The average of all 19 4PI measurements at each time point is shown, with 1 being the most basal measurement and 19 being the most vertex measurement. Intraoperatively, impedance was similar along the electrode array, with an average of 205Ω and a maximum impedance of 229Ω at the most basal measurement (measurement 1). Comparing intraoperatively to day 1, impedance increased for all electrodes, with an average impedance of 342Ω. The highest values occurred at the 8 most basal measurements, with an average of 340Ω. Impedance decreased from measurements 9 to 13, ranging from 311Ω to 248Ω, while the average of the 6 most vertex measurements was 232Ω. For measurements 1 to 10, the impedance increase from intraoperatively to day 1 postoperatively averaged 138Ω (all p<0.05). At 1 week post-implantation, the basal measurements were lower than at day 1 and were of similar size to the remaining electrodes along the array. From intraoperatively to week 1, impedance increased along the array, with an average increase of 70Ω. Impedance at 4 / 6 weeks decreased to levels similar to intraoperatively, with a slightly higher average of 220Ω. At 3 months, impedance increased across the array with a decreasing trend from base to apex. From electrodes 1 to 14, impedance decreased from a maximum of 350 Ω to 220 Ω. The remaining electrodes were of similar size with a mean of 211 Ω, a slight increase from intraoperatively, and the remaining electrodes maintained this mean. The 8 most basal measurements increased by an average of 85 Ω from intraoperatively to 3 months (all p < 0.025).
[0266] The linear trend of the 4PI was calculated at all time points, with the number of electrodes treated as a continuous variable. Fig.17 Linear trends and 95% confidence intervals (grey areas) along the array are shown. It should be noted that the trend is fitted, and the impedance data are transformed on a logarithmic scale, so there is some curvature in the line. Intraoperative, 1 week and 4-6 weeks showed similar trends, relatively straight, with a slight increase from base to apex. There was no significant difference in the trend between intraoperative and 1 week (mean = 0.0006, p = 0.850), intraoperative and 4-6 weeks (mean = 0.003, p = 0.218), and 1 week and 4-6 weeks (mean = 0.003, p = 0.350). The linear trends are similar to each other after 1 day and 3 months, characterized by an increase in base measurements and a decrease in apex (mean = -0.006, p = 0.717).
[0267] For CGI, you can Fig.18Estimated marginal means are seen in . Overall tests showed interactions between number of electrodes, time, and the two affected CGI measures (all p<0.009). Intraoperatively, impedance fluctuated across the array with a mean of 4278Ω. At 1 day, all impedances were below intraoperative levels with a mean decrease of 986Ω (p=0.043). At 1 week, impedance showed an increasing trend from base to apex with a minimum of 4693Ω at the most basal electrode and a maximum of 7119Ω at electrode 19. Electrodes 7 to 22 (excluding 12, 13, 14, and 16) were significantly different from all other time points (all p<0.045). At 4 / 6 weeks and 3 months, measurements decreased to slightly below intraoperative levels with a mean decrease of 349Ω (p=0.898) and 626Ω (p=0.497), respectively.
[0268] The linear trend of CGI was quantified at all time points ( Fig.18 , gray area). Linear trends were fitted while transforming the impedance data on a logarithmic scale. There was a decreasing trend from base to apex at intraoperative, 1 day, and 3 months. These trends were not significantly different from each other (all p>0.114). The linear trends at 1 week and 4-6 weeks increased from base to apex, but the differences were significant (mean=0.011, p<0.001).
[0269] The mean common ground and 4PI were calculated for each patient at all time points. Fig.19 Comparisons between the two impedance measurements at all time points are shown, including linear regression lines fitted to the data. There was a strong correlation between the four points and CGI at intraoperative, 1 day, 1 week, and 3 months. Further analysis was performed to assess whether the increase in 4PI observed after 1 day was associated with an increase in CGI after 1 week. The average impedance of each patient at 4PI after 1 day and CGI after 1 week was calculated. Pearson correlation was performed, and it showed no relationship between the two time points and impedance measurements (r=0.031, p=0.92, Pearson correlation).
[0270] Further analysis was performed to assess whether the greater increase in 4PI on day 1 was associated with increases at other time points. The mean 4PI for all time points was calculated and normalized to the intraoperative mean for each patient. The patients were subdivided into two groups; patients who experienced less than 10% increase in 4PI on day 1 (n=5) compared with intraoperatively, and patients with an increase greater than 10% (n=10). The 10% cutoff was based on a visual inspection of the data. All normalized changes at all time points were averaged and plotted for both groups with their corresponding 95% confidence intervals (Figure 4). Overall tests showed that for the low group, 4PI did not change significantly across time points (p=0.491), but for the high group, there were significant changes (p<0.001). At day 1, the intraoperative normalized change in the high group was an average of 1.265 higher (p<0.001) compared with the low group, and the low group decreased slightly (mean=0.973). Minimal differences were shown at 1 week and 4 / 6 weeks post-surgery, however at 3 months the normalized change was 0.710 higher than the low group on average (p=0.012). Interestingly, for electrodes 3 to 12, differences at 1 day and 3 months post-surgery were strongly correlated with intraoperative levels (r>0.560).
[0271] The same analysis was performed on CGI, keeping the same subgroups as for the 4PI data ( Fig.15 ). Overall test showed that the high group had significant changes over time (p = 0.035), while the low group did not have significant changes (p = 0.102). No significant differences between the subgroups were detected, however the high group maintained higher normalized changes at all time points. Four-point impedance and common ground impedance ( Fig.16 ). The 4PI across the electrode array was nearly identical between the groups with no significant differences. For CGI, the Low group showed higher impedance measurements across the array when compared to the High group, but not significantly.
[0272] Temporal bone CT scans were collected from 12 patients, 6 in each group. The results showed that the mean angular insertion depth was similar in both groups (<10% mean = 390°, >10% mean = 412°). The difference was not significant (p = 0.260). In addition, the surgical approach did not affect the angular insertion depth or 4PI fluctuation after implantation, because the number of patients with cochleostomy or enlarged round window was equal in both groups.
[0273] The two impedance measurements investigated in studies related to the above tests have been found to be affected by different aspects of the environment surrounding the electrode array. The common ground impedance is heavily affected by the electrode-tissue interface, representing cell adhesion to the electrode surface. However, this was found to have minimal effect on the 4PI, which instead closely represents the environment in the perilymphatic space immediately adjacent to the stimulating electrodes (16, 17, 20, 22, 23, 31).
[0274] The four-point impedance increased significantly at 1 day, especially in the basal region of the cochlea.
[0275] In this study, increases in 4PI were observed in a subgroup of patients 1 day after implantation. There was no indication that these increases were a direct result of physical trauma, considering that intraoperative impedance was similar between the two groups ( Fig.16 ). However, these increases may indicate the extent of an acute inflammatory response triggered by a cell death pathway. Since impedance measures the electrical opposition to the applied current, the influx of inflammatory cells into the perilymphatic space will affect the measured value. The impedance of a conductive fluid (such as perilymph) is relatively low because it offers little opposition to the current, but if cells infiltrate the perilymphatic space, the applied current cannot penetrate the membrane of the cell. It is believed that this lack of capacity reduces the volume available for conducting current, resulting in an increase in impedance measurements.
[0276] Further mechanical trauma may occur during insertion due to the surgical approach. In this study, either an enlarged round window or a cochleostomy was used when inserting the CI532 perimodiolar array. Both approaches require drilling of the cochlear wall to reach the scala tympani, which may result in bleeding, bone dust infiltration into the cochlea, or loss of perilymph from the scala tympani. All of the above events promote a more extensive inflammatory response and may contribute to the increased impedance in the basal region.
[0277] It is believed that the increase in 4PI is not caused by changes occurring at the electrode-tissue interface, but rather by changes within the environment of the scala tympani (since the CGI does not increase within 24 hours). The increase in CGI arrangement at 1 week is believed to be the result of electrode polarization, which is due to the accumulation of cells on the electrode surface causing an increase in impedance, which decreases when the implant is turned on. When the implant is inactive, cells are able to adhere consistently to the electrode surface, thereby increasing the impedance measurement. Once the implant is turned on 2 weeks after implantation, electrical stimulation is initiated and the cells are subsequently blown away from the electrode surface. As a result, the CGI decreases and remains relatively stable thereafter. Electrode polarization does not affect 4PI or has a negligible effect, supporting the observation that changes at the electrode-tissue interface have minimal effect on 4PI measurements.
[0278] There was an increase in 4PI in the basal region of the cochlea at 3 months, similar to 1 day post-implantation. A chronic inflammatory response is expected to begin within a few months after cochlear implantation. This may be accompanied by fibrous tissue formation as part of the natural healing process, in addition to connective tissue and new bone growth, or in combination with chronic inflammation. The increase in the basal region means that fibrotic formation is localized in this area. This is accompanied by the formation of fibrous tissue originating from the insertion site and decreasing in volume as it progresses throughout the cochlea.
[0279] Statistical analysis showed that in cochlear implant recipients, 4PI at 1 day was highly predictive of impedance at 3 months. This suggests that the severity of the acute inflammatory response in the cochlea may be associated with the extent of the chronic inflammatory response and subsequent fibrosis formation. In contrast to the strong correlation between common ground and four-point impedance ( Fig.19 ), CGI did not have the same predictive power as 4PI and did not increase at time points consistent with an inflammatory response. The subgroup with a greater than 10% change in 4PI exhibited higher CGI at all time points. This could indicate more cells adhering to the electrode surface or greater fibrosis formation around the electrode array. The increases seen in 4PI are believed to be related to a widespread inflammatory response.
[0280] At least some exemplary embodiments according to the teachings detailed herein utilize advanced learning signal processing techniques that can be trained or otherwise trained to detect higher order and / or nonlinear statistical properties of signals. An exemplary signal processing technique is a so-called deep neural network (DNN). At least some exemplary embodiments utilize DNNs (or any other advanced learning signal processing techniques) to process signals representing captured sounds, the processed signals being used to evoke hearing perception. At least some exemplary embodiments require training signal processing algorithms to process signals indicating captured light or reflected acoustic energy and / or radio frequency energy. That is, some exemplary methods utilize learning algorithms or schemes or systems, such as DNNs or any other system that may have practical value, which would otherwise enable the teachings detailed herein to analyze data captured by electrodes. Some embodiments use expert systems.
[0281] A "neural network" is a specific type of machine learning system, and embodiments include using a neural network to analyze data captured by a sensor. Any disclosure of the category "neural network" herein constitutes a disclosure of the genus "machine learning system". Although the embodiments herein are focused on this category of neural networks, it should be noted that other embodiments may utilize other types of machine learning systems accordingly, and any disclosure of neural networks herein constitutes a disclosure of any other type of machine learning system that can implement the teachings detailed herein and variations thereof. For clarity, at least some embodiments according to the teachings detailed herein are embodiments that have learning capabilities without being explicitly programmed. Therefore, with respect to some embodiments, any disclosure of an apparatus or system herein constitutes a disclosure of an apparatus and / or system that has learning capabilities without being explicitly programmed, and any disclosure of a method (constituting at least one method of analysis) constitutes an action that results in learning without being explicitly programmed for this.
[0282] Some specific details of DNNs used in some embodiments are described below, including some exemplary processes for training such DNNs. However, first, some exemplary methods of utilizing such DNNs (or any other system that may have practical value) will be described.
[0283] It should be noted that in at least some exemplary embodiments, a given functionality and / or method action as detailed herein is implemented using a DNN or product from machine learning, etc. In some cases, for the purpose of language economy, an apparatus and / or system for performing an action, etc. will be disclosed, and in some cases, a structure that produces the action or enables the action to be performed will be disclosed. Any method action detailed herein or any function detailed herein or any structure having a function as disclosed herein corresponds to the disclosure in an alternative embodiment of a DNN or product from machine learning, etc. that produces the function when used, unless otherwise indicated or unless such method action or function cannot be implemented in the art.
[0284] Thus, embodiments may use a DNN or product from a machine learning or other type of artificial intelligence system to analyze data based on data from electrodes (which may be data directly from sensors, or data compiled based on data from sensors).
[0285] In an exemplary embodiment, there is a product of machine learning that analyzes various data in this article, and the product is a chip manufactured based on the results of machine learning. In an exemplary embodiment, the product is a neural network, such as a deep neural network (DNN). The product can be based on a neural network or from a neural network. In an exemplary embodiment, the product is a code. In an exemplary embodiment, the product is a logic circuit manufactured based on the results of machine learning. The product can be an ASIC (e.g., an artificial intelligence ASIC). The product can be implemented directly on a silicon structure, etc. In at least some exemplary embodiments, any device, system and / or method that can utilize the results of artificial intelligence in a hearing prosthesis or a component that communicates with a hearing prosthesis according to the teachings detailed herein can be utilized. In fact, as will be described in detail below, in at least some exemplary embodiments, the teachings detailed herein utilize knowledge / information from an artificial intelligence system or otherwise from a machine learning system.
[0286] Exemplary embodiments include implementing or otherwise performing at least one or more of the method actions detailed herein using a trained neural network, and thus embodiments include trained neural networks configured to do so. Exemplary embodiments also utilize the knowledge of the trained neural network / information obtained from implementing the trained neural network to implement or otherwise perform at least one or more of the method actions detailed herein, and thus embodiments include devices, systems, and / or methods configured to utilize such knowledge. In some embodiments, these devices may be processors and / or chips configured using the knowledge. In some embodiments, the devices and systems herein include devices that include knowledge that is imprinted or otherwise imparted to the neural network. The teachings detailed herein include utilizing machine learning methods, etc. to establish a sensory prosthetic device or supplemental component for use with a sensory prosthetic device (e.g., a smart phone), implementing at least some of the teachings herein. As an example, additional testing may be performed, and the results of the testing may be provided to the neural network for analysis, and the product thereof may be used to confirm whether to implement a treatment regimen.
[0287] In an exemplary embodiment, there may be a component, which may be a processor or a chip, that is "programmed" or has access to programming to perform one or more functions herein.
[0288] In addition, it should be clear that in an exemplary embodiment, there is a product of a machine learning algorithm (e.g., code from a trained machine learning algorithm) included in any one or more systems / subsystems described in detail herein, which can be used to analyze the acquisition disclosed above or any data otherwise available, which can be used or otherwise used to assess the practical value of any one or more implants described in detail herein. This can be embodied in software code and / or included in (one or more) computer chips in (one or more) systems.
[0289] Exemplary systems include one or more exemplary devices that can implement the teachings detailed herein, which can utilize automation in at least some embodiments. That is, exemplary embodiments include using any of the teachings herein to perform one or more or all of the methods and variations thereof detailed herein at least partially in an automated or semi-automated manner. Conversely, embodiments include devices and / or systems and / or methods that specifically prohibit automation due to a lack of enabling of automatic features or the complete lack of such capabilities in the first instance.
[0290] It should also be noted that any disclosure of a device and / or system detailed herein also corresponds to disclosure of providing the device and / or system and / or utilizing the device and / or system in other ways.
[0291] It should also be noted that any disclosure herein of any process for making a further provided device corresponds to the disclosure of the device and / or system produced thereby. It should also be noted that any disclosure herein of any device and / or system corresponds to the disclosure of a method for producing or otherwise providing or otherwise making such a device and / or system.
[0292] The exemplary system includes one or more exemplary devices that can implement the teachings detailed herein, which can utilize automation in at least some embodiments, as will now be described in the context of an automated system. That is, the exemplary embodiments include performing one or more or all of the methods and variations thereof detailed herein at least partially in an automated or semi-automated manner using any of the teachings herein.
[0293] It should also be noted that any disclosure of a device and / or system detailed herein also corresponds to disclosure of providing the device and / or system and / or utilizing the device and / or system in other ways.
[0294] It should also be noted that any disclosure herein of any process for making a further provided device corresponds to the disclosure of the device and / or system produced thereby. It should also be noted that any disclosure herein of any device and / or system corresponds to the disclosure of a method for producing or otherwise providing or otherwise making such a device and / or system.
[0295] Unless explicitly indicated and / or unless the art does not support this, any embodiment or any feature disclosed herein may be combined with any one or more or other embodiments and / or other features disclosed herein. Any embodiment or any feature disclosed herein may be expressly excluded from use in combination with any one or more or other embodiments and / or other features disclosed herein, unless such combination is explicitly indicated and / or unless the art does not support such exclusion.
[0296] Any functional or methodological acts detailed herein correspond to disclosures for doing so in an automated or semi-automated manner.
[0297] Although various embodiments of the present invention have been described above, it should be understood that they are presented by way of example only and not limitation. It will be apparent to those skilled in the relevant art that various changes in form and detail may be made therein without departing from the spirit and scope of the present invention.
Claims
1. A method comprising: obtaining data based on impedance values within a cochlea of a person at a first time location and at a second time location subsequent to the first time location; evaluating said data obtained; as well as Treatment is administered based on the assessment.
2. The method according to claim 1, wherein: Said treatment is carried out by administering a therapeutic substance to said human.
3. The method according to claim 1 or 2, wherein: said evaluation of said acquired data indicates an increase in impedance value from said first time location to said second time location; and The action of implementing the treatment is an action that would not be performed if the evaluation did not indicate the increase.
4. The method according to claim 1, 2 or 3, wherein: The evaluation of the acquired data indicates that impedance values increase by at least 5% from the first time location to the second time location.
5. The method according to claim 1, 2, 3 or 4, wherein: said evaluation of said acquired data indicates that impedance value increases by at least 7.5% from said first time location to said second time location; and The action of implementing the treatment is an action that would not be performed if the evaluation did not indicate the increase.
6. The method of claim 1, 2, 3 or 4, wherein: The evaluation of the acquired data indicates that impedance values increase by at least 10% from the first time location to the second time location.
7. The method according to claim 5, wherein: Said treatment is carried out by administering a therapeutic substance to said human.
8. The method according to claim 6, wherein: The first time position is spaced no more than 72 hours from the second time position.
9. The method according to claim 6, wherein: obtaining the impedance values within the cochlea at the first time location and the second time location using a cochlear implant electrode array; The first temporal position occurs within 5 minutes of the electrode array entering the cochlea; and The second time position is 23-25 hours after the electrode array first enters the cochlea.
10. The method according to claim 6, wherein: obtaining the impedance values within the cochlea at the first time location and the second time location using a cochlear implant electrode array; The first temporal position is an intraoperative temporal position relative to implantation of the cochlear implant electrode array; and The second time position is the intraoperative time position plus the one-day time position.
11. The method of claim 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10, wherein: The treatment is performed by performing an optional cleavage of a prodrug previously provided to the cochlea.
12. The method of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11, further comprising: obtaining additional data based on impedance values within the cochlea at a third time location at least 10 weeks after the second time location; evaluating the additional data obtained; as well as Continue, discontinue and / or adjust implant therapy based on said evaluation of said additional data.
13. The method of claim 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12, wherein: The treatment administered includes prescribing one or more of systemic steroids, anticoagulants, thrombolytics, antifibrotics, antiproliferatives, or NSAIDs.
14. A method comprising: obtaining first data based on a first impedance value obtained using a cochlear implant electrode array located in a human cochlea, wherein the impedance value is a value of impedance existing in the cochlea within 6 hours after the electrode array is first placed in the cochlea; obtaining second data based on a second impedance value obtained with the cochlear implant electrode array still in the cochlea of the person, wherein the second impedance value is for impedance present in the cochlea at least 12 hours after the electrode array is first placed in the cochlea; as well as Treatment is administered and / or the aggressiveness of treatment is increased only when the second impedance value is greater than the first impedance value.
15. The method according to claim 14, wherein: the treatment administered is a treatment that could have a harmful effect on the person; and Said increase in the aggressiveness of said treatment can have a deleterious effect on said person.
16. The method according to claim 14 or 15, wherein: The first impedance value and the second impedance value obtained using the cochlear implant electrode array are obtained using a four-point impedance technique.
17. The method according to claim 14, 15 or 16, wherein: The first impedance value is the impedance value existing within 2 hours after the electrode array first enters the cochlea; and The second impedance value is an impedance value that exists for more than 18 hours and less than 30 hours since the electrode array first entered the cochlea.
18. The method of claim 14 or 15 or 16 or 17, wherein: The first impedance value and the second impedance value obtained using the cochlear implant electrode array are mainly affected by the environment near the electrodes used to measure the first impedance value and the second impedance value.
19. The method of claim 14 or 15 or 16 or 17 or 18, wherein: The treatment administered is for a disease for which symptoms are not present when the treatment is administered; and Such treatment of increased aggressiveness is a treatment for a disease that would not have had symptoms at the time of the increase.
20. The method according to claim 14 or 15 or 16 or 17 or 18 or 19, further comprising: The first data is normalized to account for statistical variations in impedance measurements that may dissipate over time.
21. The method of claim 14 or 15 or 16 or 17 or 18 or 19 or 20, wherein: The first impedance value is the impedance value of the first 8 reading electrodes of the electrode array, the first electrode of the 8 electrodes being the most basal electrode; and The second impedance value is the impedance value of the first 8 reading electrodes.
22. The method of claim 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21, wherein: The first impedance value is an impedance value of a first number of reading electrodes of the electrode array, a first electrode of the first number of electrodes is a most basal electrode, and the first number of reading electrodes are located in a basal portion of the cochlea; and The second impedance value is an impedance value of the first number of read electrodes.
23. The method of claim 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22, wherein: The first impedance value is an impedance value of a first number of reading electrodes of the electrode array, a first electrode of the first number of electrodes being a most basal electrode, and the first number of reading electrodes subtending an angle of at least 210 degrees within the cochlea; and The second impedance value is an impedance value of the first number of read electrodes.
24. The method of claim 14 or 15 or 16 or 17 or 18 or 19 or 20 or 21 or 22 or 23, further comprising: obtaining third data based on a third impedance value obtained with the cochlear implant electrode array still located in the cochlea of the person, wherein the third impedance value is for impedance present in the cochlea between 7 and 30 days after the second impedance value was present, wherein the third impedance value is less than the second impedance value; as well as The treatment is continued and / or the aggressiveness of the treatment is increased for at least 30 days after obtaining the third data.
25. A method comprising: using a cochlear implant electrode array to detect recent physiological changes caused by implantation of the cochlear implant electrode array in the cochlea and / or to detect recent changes in potential variables affected by physiological changes caused by implantation of the cochlear implant electrode array; Evaluate the percentage change in recent detected physiological changes and / or recent detected changes in latent variables; and Based on the evaluation, a component of the cochlear implant and / or another implant component implanted in the person is controlled.
26. The method according to claim 25, further comprising: The components of the cochlear implant are controlled based on the evaluation, wherein the act of controlling the cochlear implant performs implementation of a therapeutic substance delivery regimen.
27. The method according to claim 25 or 26, further comprising: The components of the cochlear implant are controlled based on the evaluation, wherein the act of controlling the cochlear implant releases a therapeutic substance from the cochlea implanted in the person when the cochlear implant is implanted.
28. The method of claim 25, 26 or 27, further comprising: The components of the cochlear implant are controlled based on the evaluation, wherein the act of controlling the cochlear implant provides therapy to the person to limit future increases in impedance within the cochlea.
29. The method according to claim 25 or 26 or 27 or 28, further comprising: and controlling the component of the cochlear implant based on the assessment, wherein the act of controlling the cochlear implant controls a mechanical component of the cochlear implant to release a chemical from the cochlear implant that will not be released within a short period of time without assessing that the percentage change is above or at a certain level.
30. The method of claim 25 or 26 or 27 or 28 or 29, further comprising: and controlling the other implant component, wherein the act of controlling the cochlear implant controls a mechanical component of the other component to release a chemical from the other component, the chemical not being released within a short-term period without assessing that the percentage change is above or at a certain level.
31. The method of claim 25 or 26 or 27 or 28 or 29 or 30, wherein: One of the changes detected is an increase in impedance within the duct of the cochlea where the electrode array is located.
32. The method of claim 25 or 26 or 27 or 28 or 29 or 30 or 31, wherein: The recent physiological changes occur within 24 hours of implantation of the cochlear implant.
33. The method of claim 25, wherein: The act of evaluating the percent change includes comparing first data effectively obtained during or immediately after the procedure with second data obtained 18 hours after the first data was obtained.
34. The method of claim 25 or 26 or 27 or 28 or 29 or 30 or 31 or 32 or 33, further comprising: detecting a second recent physiological change and / or detecting a second recent latent variable change affected by the physiological change using a second cochlear implant electrode array implanted in a second person; evaluating a percentage change in the second detected recent physiological change and / or the second detected recent latent variable change; and Based on the evaluation of the percent change of at least one of the second changes, wherein the percent change of at least one of the second changes is less than 7.5% and the percent change of the recent first change exceeds 7.5%, not implementing the therapeutic substance delivery regimen.
35. The method of claim 25, wherein: The percent change in recent change detected is an increase of at least 10% in the average of four-point impedance values at at least 5 measurement locations along the electrode array.
36. The method of claim 25, wherein: The percent change in the detected recent change is an increase of at least 10% in the average of four-point impedance values at at least 15 measurement locations along the electrode array.
37. The method of claim 14, wherein: The method comprises implementing a therapeutic substance delivery regimen, wherein the therapeutic substance delivery regimen is supplemental to dexamethasone treatment.
38. A method comprising: obtaining a first set of intra-cochlear measurements, wherein the first set of intra-cochlear measurements represents four-point impedance measurements taken by the cochlear implant on the day of implantation; obtaining a second set of intra-cochlear measurements, wherein the second set of intra-cochlear measurements represents four-point impedance measurements taken by the cochlear implant on the second day after implantation; comparing data based on the first group with data based on the second group; as well as A prognosis is formulated based on the comparison and / or a performance assessment is formulated based on the comparison.
39. The method of claim 38, wherein: The method includes formulating the prognosis, and the prognosis is a prognosis regarding future physiology within the cochlea.
40. The method of claim 38 or 39, wherein: The method includes developing the prognosis, and the prognosis is a prognosis for future efficacy of the cochlear implant sometime after 10 weeks after obtaining the first group.
41. The method of claim 38, 39 or 40, wherein: The method includes developing the prognosis, and the prognosis is a prognosis regarding electrical impedance within the cochlea at a time later than 10 weeks after obtaining the first set.
42. The method of claim 38, 39, 40 or 41, wherein: The method includes developing the prognosis, and the prognosis is a prognosis for fibrous tissue growth at a time later than 10 weeks after obtaining the first group.
43. The method of claim 38, 39, 40, 41 or 42, wherein: The method includes formulating the prognosis, and the method includes controlling the cochlear implant based on the prognosis.
44. The method of claim 38, further comprising: Intervention is recommended when the comparison indicates that the second set of intra-cochlear measurements represents an impedance increase of 7% or more compared to the first set of intra-cochlear measurements.
45. The method of claim 38, 39, 40, 41, 42, 43 or 44, wherein the second set of intracochlear measurements comprises average impedances obtained from a subset of intracochlear electrodes of the cochlear implant, wherein the subset of electrodes comprises electrodes implanted in the basal region of the recipient's cochlea up to the basal gyrus.
46. The method of claim 45, wherein the first set of intra-cochlear measurements comprises average impedance measurements obtained from all electrodes implanted within the cochlea of the recipient.
47. The method of claim 38, 39, 40, 41, 42, 43, 44, 45 or 46, wherein: The first set of intracochlear measurements includes first representative impedances obtained from all electrodes implanted within the cochlea of the recipient; and The second set of intracochlear measurements includes second representative impedances obtained from a subset of electrodes implanted within the cochlea of the recipient.
48. The method of claim 38, 39, 40, 41, 42, 43, 44, 45, 46 or 47, wherein the method comprises delaying opening of the cochlear implant based on the prognostic recommendation.
49. The method of claim 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 or 48, wherein the method comprises delaying opening the cochlear implant for a period of at least 20 days based on the prognostic recommendation.
50. The method of claim 38, 39, 40, 41, 42, 43, 44, 45, 46, 47 or 48, wherein: The method includes formulating the performance assessment based on the comparison.
51. The method of claim 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49 or 50, wherein: The method includes formulating the performance assessment based on the comparison, and the performance assessment is used to assess a level of reproducibility of trauma associated with a type of electrode array inserted into the cochlea.
52. The method of claim 38, wherein: The method includes developing the performance assessment based on the comparison, and the performance assessment is used to assess a level of reproducibility of trauma associated with a type of surgical technique used to insert the electrode array into the cochlea.
53. The method of claim 38, wherein: The occurrence of an increase in the amount of a substance that causes subsequent fibrous tissue growth in the cochlea occurs within 24 hours of the cochlear implant electrode array being first placed in the cochlea; and The second set of intra-cochlear measurements captures latent variables associated with the increase.
54. The method of claim 38, wherein: The method includes formulating the performance assessment based on the comparison, and the performance assessment is used to assess the efficacy of a treatment regimen implemented based on the comparison.
55. A non-transitory computer readable medium having recorded thereon a computer program for performing at least a portion of a method, the computer program comprising: code for statistically analyzing first data based on four-point impedance data acquired during different time periods using an implanted cochlear implant electrode array in the cochlea; as well as Code for outputting an indication and / or an alert based on the results of the statistical analysis.
56. The medium of claim 55, further comprising: Code for automatically controlling an implantable component of a cochlear implant of which the electrode array is a part to perform a four-point impedance test to obtain the four-point impedance data.
57. The medium of claim 55 or 56, further comprising: Code for automatically implementing therapeutic actions based on the statistical analysis.
58. A medium according to claim 55, 56 or 57, wherein: The warning is the increased likelihood of deleterious fibrosis in the cochlea.
59. The medium of claim 55, 56, 57 or 58, further comprising: Code for controlling an implantable component of a cochlear implant of which the electrode array is a part to release a therapeutic substance based on the statistical analysis.
60. A method comprising: obtaining a first set of intra-cochlear measurements, wherein the first set of intra-cochlear measurements represents four-point impedance measurements taken by the cochlear implant on the day of implantation; obtaining a second set of intra-cochlear measurements, wherein the second set of intra-cochlear measurements represents four-point impedance measurements taken by the cochlear implant on the second day after implantation; as well as A fitting profile for the cochlear implant is determined based on a comparison of the first set of intra-cochlear measurements and the second set of intra-cochlear measurements.
61. The method of claim 60, further comprising: The cochlear implant is adapted using the determined adaptation profile.
62. The method of claim 60 or 61, wherein: The fitting profile is a fitting profile for a statistically normal impedance profile within the cochlea.
63. The method of claim 60, 61 or 62, wherein the method further comprises determining a first mapping for the cochlear implant based on a comparison of the first set of intra-cochlear measurements with the second set of intra-cochlear measurements, wherein the first mapping is a default mapping for turning on the cochlear implant.
64. The method of claim 63, wherein the method further comprises determining a second mapping for the cochlear implant based on a comparison of the first set of intra-cochlear measurements with the second set of intra-cochlear measurements, wherein the second mapping is a default mapping for the cochlear implant at a period of approximately one month from implantation.
65. The method of claim 60, 61, 62, 63 or 64, wherein the method further comprises: determining a first mapping for the cochlear implant based on a comparison of the first set of intra-cochlear measurements and the second set of intra-cochlear measurements, wherein the first mapping is a default mapping for turning on the cochlear implant; determining a second mapping for the cochlear implant based on a comparison of the first set of intra-cochlear measurements and the second set of intra-cochlear measurements, wherein the second mapping is a default mapping for the cochlear implant at a time period of about one month from implantation; as well as A transition profile from the first mapping to the second mapping is determined.
66. The method of claim 60, 61, 62, 63, 64 or 65, wherein: The fitting profile is an fitting profile for a statistically high impedance profile within the cochlea.
67. A system comprising: The implantable portion of a cochlear implant electrode array comprising: rear telemetry circuit; and a plurality of electrodes in direct or indirect signal communication with the rear telemetry circuit; and an external device configured to be in signal communication with the implantable portion and configured to receive data from the implantable portion via the post-telemetry circuit, wherein The implantable component is configured to perform four-point impedance measurements and provide the results of the measurements to the external device via the back telemetry circuit, and The system includes circuitry and / or software configured to evaluate the results and provide an indication that there is an impedance increase relative to a previous measurement that predicts future adverse development within the cochlea in which the electrode array is implanted.
68. A method wherein one or more of the following is true: The method includes obtaining data based on impedance values within a cochlea of a person at a first time location and at a second time location subsequent to the first time location; The method comprises evaluating the data obtained; The method includes implementing treatment based on the assessment; said treatment being carried out by administering a therapeutic substance to said human; said evaluation of said acquired data indicates an increase in impedance value from said first time location to said second time location; the action of implementing said treatment is an action that would not be performed if said evaluation did not indicate said increase; said evaluation of said acquired data indicates an increase in impedance value of at least 5% from said first time location to said second time location; said evaluation of said acquired data indicates an increase in impedance value of at least 7.5% from said first time location to said second time location; the action of implementing said treatment is an action that would not be performed if said evaluation did not indicate said increase; said evaluation of said acquired data indicates an increase in impedance value of at least 10% from said first time location to said second time location; said treatment being carried out by administering a therapeutic substance to said human; The first time position is no more than 72 hours away from the second time position; obtaining the impedance values within the cochlea at the first time location and the second time location using a cochlear implant electrode array; The first time position occurs within 5 minutes of the electrode array entering the cochlea; The second time position is 23-25 hours after the electrode array first enters the cochlea; obtaining the impedance values within the cochlea at the first time location and the second time location using a cochlear implant electrode array; The first temporal position is an intraoperative temporal position relative to implantation of the cochlear implant electrode array; The second time position is the intraoperative time position plus a day time position; Said treatment is carried out by performing an optional cleavage of a prodrug previously provided to said cochlea; The method includes obtaining additional data based on impedance values within the cochlea at a third time location at least 10 weeks after the second time location; The method comprises evaluating the additional data obtained; The method includes continuing, discontinuing and / or adjusting implant therapy based on said evaluation of said additional data; The treatment administered includes prescribing one or more of a systemic steroid, an anticoagulant, a thrombolytic, an antifibrotic, an antiproliferative, or an NSAID; The method includes obtaining first data based on a first impedance value obtained using a cochlear implant electrode array positioned in a cochlea of a person, wherein the impedance value is a value of impedance present in the cochlea within 6 hours of the electrode array first being placed in the cochlea; The method includes obtaining second data based on a second impedance value obtained with the cochlear implant electrode array still located in the cochlea of the person, wherein the second impedance value is for impedance present in the cochlea at least 12 hours after the electrode array is first placed in the cochlea; The method includes administering treatment and / or increasing the aggressiveness of treatment only when the second impedance value is greater than the first impedance value; The treatment administered is a treatment that could have a harmful effect on the person; The increase in aggressiveness of the treatment could have a deleterious effect on the person; The first impedance value and the second impedance value obtained using the cochlear implant electrode array are obtained using a four-point impedance technique; The first impedance value is the impedance value existing within 2 hours after the electrode array first enters the cochlea; The second impedance value is an impedance value that exists for more than 18 hours and less than 30 hours since the electrode array first enters the cochlea; The first impedance value and the second impedance value obtained by using the cochlear implant electrode array are mainly affected by the environment near the electrodes used to measure the first impedance value and the second impedance value; The treatment administered is a treatment for a disease for which symptoms are absent at the time of administration; Said treatment of increased aggressiveness is a treatment for a disease in which symptoms are absent at the time of the increase; normalizing the first data to account for statistical variations in impedance measurements that may dissipate over time; The first impedance value is the impedance value of the first 8 reading electrodes of the electrode array, and the first electrode of the 8 electrodes is the most basal electrode; The second impedance value is the impedance value of the first 8 reading electrodes; The first impedance value is an impedance value of a first number of reading electrodes of the electrode array, a first electrode of the first number of electrodes is a most basal electrode, and the first number of reading electrodes are located in a basal portion of the cochlea; The second impedance value is the impedance value of the first number of reading electrodes; The first impedance value is an impedance value of a first number of reading electrodes of the electrode array, a first electrode of the first number of electrodes being a most basal electrode, and the first number of reading electrodes subtend an angle of at least 210 degrees within the cochlea; The second impedance value is the impedance value of the first number of reading electrodes; The method includes obtaining third data based on a third impedance value obtained with the cochlear implant electrode array still located in the cochlea of the person, wherein the third impedance value is for impedance present in the cochlea between 7 and 30 days after the second impedance value was present, wherein the third impedance value is less than the second impedance value; The method comprises continuing the treatment and / or increasing the aggressiveness of the treatment for at least 30 days after obtaining the third data; The method includes using a cochlear implant electrode array to detect recent physiological changes caused by implantation of the cochlear implant electrode array in the cochlea and / or detecting recent changes in potential variables affected by physiological changes caused by implantation of the cochlear implant electrode array; The method includes evaluating a percent change in a detected recent physiological change and / or a detected recent change in a latent variable; The method comprises controlling a component of the cochlear implant and / or another implant component implanted in a person based on the evaluation; The method includes controlling the component of the cochlear implant based on the evaluation, wherein the act of controlling the cochlear implant performs implementation of a therapeutic substance delivery regimen; The method includes controlling the component of the cochlear implant based on the evaluation, wherein the act of controlling the cochlear implant releases a therapeutic substance from the cochlea implanted in a person when the cochlear implant is implanted; The method includes controlling the component of the cochlear implant based on the assessment, wherein the act of controlling the cochlear implant provides therapy to the person to limit future impedance increases within the cochlea; The method includes controlling the component of the cochlear implant based on the assessment, wherein the act of controlling the cochlear implant controls a mechanical component of the cochlear implant to release a chemical substance from the cochlear implant, and in the absence of an assessment that the percentage change is above or at a certain level, the chemical substance will not be released for a short period of time; The method includes controlling the other implant component, wherein the act of controlling the cochlear implant controls a mechanical component of the other component to release a chemical substance from the other component, the chemical substance not being released for a short-term period of time without assessing that the percentage change is above or at a certain level; One of the changes detected is an increase in impedance within the duct of the cochlea where the electrode array is located; The recent physiological changes occur within 24 hours of implantation of the cochlear implant; The act of evaluating the percent change comprises comparing first data effectively obtained during or immediately after the procedure with second data obtained 18 hours after the first data was obtained; The method includes detecting a second recent physiological change and / or detecting a second recent latent variable change affected by the physiological change using a second cochlear implant electrode array implanted in a second person; The method includes evaluating a percentage change in the second detected recent physiological change and / or a detected change in the second recent latent variable; The method includes not implementing a therapeutic substance delivery regimen based on said evaluation of a percent change in at least one of the second changes, wherein the percent change in at least one of the second changes is less than 7.5% and the percent change in the recent first change exceeds 7.5%; The percent change in the recent change detected is an increase of at least 10% of an average of four-point impedance values at at least 5 measurement locations along the electrode array; The percent change in the detected recent change is an increase of at least 10% in the average of four-point impedance values at at least 15 measurement locations along the electrode array; The therapeutic substance delivery regimen is in addition to dexamethasone treatment; One or more method actions herein are performed using a non-transitory computer-readable medium having recorded thereon a computer program for performing at least a portion of the method; The method includes statistically analyzing first data based on four-point impedance data acquired during different time periods using an implanted cochlear implant electrode array in the cochlea; The method includes outputting an indication and / or an alert based on the analysis; automatically controlling an implantable component of a cochlear implant of which the electrode array is a part to perform a four-point impedance test to obtain the four-point impedance data; The method includes automatically implementing therapeutic actions based on the statistical analysis; The warning is the increased likelihood of deleterious fibrosis in the cochlea; The method includes controlling an implantable component of a cochlear implant of which the electrode array is a part to release a therapeutic substance based on the statistical analysis; The method includes obtaining a first set of intra-cochlear measurements, wherein the first set of intra-cochlear measurements represents four-point impedance measurements taken by a cochlear implant on a day of implantation; The method includes obtaining a second set of intra-cochlear measurements, wherein the second set of intra-cochlear measurements represents four-point impedance measurements taken by the cochlear implant on a day after implantation; The method includes comparing data based on the first set with data based on the second set; The method includes formulating a prognosis based on the comparison and / or formulating a performance assessment based on the comparison; The method includes formulating the prognosis, and the prognosis is a prognosis regarding future physiology within the cochlea; The method includes developing the prognosis, and the prognosis is a prognosis regarding the future efficacy of the cochlear implant sometime after 10 weeks after obtaining the first group; The method includes developing the prognosis, and the prognosis is a prognosis regarding electrical impedance within the cochlea at a time later than 10 weeks after obtaining the first set; The method includes developing the prognosis, and the prognosis is a prognosis for fibrous tissue growth at a time later than 10 weeks after obtaining the first group; The method includes developing the prognosis, and the method includes controlling the cochlear implant based on the prognosis; recommending intervention when the comparison indicates that the second set of intracochlear measurements represents an impedance increase of 7% or more compared to the first set of intracochlear measurements; the second set of intracochlear measurements comprising average impedances obtained from a subset of intracochlear electrodes of the cochlear implant, wherein the subset of electrodes comprises electrodes implanted in a basal region of the cochlea of the recipient up to the basal gyrus; The first set of intracochlear measurements includes average impedance measurements obtained from all electrodes implanted within the cochlea of the recipient; The first set of intracochlear measurements includes first representative impedances obtained from all electrodes implanted within the cochlea of the recipient; the second set of intracochlear measurements comprising second representative impedances obtained from a subset of electrodes implanted within the cochlea of the recipient; The method includes recommending delayed opening of the cochlear implant based on the prognostic; The method includes recommending, based on the prognosis, delaying opening of the cochlear implant for a period of at least 20 days; The method includes formulating the performance assessment based on the comparison; The method includes formulating the performance assessment based on the comparison, and the performance assessment is used to assess a level of reproducibility of trauma associated with a type of electrode array inserted into the cochlea; The method includes developing the performance assessment based on the comparison, and the performance assessment is used to assess a level of reproducibility of trauma associated with a type of surgical technique used to insert the electrode array into the cochlea; The occurrence of an increase in the amount of a substance in the cochlea that causes subsequent fibrous tissue growth within 24 hours of the cochlear implant electrode array first being placed in the cochlea; said second set of intracochlear measurements captures latent variables associated with said increase; The method includes formulating the performance assessment based on the comparison, and the performance assessment is used to assess the efficacy of a treatment regimen implemented based on the comparison; The method includes obtaining a first set of intra-cochlear measurements, wherein the first set of intra-cochlear measurements represents four-point impedance measurements taken by a cochlear implant on a day of implantation; The method includes obtaining a second set of intra-cochlear measurements, wherein the second set of intra-cochlear measurements represents four-point impedance measurements taken by the cochlear implant on a day after implantation; The method includes determining a fit profile for the cochlear implant based on a comparison of the first set of intra-cochlear measurements and the second set of intra-cochlear measurements; The method comprises fitting the cochlear implant using the determined fitting profile; The fitting profile is a fitting profile for a statistically high impedance profile within the cochlea; The fitting profile is a fitting profile for a statistically normal impedance profile within the cochlea; The method further includes determining a first mapping for the cochlear implant based on a comparison of the first set of intra-cochlear measurements with the second set of intra-cochlear measurements, wherein the first mapping is a default mapping for turning on the cochlear implant; The method further includes determining a second mapping for the cochlear implant based on a comparison of the first set of intra-cochlear measurements with the second set of intra-cochlear measurements, wherein the second mapping is a default mapping for the cochlear implant at a time period of about one month from implantation; The method further includes determining a first mapping for the cochlear implant based on a comparison of the first set of intra-cochlear measurements and the second set of intra-cochlear measurements, wherein the first mapping is a default mapping for turning on the cochlear implant; The method includes determining a second mapping for the cochlear implant based on a comparison of the first set of intra-cochlear measurements and the second set of intra-cochlear measurements, wherein the second mapping is a default mapping for the cochlear implant at a period of about one month from implantation; The method comprises determining a transition profile from the first mapping to the second mapping; using the impedance measurements to detect biomarkers indicative of changes within the cochlea that will cause, after at least 2, 3, or 4 months, an increase in impedance between electrodes of a cochlear implant that, if allowed to occur, is high enough that the increase will have a deleterious effect on the operation of the cochlear implant; The impedance increase is capable of causing the load on the cochlear implant to increase by at least 10, 15, 20, 25 or 30% or any value or range of values in 1% increments therebetween above what would otherwise be the case, all other things being equal; More than 20, 25, 30, 35, 40, 45, 50, 55, 60, 65, 70, 75, 80, 85, 90, 91, 92, 93, 94, 95, 96, 97, 98 or 99% of the data collected and / or utilized to perform one or more of the method actions is from electrodes at and / or before the bottom loop; the electrode used for comparison / evaluation / the electrode from which data is used for comparison / evaluation is located no more than 8, 9, 10, 11, 12, 13, 14, 15, 16 or 17 mm (as measured along the length of the array) from the proximal portion of the cochlea where the electrode array enters the cochlea and / or no less than 2, 3, 4, 5, 6, 7, 8, 9 or 10 mm from that location; the first time position and the second time position are separated by at least (inclusive) 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45 or 50 hours or any value or range of values in increments of 0.1 hour therebetween; the interval between the first time position and the second time position is not more than (inclusive of) 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 45, 50, 55, 60, 65 or 70 hours or any value or range of values therebetween in increments of 0.1 hour; The act of obtaining data based on impedance values within a person's cochlea can include physically operating the cochlear implant electrode array using four-point impedance measurements; The act of obtaining data based on impedance values within a cochlea of a person does not include actually operating the cochlear implant; The method may further include taking into account other factors, such as age and / or gender, in the act of evaluating and / or comparing; Therapies implemented included provision of steroids; Therapies administered can have harmful side effects; The data obtained indicates that the impedance value (e.g., average impedance value) increases by at least 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15% or more or any value or range of values therebetween in increments of 0.1%; The method includes administering therapy when the average impedance value increases by at least 10% from the first time location to the second time location while considering at least 30, 35, 40, 45, 50, 55, 60, 65, 70, 75 or 80% of the read electrodes (values from these read electrodes, again, some read electrodes will not be used for various reasons) or any value or range of values in 1% increments therebetween; The first time location occurs when the patient is in a surgical room where he or she receives the cochlear implant; The first time position occurs before the closure of an incision for implanting the cochlear implant; The first time position occurs within 1 hour of closure of an incision for implanting the cochlear implant; The first impedance value is the impedance value of all or a subset of a first number of reading electrodes of the electrode array, a first electrode of the first number of electrodes being the most basal electrode, and the first number of reading electrodes being oriented at least 110, 120, 130, 140, 150, 160, 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350, 360, 370, 380, 390, 400, 410, 420, 430, 440, 450, 460, 470, 480, 490, 500, 510, 520, 530, 540, 550, 560, 570, 580, 590, 600, 610, 620, 630, 640, 650, 660, 670, 680, 690, 700, 710, 720, 730, 740, 750, 760, 770, 780, 790, 800 0, 300, 310, 320 or 330 degrees, or any value or range of values in 1 degree increments therebetween, and / or subtends an angle within said cochlea of no more than 170, 180, 190, 200, 210, 220, 230, 240, 250, 260, 270, 280, 290, 300, 310, 320, 330, 340, 350 or 360 degrees, or any value or range of values in 1 degree increments therebetween; the base-most first, second, third, fourth, fifth, sixth and / or seventh reading electrodes are excluded from the electrodes for the first value and / or the second value; said near-term physiological changes occur within 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.5, 2, 2.5, 3, 3.5, 4, 4.5, 5, 5.5, 6, 6.5, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23 or 24 hours of implantation of said cochlear implant, or any value or range of values therebetween in 0.1 hour increments, or at least within the first entry of said array and / or a member for accessing said cochlea (e.g., a drill) into said cochlea and / or final placement of said array in said cochlea; The value used to analyze the first time position can be different from the value used to analyze the second time position; The method includes removing and / or smoothing extraneous data points from the first set of data and / or the second set of data; The prognosis is that the impedance will increase on average (mean, median and / or mode) by at least 15, 20, 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, 100, 125, 150, 175 or 200% or more or any value or range of values in 1% increments therebetween over 2, 3 or 4 months; the prognosis being a prognosis of future efficacy of the cochlear implant at a time before and / or after obtaining the first set and / or at 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 weeks or more after obtaining the first set or any value or range of values in 1 day increments therebetween, to accurately reproduce sound, wherein the accuracy is at least partially affected by an increase in impedance in the cochlea relative to, for example, a situation in which there is no increase in fibrous tissue growth in the cochlea; The method includes obtaining data based on one or more intra-cochlear measurements, wherein the one or more intra-cochlear measurements are acquired by a cochlear implant; The method includes formulating, based on the data, a prediction of the likelihood of a future occurrence of vertigo in a recipient of the cochlear implant caused by implantation of the cochlear implant; Said prediction is that vertigo will occur in the future; The prediction is that vertigo will not occur; The method includes evaluating one or more corresponding levels of one or more of the measured values, wherein the act of formulating the prediction is based on the evaluating of the one or more corresponding levels; The one or more intra-cochlear measurements are one or more impedance measurements; The one or more intra-cochlear measurements are one or more four-point impedance measurements; The one or more intra-cochlear measurements are one or more impedance measurements; The method further includes evaluating one or more relative levels of the one or more impedance measurements and formulating the prediction based on the relative levels; The data is one or more of the following: an average four-point impedance across at least eight electrodes of the cochlear implant; The maximum four-point impedance within the cochlea; The average impedance within the cochlea; or maximum impedance within the cochlea at locations corresponding to the basal, middle, and / or apical third of the cochlea; The method includes obtaining data indicating whether the recipient experienced vertigo prior to implantation of the cochlear implant, wherein the developed prediction is in addition to any prediction of vertigo other than vertigo caused by implantation of the cochlear implant; One or more of the following is true: The data include average substrate four-point impedance values; or The method includes generating the average substrate four-point impedance value; The prediction of the occurrence of vertigo was formulated based on the average basal four-point impedance value; The predictions formulated are: there is a probability that said recipient will experience vertigo; The method further comprises: obtaining second data based on one or more second intra-cochlear measurements, wherein the one or more second intra-cochlear measurements are acquired by the cochlear implant at least 7 days after the one or more intra-cochlear measurements are acquired; The method includes formulating a second prediction that vertigo caused by implantation of the cochlear implant is unlikely to occur in the recipient after a time location at which the second data is obtained; The method includes taking remedial action based on the likelihood of vertigo occurring; The method includes discontinuing the remedial action based on the second prediction; The method includes obtaining data indicating the presence and / or absence of inflammation and / or blood within a cavity of a person following a surgical procedure; The method includes formulating a prediction of a future occurrence of vertigo caused by the surgical procedure based on the acquired data; The surgical procedure is implantation of a cochlear implant electrode array implanted in the cochlea; The data obtained indicated the presence of inflammation and / or blood within the human cochlea; The prediction for the occurrence of vertigo is that it will occur within 10 days; The data obtained are data indicative of the impedance between electrodes within the cochlea; The impedance is indicative of inflammation and / or blood and / or cellular structures within the cochlea, and thus the data is indicative of the presence of inflammation and / or blood within the human body; obtaining impedance between electrodes within the cochlea within 36 hours of completing the surgical procedure; The method includes treating the person with a therapeutic substance and / or an electrical stimulation device to reduce the likelihood and / or magnitude of future vertigo caused by the surgical procedure relative to what would otherwise occur without the treatment; The data is one or more impedance measurements from within the cavity and / or statistically analyzed data from one or more impedance measurements from within the cavity; The method comprises comparing the data obtained with predetermined data, wherein the act of formulating the prediction is based on whether the comparison indicates that the data obtained is above and / or below and / or at the predetermined data; The data obtained is data indicative of impedance between electrodes in at least a basal portion of the cochlea; The data is data acquired at at least a first time position; The method further includes obtaining second data acquired at a second time location at least 120 hours after the first time location; The data acquired at the first time position is consistent with the data acquired at the second time position; The method includes identifying a therapy and / or a recommended course of action based on the data; The method includes continuing the therapy and / or recommended course of action based on the agreement; prescribing and / or imposing alternative care supports for the person, based on the prognosis, relative to what would otherwise have happened without the prognosis; The method includes prescribing an extended stay in a health care facility after the surgical procedure and / or mandating an extended stay in a health care facility after the surgical procedure based on the prediction relative to what would otherwise be the case without the prediction; Based on the prediction, prescribing and / or mandating that the person remain in a health care facility for at least 5 days longer after the procedure than would otherwise have been the case without the prediction; or The cavity is the cochlea.
69. A method comprising: obtaining data based on one or more intra-cochlear measurements, wherein the one or more intra-cochlear measurements are acquired by a cochlear implant; as well as A prediction of the likelihood of a future onset of vertigo in a recipient of the cochlear implant resulting from implantation of the cochlear implant is formulated based on the data.
70. The method of claim 69, wherein: The prediction is that vertigo will occur in the future.
71. The method of claim 69, wherein: The prediction is that vertigo will not occur.
72. The method of claim 69, 70 or 71 further comprising: evaluating one or more corresponding levels of one or more of said measured values, wherein The act of formulating the prediction is based on the evaluation of the one or more corresponding levels.
73. The method of claim 69, 70, 71 or 72, wherein: The one or more intra-cochlear measurements are one or more impedance measurements.
74. The method of claim 69, 70, 71 or 72, wherein: The one or more intra-cochlear measurements are one or more four-point impedance measurements.
75. The method of claim 69, 70, 71 or 72, wherein: The one or more intra-cochlear measurements are one or more impedance measurements; and The method also includes evaluating one or more relative levels of the one or more impedance measurements and formulating the prediction based on the relative levels.
76. The method of claim 69, 70, 71 or 72, wherein the data is one or more of: an average four-point impedance across at least eight electrodes of the cochlear implant; The maximum four-point impedance within the cochlea; The average impedance within the cochlea; or The maximum impedance at locations within the cochlea corresponding to the basal, middle and / or apical third of the cochlea.
77. The method of claim 69, 70, 71, 72, 73, 74, 75 or 76, further comprising: obtaining data indicating whether the recipient experienced vertigo prior to implantation of the cochlear implant, wherein The predictions developed are in addition to any predictions of vertigo other than vertigo caused by implantation of the cochlear implant.
78. The method of claim 69, 70, 71 or 72, wherein: One or more of the following is true: The data include average substrate four-point impedance values; or The method includes generating the average substrate four-point impedance value; A prediction of the occurrence of vertigo was made based on the average basal four-point impedance values.
79. The method of claim 69, 70, 71, 72, 73, 74, 75, 76, 77 or 78, wherein: The predictions formulated are: there is a probability that said recipient will experience vertigo; and The method further comprises: obtaining second data based on one or more second intra-cochlear measurements, wherein the one or more second intra-cochlear measurements are acquired by the cochlear implant at least 7 days after the one or more intra-cochlear measurements are acquired; as well as A second prediction is formulated that vertigo caused by implantation of the cochlear implant is unlikely to occur in the recipient after the time location at which the second data is obtained.
80. The method of claim 69, 70, 71, 72, 73, 74, 75, 76, 77, 78 or 79, further comprising: Take remedial actions based on the likelihood of vertigo occurring; as well as The remedial action is discontinued based on the second prediction.
81. A method comprising: obtaining data indicating the presence and / or absence of inflammation and / or blood within a cavity of a person following a surgical procedure; as well as A prediction of future occurrences of vertigo caused by the surgical procedure is formulated based on the data obtained.
82. The method of claim 81, wherein: The surgical procedure is the implantation of a cochlear implant electrode array into the cochlea.
83. The method of claim 81 or 82, wherein: The data obtained indicates the presence of inflammation and / or blood within the person's cochlea; and The prediction for the occurrence of vertigo is that it will occur within 10 days.
84. The method of claim 81, 82 or 83, wherein: The data obtained are data indicative of the impedance between electrodes within the cochlea; The impedance is indicative of inflammation and / or blood and / or cellular structures within the cochlea, and thus the data is indicative of the presence of inflammation and / or blood within the human body; and Impedance between electrodes within the cochlea was obtained within 36 hours of completing the surgical procedure.
85. The method of claim 81, 82, 83 or 84, further comprising: The person is treated with a therapeutic substance and / or an electrical stimulation device to reduce the likelihood and / or magnitude of future vertigo caused by the surgical procedure relative to what would otherwise occur without the treatment.
86. The method of claim 81, 82, 83, 84 or 85, wherein: The data is data from one or more impedance measurements within the cavity and / or statistically analyzed data from one or more impedance measurements within the cavity.
87. The method of claim 81, 82, 83, 84, 85 or 86, further comprising: The obtained data is compared with predetermined data, wherein The act of formulating the prediction is based on whether the comparison indicates that the data obtained is above and / or below and / or at the predetermined data.
88. The method of claim 84, wherein: The data obtained is data indicative of impedance between electrodes in at least a basal portion of the cochlea.
89. The method of claim 81, 82, 83, 84, 85, 86, 87 or 88, wherein: The data is data acquired at at least a first time position; The method further includes obtaining second data acquired at a second time location at least 120 hours after the first time location; The data acquired at the first time position is consistent with the data acquired at the second time position.
90. The method of claim 89, further comprising: identifying a therapy and / or a recommended course of action based on the data; as well as The therapy and / or recommended course of action is continued based on the agreement.
91. The method of claim 81, 82, 83 or 84, further comprising: Based on the prognosis, alternative care supports are prescribed and / or mandated for the person relative to what would otherwise be the case without the prognosis.
92. The method of claim 81, 82, 83 or 84, further comprising: Based on the prediction, a prolonged stay in a health care facility after the surgical procedure is prescribed and / or mandated relative to otherwise in the absence of the prediction.
93. The method of claim 81, 82, 83 or 84, further comprising: Based on the prediction, prescribing and / or mandating an extended stay of the person in the health care facility for at least 5 days after the surgical procedure relative to otherwise being in the absence of the prediction.
94. The method of claim 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92 or 93, wherein: The cavity is the cochlea.
